n n u l r e p r march shareholders alex gorsky chairman chief executive officer ve work health care industry true innovation result unite nearly year honor collaboration collaboration inspire privilege work johnson johnson drive diversity idea individual credo company touch live discipline work ring billion people day common goal true today world look todays health care landscape incredibly clear today world need write pace change great leader commit work frankly exciting help bring improved health year ago wellness person todays rapid change bring corner globe world large opportunity risk company broadly base health care health care prepare company uniquely position help address significant transform global health care shine light challenge overcome tool important issue face insight technology innovation collaborate boundary evolution revolution border uncover scientific insight combine today idea dedicate resource promise time human health create tomorrow breakthroughs johnson johnson united inspire credo year company ring true today invent future health care write year ago begin learn innovation remind responsibility seldom product solitary genius customer patient chairman letter icompel deliver responsibility world large comprehensive employee communitie health care company well environment shareholder position johnson johnson lead important work strong foundation continue use breadth addition commitment advance comprehensively advance human health health comprehensively employ invest endure longterm impact discipline portfolio management position business deliver strong ensure focused solve consistent sustainable result important medical consumer hold accountable health need invest promise future responsibility people growth area business continue meet expectation advance human health complete acquisition believe business significant licensing deal patient broadly base health care divestiture position continue center continue major profitable growth reward factor success allow innovation deliver strong consistent growth acquisition abbott medical optics drive return significant value close early excellent well shareholder example flexibility invest area outcomes economic cycle opportunity spectrum longterm health care consumer expertise value company structure allow particularly vision care space interconnect breadth depth combine medical device drive innovation advantage expertise opportunity uniquely growth opportunity complementary portfolio dynamic health industry excite add strong particularly important industry differentiate surgical ophthalmic offering continue evolve political particularly cataract surgery environment pose new challenge vision care business couple opportunity incredibly worldleade acuvue contact lens clear emerge area healthtech business help broad potential intersection base leader vision care transaction technology health care completely excellent example approach change disrupt exist health care acquisition right deal ecosystem imminent right time right price new healthtech space drive growth create value integral shareholders ii chairmans letterour broad base health care invest longterm strong global footprint give unique growth insight opportunity work way drive broad government health care system save improve life base human world influence investment clear perspective imperative health care health volatility financial performance objective extend emerge market health care cost johnson johnson grow sale reach challenge exist develop organically fast rate market capability emerge market clearly demonstrate grow earning fast sale strategic importance advocate improve objective meet advantage access quality health care patient reward innovation drive well additionally focus strong provider outcome longterm value cash flow ensure able consumer continue lead voice appropriate investment discussion advocate solution business capitalize right world good interest health opportunity create great longterm wellness patient consumer value shareholder start fund internal growth initiative include investment research development b rd investment total fund organic growth billion strategic capital allocation framework outline use remain free cash flow b free priority deliver competitive cash flow dividend shareholder billion increase consecutive year b pay billion dividend meet dividend goal target value create acquisition b invest approximately billion finally consider prudent way acquisition major return value shareholder licensing deal share repurchase programs b complete twothird billion share repurchase program chairman letter iiiour total shareholder return expect key catalyst strong significantly exceed growth include competitor composite continue strong performance exceed major index include inline product increase penetration sp true market anticoagulant m proud case psoriasis longacte antipsychotic year capitalize early launch success period historically approximately key product darzalex percent free cash flow deploy imbruvica stelara year return crohns disease shareholder form dividend anticipate regulatory approval share repurchase new immunology product guselkumab sirukumab great business strong record total shareholder billion sale potential sector return result approach manage long term relentless continue vigorously position drive innovation discipline portfolio defend patent remicade meet management capital allocation remain competitive atrisk change strategy regularly biosimilar entry give product long need discuss ongoing strategic track record efficacy safety patient plan board director consumer confident robust drive strong consistent pharmaceutical pipeline continue sustainable result work goal file new health care landscape continue product evolve business sector billion potential sale filing wellpositione meet change need additional line extension patient consumer term million financial performance expect potential sale business segment grow contribute sale income growth addition january announce definitive agreement acquire actelion pharmaceuticals ltd approximately billion pharmaceutical business transaction expect accelerate priority drive continue growth near longterm revenue deliver nearterm pipeline earning growth rate immediately focus therapeutic accretive johnson johnsons adjust area high unmet medical need earning share acquisition robust innovation engine strong expand complement exist commercial capability janssen portfolio differentiate iv chairmans lettermarket medicine pulmonary arterial opportunity large grow market hypertension reinforce janssen significant unmet need robust latestage pipeline transaction subject satisfaction goal return market closing condition expect close growth second half year end second quarter plan drive growth double number new consumer product major consumer segment nearterm launch plan priority enhance leadership accelerate impact strategic priority category continue improve acquisition profitability benchmark level focus incorporate suite holistic insight critical geography iconic drive capability help health system unique megabrand navigate valuebased care perspective careadvantage orthopaedic episode plan consumer growth health ofcare partnership include wellness continue progress restructuring need want continue grow fast initiative hospital medical device hope market gain market share business track achieve fear mega brand saving million billion people bring innovation market majority expect realize life touch launch key sciencebase new end product responsibility world accelerate growth recent world large broadly day acquisition beauty franchise include vogue international ogx base health care company proganix hair care brand unique perspective health wellness need want hope fear continue utilize supply chain operational efficiency ensure people life touch operating margin benchmark world day level continue provide leadership medical device health wellness issue nearterm priority medical device understand well accelerate growth innovation continue report social portfolio management new business environmental performance business model drive growth priority citizenship sustainability platform sustain leadership report available wwwjnjcomcare core platform implement novel commercial model seek expansion september addition chairman letter vcitizenship sustainability goal health care system address important announce comprehensive un issue health care cost sustainable development goal sdg commitment focus key area continue defend interest uniquely position stakeholder define create sustainable scalable impact credo doctor nurse patient global disease challenge essential mother father use surgery women children health product employee supplier health workforce environmental community live health sdg vision work continue provide galvanize partner mobilize positive economic impact employee engage community business pay fair share taxis profoundly improve course deliver fair return shareholder human health put people industry leader keep humancentere insight patient consumer center drive innovation breakthrough year product advocacy access health commit take unprecedented step care humanitarian work treat put like create johnson johnson world debilitate people bioethics committee industry disease commit compassionate use advisory committee put people collaborate develop massive real world datum set observational health true support datum sciences informatic ohdsi employee develop industryleade clinical trial world compelling strategy datum transparency yale open strong result possible datum access yoda project talented diverse dedicated employee commitment quarter passion help johnson johnson please release inaugural janssen name industry business transparency report publication disclose information admire respect innovative business practice include good place work year year relate pricing report build history responsible pricing practice ensure success ongoing effort provide believe employer opportunity transparency operate responsibility incentive disclosure way ensure employee healthy continue work engage goal vi chairmans letterto lead example cultivate world resilience way achieve healthy workforce practice gratitude like grateful number program place chairman chief executive officer help achieve goal johnson johnson grateful facet employee live passion commitment unique program encourage healthy eat contribution movement resilience ensure employee world grateful financial health employee billion health care worker competitive compensation program parent consumer place health wellness benefit recognition trust product day finally program longterm incentive robust grateful board director retirement plan include define shareholder entrust benefit pension plan great responsibility lead support healthy family amazing company thank program new parental leave support policy fertility benefit global breast milk shipping benefit credo inspiration strength broad base human feel right thing health care commitment believe program deliver strong consistent longterm help achieve goal attract growth incredibly confident develop retain good talent continue success johnson johnson deliver good outcome position deliver year strong growth sincerely shareholder return confident future johnson johnson alex gorsky teaching wellness chairman chief executive officer business importance mindfulness johnson johnson nongaap measure free cash flow define operate cash flow capital spend billion billion billion nongaap measure exclude intangible amortization expense special item note forwardlooke statement letter contain forwardlooke statement relate thing future operate financial performance product development market position business strategy reader caution rely statement base current expectation future event important information statement include risk uncertainty factor cause actual result vary materially assumption expectation projection express forwardlooke statement reader review enclose annual report fiscal year end january include section caption cautionary note forwardlooke statement item risk factor johnson johnson undertake update forwardlooke statement result new information future event development chairmans letter viiunite states securities exchange commission washington dc annual report pursuant section security exchange act forthefiscalyearendedjanuary commissionfilenumber johnson johnson exactnameofregistrantasspecifiedinitscharter newjersey stateofincorporation irsemployeridentificationno onejohnsonjohnsonplaza newbrunswicknewjersey addressofprincipalexecutiveoffice zipcode registrantstelephonenumberincludingareacode securitiesregisteredpursuanttosectionboftheact titleofeachclass nameofeachexchangeonwhichregistered commonstockparvalue newyorkstockexchange notesduenovember newyorkstockexchange notesduejanuary newyorkstockexchange notesduemay newyorkstockexchange notesduenovember newyorkstockexchange notesduenovember newyorkstockexchange notesduemay newyorkstockexchange indicatebycheckmarkiftheregistrantisawellknownseasonedissuerasdefinedinruleofthesecurities act yes indicatebycheckmarkiftheregistrantisnotrequiredtofilereportspursuanttosectionorsectiondofthe exchangeact yes indicatebycheckmarkwhethertheregistranthasfiledallreportsrequiredtobefiledbysectionordofthe exchangeactduringtheprecedingmonthsorforsuchshorterperiodthattheregistrantwasrequiredtofilesuch reportsandhasbeensubjecttosuchfilingrequirementsforthepastday yes indicatebycheckmarkwhethertheregistranthassubmittedelectronicallyandpostedonitscorporatewebsiteifany everyinteractivedatafilerequiredtobesubmittedandpostedpursuanttoruleofregulationstduringthe precedingmonthsorforsuchshorterperiodthattheregistrantwasrequiredtosubmitandpostsuch file yes indicatebycheckmarkifdisclosureofdelinquentfilerspursuanttoitemofregulationskisnotcontainedherein andwillnotbecontainedtothebestofregistrantsknowledgeindefinitiveproxyorinformationstatement incorporatedbyreferenceinpartiiiofthisformkoranyamendmenttothisformk indicatebycheckmarkwhethertheregistrantisalargeacceleratedfileranacceleratedfileranonacceleratedfileror asmallerreportingcompanyseethedefinitionsoflargeacceleratedfileracceleratedfilerandsmallerreporte companyinruleboftheexchangeact largeacceleratedfiler acceleratedfiler nonacceleratedfiler smallerreportingcompany donotcheckifasmallerreportingcompany indicatebycheckmarkwhethertheregistrantisashellcompanyasdefinedinruleboftheexchange act yes theaggregatemarketvalueofthecommonstockheldbynonaffiliatescomputedbyreferencetothepriceatwhich thecommonstockwaslastsoldasofthelastbusinessdayoftheregistrantsmostrecentlycompletedsecondfiscal quarterwasapproximatelybillion onfebruarythereweresharesofcommonstockoutstande documentsincorporatedbyreference partsiandiii portionsofregistrantsproxystatementforitsannualmeetingofshareholdersfile withindaysafterthecloseoftheregistrantsfiscalyeartheproxystatementare incorporatedbyreferencetothisreportonformkthisreportitem parti business general segmentsofbusiness geographicareas rawmaterial patent trademarks seasonality competition researchanddevelopment environment regulation availableinformation riskfactor b unresolvedstaffcomment property legalproceeding minesafetydisclosure executiveofficersoftheregistrant partii marketforregistrantscommonequityrelatedstockholdermattersandissuerpurchasesof equitysecuritie selectedfinancialdata managementsdiscussionandanalysisofresultsofoperationsandfinancialcondition quantitativeandqualitativedisclosuresaboutmarketrisk financialstatementsandsupplementarydata changesinanddisagreementswithaccountantsonaccountingandfinancialdisclosure controlsandprocedures b otherinformation partiii directorsexecutiveofficersandcorporategovernance executivecompensation securityownershipofcertainbeneficialownersandmanagementandrelatedstockholder matter certainrelationshipsandrelatedtransactionsanddirectorindependence principalaccountantfeesandservice partiv exhibitsandfinancialstatementschedule formksummary signature exhibitindex cautionary note forwardlooke statement thisannualreportonformkandjohnsonjohnsonsotherpubliclyavailabledocumentscontainforwardlooke statementswithinthemeaningofthesafeharborprovisionsoftheusprivatesecuritieslitigationreformactof managementandrepresentativesofjohnsonjohnsonanditssubsidiariesthecompanyalsomayfromtimetotime makeforwardlookingstatementsforwardlookingstatementsdonotrelatestrictlytohistoricalorcurrentfactsandreflect managementsassumptionsviewsplansobjectivesandprojectionsaboutthefutureforwardlookingstatementsmaybe identifiedbytheuseofwordssuchasplansexpectswillanticipatesestimatesandotherwordsofsimilar meaninginconjunctionwithamongotherthingsdiscussionsoffutureoperationsexpectedoperatingresultsand financialperformanceimpactofplannedacquisitionsanddispositionsthecompanysstrategyforgrowthproduct developmentregulatoryapprovalsmarketpositionandexpenditure becauseforwardlookingstatementsarebasedoncurrentbeliefsexpectationsandassumptionsregardingfutureevent theyaresubjecttouncertaintiesrisksandchangesthataredifficulttopredictandmanyofwhichareoutsideofthe companyscontrolinvestorsshouldrealizethatifunderlyingassumptionsproveinaccurateorknownorunknownrisksor uncertaintiesmaterializethecompanysactualresultsandfinancialconditioncouldvarymateriallyfromexpectationsand projectionsexpressedorimpliedinitsforwardlookingstatementsinvestorsarethereforecautionednottorelyonthese forwardlookingstatementsrisksanduncertaintiesincludebutarenotlimitedto risksrelatedtoproductdevelopmentmarketsuccessandcompetition challengesanduncertaintiesinherentininnovationanddevelopmentofnewandimprovedproductsandtechnologie onwhichthecompanyscontinuedgrowthandsuccessdependincludinguncertaintyofclinicaloutcomesobtaine regulatoryapprovalshealthplancoverageandcustomeraccessandinitialandcontinuedcommercialsuccess challengestothecompanysabilitytoobtainandprotectadequatepatentandotherintellectualpropertyrightsfornew andexistingproductsandtechnologiesintheusandotherimportantmarket theimpactofpatentexpirationstypicallyfollowedbytheintroductionofcompetingbiosimilarsandgenericsand resultingrevenueandmarketsharelosse increasinglyaggressiveandfrequentchallengestothecompanyspatentsbycompetitorsandothersseekingtolaunch competinggenericbiosimilarorotherproductspotentiallyresultinginlossofmarketexclusivityandrapiddeclinein salesfortherelevantproduct competitioninresearchanddevelopmentofnewandimprovedproductsprocessesandtechnologieswhichcanresult inproductandprocessobsolescence competitiontoreachagreementwiththirdpartiesforcollaborationlicensingdevelopmentandmarketingagreement forproductsandtechnologie competitiononthebasisofcosteffectivenessproductperformancetechnologicaladvancesandpatentsattainedby competitorsand allegationsthatthecompanysproductsinfringethepatentsandotherintellectualpropertyrightsofthirdpartieswhich couldadverselyaffectthecompanysabilitytoselltheproductsinquestionandrequirethepaymentofmoneydamage andfutureroyaltie risksrelatedtoproductliabilitylitigationandregulatoryactivity productefficacyorsafetyconcernswhetherornotbasedonscientificevidencepotentiallyresultinginproduct withdrawalsrecallsregulatoryactiononthepartoftheusfoodanddrugadministrationorinternational counterpartsdecliningsalesandreputationaldamage impactofsignificantlitigationorgovernmentactionadversetothecompanyincludingproductliabilityclaim increasedscrutinyofthehealthcareindustrybygovernmentagenciesandstateattorneysgeneralresultingin investigationsandprosecutionswhichcarrytheriskofsignificantcivilandcriminalpenaltiesincludingbutnotlimite todebarmentfromgovernmentbusiness failuretomeetcomplianceobligationsinthemcneilppcincconsentdecreeorthecorporateintegrityagreement ofthejohnsonjohnsonpharmaceuticalaffiliatesoranyothercomplianceagreementswithgovernmentsor governmentagencieswhichcouldresultinsignificantsanction potentialchangestoapplicablelawsandregulationsaffectingusandinternationaloperationsincludingrelatingto approvalofnewproductslicensingandpatentrightssalesandpromotionofhealthcareproductsaccesstoand reimbursementandpricingforhealthcareproductsandservicesenvironmentalprotectionandsourcingofrawmaterials johnsonjohnsonannualreport changesintaxlawsandregulationsincreasingauditscrutinybytaxauthoritiesaroundtheworldandexposuresto additionaltaxliabilitiespotentiallyinexcessofreservesand issuanceofneworrevisedaccountingstandardsbythefinancialaccountingstandardsboardandthesecuritiesand exchangecommission risksrelatedtothecompanysstrategicinitiativesandhealthcaremarkettrend pricingpressuresresultingfromtrendstowardhealthcarecostcontainmentincludingthecontinuedconsolidation amonghealthcareproviderstrendstowardmanagedcareandtheshifttowardgovernmentsincreasinglybecomingthe primarypayersofhealthcareexpense restrictedspendingpatternsofindividualinstitutionalandgovernmentalpurchasersofhealthcareproductsand servicesduetoeconomichardshipandbudgetaryconstraint challengestothecompanysabilitytorealizeitsstrategyforgrowthincludingthroughexternallysourcedinnovation suchasdevelopmentcollaborationsstrategicacquisitionslicensingandmarketingagreementsandthepotential heightenedcostsofanysuchexternalarrangementsduetocompetitivepressure thepotentialthattheexpectedstrategicbenefitsandopportunitiesfromanyplannedorcompletedacquisitionor divestiturebythecompanyincludingtheplannedacquisitionofactelionltdmaynotberealizedormaytakelongerto realizethanexpecte thepotentialthattheexpectedbenefitsandopportunitiesrelatedtotheplannedrestructuringactionsinthemedical devicesegmentmaynotberealizedormaytakelongertorealizethanexpectedincludingduetoanyrequire consultationproceduresrelatingtorestructuringofworkforceand marketconditionsandthepossibilitythatthecompanyssharerepurchaseprogrammaybedelayedsuspendedor discontinue risksrelatedtoeconomicconditionsfinancialmarketsandoperatinginternationally impactofinflationandfluctuationsininterestratesandcurrencyexchangeratesandthepotentialeffectofsuch fluctuationsonrevenuesexpensesandresultingmargin potentialchangesinexportimportandtradelawsregulationsandpoliciesoftheusukandothercountrie includinganyincreasedtraderestrictionsandpotentialdrugreimportationlegislation theimpactoninternationaloperationsfromfinancialinstabilityininternationaleconomiessovereignriskpossible impositionofgovernmentalcontrolsandrestrictiveeconomicpoliciesandunstableinternationalgovernmentsandlegal system changestoglobalclimateextremeweatherandnaturaldisastersthatcouldaffectdemandforthecompanysproduct andservicescausedisruptionsinmanufacturinganddistributionnetworksaltertheavailabilityofgoodsandservice withinthesupplychainandaffecttheoveralldesignandintegrityofthecompanysproductsandoperationsand theimpactofarmedconflictsandterroristattacksintheusandotherpartsoftheworldincludingsocialand economicdisruptionsandinstabilityoffinancialandothermarket risksrelatedtosupplychainandoperation difficultiesanddelaysinmanufacturinginternallyorwithinthesupplychainthatmayleadtovoluntaryorinvoluntary businessinterruptionsorshutdownsproductshortageswithdrawalsorsuspensionsofproductsfromthemarketand potentialregulatoryaction interruptionsandbreachesofthecompanysinformationtechnologysystemsandthoseofthecompanysvendor couldresultinreputationalcompetitiveoperationalorotherbusinessharmaswellasfinancialcostsandregulatory actionand relianceonglobalsupplychainsandproductionanddistributionprocessesthatarecomplexandsubjecttoincreasing regulatoryrequirementsthatmayadverselyaffectsupplysourcingandpricingofmaterialsusedinthecompany products investorsalsoshouldcarefullyreadtheriskfactorsdescribedinitemaofthisannualreportonformkfora descriptionofcertainrisksthatcouldamongotherthingscausethecompanysactualresultstodiffermateriallyfrom thoseexpressedinitsforwardlookingstatementsinvestorsshouldunderstandthatitisnotpossibletopredictoridentify allsuchfactorsandshouldnotconsidertherisksdescribedaboveandinitematobeacompletestatementofall potentialrisksanduncertaintiesthecompanydoesnotundertaketopubliclyupdateanyforwardlookingstatementthat maybemadefromtimetotimewhetherasaresultofnewinformationorfutureeventsordevelopment johnsonjohnsonannualreportpart item business general johnsonjohnsonanditssubsidiariesthecompanyhaveapproximatelyemployeesworldwideengagedin theresearchanddevelopmentmanufactureandsaleofabroadrangeofproductsinthehealthcarefieldjohnson johnsonisaholdingcompanywhichhasmorethanoperatingcompaniesconductingbusinessinvirtuallyall countriesoftheworldthecompanysprimaryfocusisproductsrelatedtohumanhealthandwellbeingjohnson johnsonwasincorporatedinthestateofnewjerseyin theexecutivecommitteeofjohnsonjohnsonistheprincipalmanagementgroupresponsibleforthestrategic operationsandallocationoftheresourcesofthecompanythiscommitteeoverseesandcoordinatestheactivitiesofthe companysthreebusinesssegmentsconsumerpharmaceuticalandmedicaldeviceswithinthestrategicparameter providedbythecommitteeseniormanagementgroupsatusandinternationaloperatingcompaniesareeach responsiblefortheirownstrategicplansandthedaytodayoperationsofthosecompanieseachsubsidiarywithinthe businesssegmentsiswithlimitedexceptionsmanagedbyresidentsofthecountrywherelocated segment business thecompanyisorganizedintothreebusinesssegmentsconsumerpharmaceuticalandmedicaldevicesadditional informationrequiredbythisitemisincorporatedhereinbyreferencetothenarrativeandtabulardescriptionsofsegments andoperatingresultsunderitemmanagementsdiscussionandanalysisofresultsofoperationsandfinancial conditionofthisreportandnotesegmentsofbusinessandgeographicareasofthenotestoconsolidate financialstatementsincludedinitemofthisreport consumer theconsumersegmentincludesabroadrangeofproductsusedinthebabycareoralcarebeautypreviouslyreferredto asskincareoverthecounterpharmaceuticalwomenshealthandwoundcaremarketsbabycareincludesthe johnsonslineofproductsoralcareincludesthelisterineproductlinemajorbrandsinbeautyincludethe aveenocleancleardabaojohnsonsadultlepetitemarseillaisneutrogenaroc andogxproductlinesoverthecountermedicinesincludethebroadfamilyoftylenolacetaminophenproduct sudafedcoldfluandallergyproductsbenadrylandzyrtecallergyproductsmotrinibibuprofen productsandthepepcidlineofacidrefluxproductsmajorbrandsinwomenshealthoutsideofnorthamericaare stayfreeandcarefreesanitarypadsandobtamponbrandswoundcarebrandsincludethebandaid brandadhesivebandagesandneosporinfirstaidproductlinestheseproductsaremarketedtothegeneralpublic andsoldbothtoretailoutletsanddistributorsthroughouttheworld pharmaceutical thepharmaceuticalsegmentisfocusedonfivetherapeuticareasimmunologyegrheumatoidarthritisinflammatory boweldiseaseandpsoriasisinfectiousdiseasesandvaccineseghivhepatitisrespiratoryinfectionsand tuberculosisneuroscienceegalzheimersdiseasemooddisordersandschizophreniaoncologyegprostate cancerhematologicmalignanciesandlungcancerandcardiovascularandmetabolicdiseasesegthrombosisand diabetesproductsinthissegmentaredistributeddirectlytoretailerswholesalershospitalsandhealthcare professionalsforprescriptionusekeyproductsinthepharmaceuticalsegmentincluderemicadeinfliximaba treatmentforanumberofimmunemediatedinflammatorydiseasessimponigolimumabasubcutaneoustreatment foradultswithmoderatetosevererheumatoidarthritisactivepsoriaticarthritisactiveankylosingspondylitisand moderatelyactivetoseverelyactiveulcerativecolitissimponiariagolimumabanintravenoustreatmentforadults withmoderatetosevererheumatoidarthritisstelaraustekinumabatreatmentforadultswithmoderatetosevere plaquepsoriasisandactivepsoriaticarthritisandforadultswithmoderatelytoseverelyactivecrohnsdisease prezistadarunaviredurantrilpivirineandprezcobixrezolstadarunavircobicistatantiretroviral medicinesforthetreatmentofhumanimmunodeficiencyvirushivincombinationwithotherantiretroviralproduct johnsonjohnsonannualreport concertamethylphenidatehclextendedreleasetabletsciiatreatmentforattentiondeficithyperactivitydisorder invegapaliperidoneextendedreleasetabletsforthetreatmentofschizophreniaandschizoaffectivedisorder invegasustennaxeplionpaliperidonepalmitateforthetreatmentofschizophreniaandschizoaffective disorderinadultsinvegatrinzatrevictapaliperidonepalmitateforthetreatmentofschizophreniainpatient aftertheyhavebeenadequatelytreatedwithinvegasustennaforatleastfourmonthsrisperdalconsta risperidonelongactinginjectionforthetreatmentofschizophreniaandthemaintenancetreatmentofbipolardisorder inadultsvelcadebortezomibatreatmentformultiplemyelomaandforuseincombinationwithrituximab cyclophosphamidedoxorubicinandprednisoneforthetreatmentofadultpatientswithpreviouslyuntreatedmantlecell lymphomazytigaabirateroneacetateusedincombinationwithprednisoneasatreatmentformetastaticcastration resistantprostatecancerimbruvicaibrutinibanoraloncedailytherapyapprovedforuseintreatingcertainbcell malignanciesorbloodcancersandwaldenstrmsmacroglobulinemiadarzalexdaratumumabforthetreatmentof relapsedrefractorymultiplemyelomaprocritepoetinalfasoldoutsidetheusaseprextostimulateredblood cellproductionxareltorivaroxabananoralanticoagulantforthepreventionofdeepveinthrombosisdvtwhich mayleadtopulmonaryembolismpeinpatientsundergoinghiporkneereplacementsurgerytoreducetheriskofstroke andsystemicembolisminpatientswithnonvalvularatrialfibrillationforthetreatmentandreductionofriskofrecurrenceof dvtandpeinvokanacanagliflozinforthetreatmentofadultswithtypediabetesinvokametvokanamet canagliflozinmetforminhclacombinationtherapyoffixeddosesofcanagliflozinandmetforminhydrochlorideforthe treatmentofadultswithtypediabetesandinvokametxrcanagliflozinmetforminhydrochlorideextendedrelease aoncedailyfixeddosecombinationtherapyofcanagliflozinandmetforminhydrochlorideextendedreleaseforthe treatmentofadultswithtypediabetesmanyofthesemedicinesweredevelopedincollaborationwithstrategicpartner orarelicensedfromothercompaniesandmaintainactivelifecycledevelopmentprogram medicaldevice themedicaldevicessegmentincludesabroadrangeofproductsusedintheorthopaedicsurgerycardiovascular diabetescareandvisioncarefieldstheseproductsaredistributedtowholesalershospitalsandretailersanduse principallyintheprofessionalfieldsbyphysiciansnurseshospitalseyecareprofessionalsandclinicstheyinclude orthopaedicproductsgeneralsurgerybiosurgicalendomechanicalandenergyproductselectrophysiologyproductsto treatcardiovasculardiseasesterilizationanddisinfectionproductstoreducesurgicalinfectiondiabetescareproduct suchasbloodglucosemonitoringandinsulindeliveryproductsanddisposablecontactlense fordetailsregardingacquisitionsanddivestituresseenotetotheconsolidatedfinancialstatementsincludedin item geographic area thebusinessofjohnsonjohnsonisconductedbymorethanoperatingcompanieslocatedincountrie includingtheusinvirtuallyallcountriesthroughouttheworldtheproductsmadeandsoldintheinternationalbusiness includemanyofthosedescribedaboveundersegmentsofbusinessconsumerpharmaceuticalandmedical deviceshowevertheprincipalmarketsproductsandmethodsofdistributionintheinternationalbusinessvarywiththe countryandtheculturetheproductssoldininternationalbusinessincludethosedevelopedintheusandby subsidiariesabroad investmentsandactivitiesinsomecountriesoutsidetheusaresubjecttohigherrisksthancomparableusactivitie becausetheinvestmentandcommercialclimatemaybeinfluencedbyfinancialinstabilityininternationaleconomie restrictiveeconomicpoliciesandpoliticalandlegalsystemuncertaintie raw material rawmaterialsessentialtothecompanysbusinessaregenerallyreadilyavailablefrommultiplesourceswherethereare exceptionsthetemporaryunavailabilityofthoserawmaterialswouldnotlikelyhaveamaterialadverseeffectonthe financialresultsofthecompany patent thecompanyssubsidiarieshavemadeapracticeofobtainingpatentprotectionontheirproductsandprocesseswhere possibletheyownorarelicensedunderasignificantnumberofpatentsintheusandothercountriesrelatingtotheir productsproductusesformulationsandmanufacturingprocesseswhichintheaggregatearebelievedtobeofmaterial johnsonjohnsonannualreportimportancetothecompanyintheoperationofitsbusinessesthecompanyssubsidiariesfacepatentchallengesfrom thirdpartiesincludingchallengesseekingtomanufactureandmarketgenericandbiosimilarversionsofthecompanys keypharmaceuticalproductspriortoexpirationoftheapplicablepatentscoveringthoseproductssignificantlegal proceedingsandclaimsinvolvingthecompanyspatentandotherintellectualpropertyaredescribedinnotelegal proceedingsintellectualpropertyofthenotestoconsolidatedfinancialstatementsincludedinitemofthisreport salesofthecompanyslargestproductremicadeinfliximabaccountedforapproximatelyofthecompany totalrevenuesforfiscalaccordinglythepatentsrelatedtothisproductarebelievedtobematerialtothecompany therearetwosetsofpatentsrelatedspecificallytoremicadethefirstsetofpatentsiscoownedbyjanssen biotechincawhollyownedsubsidiaryofjohnsonjohnsonandnyulangonemedicalcenternyujanssen biotechinchasanexclusivelicensetonyusinterestsinthepatentsthesepatentshaveexpiredinallcountriesoutside theunitedstatesintheunitedstatestheoneremainingpatentwhichexpiresinseptemberstandsrejecte followingreexaminationproceedingsinstitutedbyathirdpartyintheunitedstatespatentandtrademarkofficeuspto thepatenthasalsobeenheldinvalidbythefederaldistrictcourtinthedistrictofmassachusettsthedecisionsbythe usptoandthefederaldistrictcourthavebeenappealedtotheuscourtofappealsforthefederalcircuitthe appealsarepende thesecondsetofpatentsspecificallyrelatedtoremicadewasgrantedtothekennedyinstituteofrheumatologyin europecanadaaustraliaandtheunitedstatesjanssenbiotechinchaslicensesexclusiveforhumanantitnf antibodiesandsemiexclusivefornonhumanantitnfantibodiestothesepatentswhichexpireinoutsideofthe unitedstatesandintheunitedstatescertainofthesepatentshavebeensuccessfullychallengedandinvalidated andothersareunderreviewinvariouspatentofficesaroundtheworldandarealsosubjecttolitigationincanada thecompanydoesnotexpectthatanyextensionswillbeavailablefortheabovedescribedpatentsspecificallyrelatedto remicadeinathirdpartyreceivedapprovalfromthefoodanddrugadministrationforsaleofitsinfliximab biosimilarintheunitedstatesandintroduceditsbiosimilartotheusmarketinlateforamoreextensive descriptionoflegalmattersregardingthepatentsrelatedtoremicadeseenotelegalproceedingsintellectual propertypharmaceuticalremicaderelatedcasesofthenotestoconsolidatedfinancialstatementsincludedin itemofthisreport inadditiontocompetingintheimmunologymarketwithremicadethecompanyiscurrentlymarketingstelara ustekinumabsimponigolimumabandsimponiariagolimumabnextgenerationimmunologyproductswith remainingpatentlivesofuptosevenyear trademark thecompanyssubsidiarieshavemadeapracticeofsellingtheirproductsundertrademarksandofobtainingprotection forthesetrademarksbyallavailablemeansthesetrademarksareprotectedbyregistrationintheusandothercountrie wheresuchproductsaremarketedthecompanyconsidersthesetrademarksintheaggregatetobeofmaterial importanceintheoperationofitsbusinesse seasonality worldwidesalesdonotreflectanysignificantdegreeofseasonalityhoweverspendinghasbeenheavierinthefourth quarterofeachyearthaninotherquartersthisreflectsincreasedspendingdecisionsprincipallyforadvertisingand researchanddevelopmentactivity competition inalloftheirproductlinesthecompanyssubsidiariescompetewithcompaniesbothlocallyandgloballycompetition existsinallproductlineswithoutregardtothenumberandsizeofthecompetingcompaniesinvolvedcompetitionin researchbothinternallyandexternallysourcedinvolvingthedevelopmentandtheimprovementofnewandexiste productsandprocessesisparticularlysignificantthedevelopmentofnewandinnovativeproductsaswellasprotecting theunderlyingintellectualpropertyofthecompanysproductportfolioisimportanttothecompanyssuccessinallarea ofitsbusinessthecompetitiveenvironmentrequiressubstantialinvestmentsincontinuingresearchinadditionthe developmentandmaintenanceofcustomerdemandforthecompanysconsumerproductsinvolvesignificant expendituresforadvertisingandpromotion johnsonjohnsonannualreport research development researchactivitiesrepresentasignificantpartofthecompanysbusinessesresearchanddevelopmentexpenditure relatetotheprocessesofdiscoveringtestinganddevelopingnewproductsimprovingexistingproductsaswella demonstratingproductefficacyandregulatorycompliancepriortolaunchthecompanyremainscommittedtoinveste inresearchanddevelopmentwiththeaimofdeliveringhighqualityandinnovativeproductsworldwidecostsofresearch anddevelopmentactivitiesamountedtobillionbillionandbillionforfiscalyearsand respectivelyresearchfacilitiesarelocatedintheunitedstatesbelgiumbrazilcanadachinafrancegermanyindia israeljapanthenetherlandssingaporeswitzerlandandtheunitedkingdom environment thecompanyissubjecttoavarietyofusandinternationalenvironmentalprotectionmeasuresthecompanybelieve thatitsoperationscomplyinallmaterialrespectswithapplicableenvironmentallawsandregulationsthecompanys compliancewiththeserequirementsdidnotchangeduringthepastyearandisnotexpectedtohaveamaterialeffect uponitscapitalexpenditurescashflowsearningsorcompetitiveposition regulation thecompanysbusinessesaresubjecttovaryingdegreesofgovernmentalregulationinthecountriesinwhichoperation areconductedandthegeneraltrendistowardincreasinglystringentregulationintheusthedrugdeviceandcosmetic industrieshavelongbeensubjecttoregulationbyvariousfederalandstateagenciesprimarilyastoproductsafety efficacymanufacturingadvertisinglabelingandsafetyreportingtheexerciseofbroadregulatorypowersbytheus foodanddrugadministrationthefdacontinuestoresultinincreasesintheamountsoftestinganddocumentation requiredforfdaapprovalofnewdrugsanddevicesandacorrespondingincreaseintheexpenseofproductintroduction similartrendsarealsoevidentinmajormarketsoutsideoftheus thecostsofhumanhealthcarehavebeenandcontinuetobeasubjectofstudyinvestigationandregulationby governmentalagenciesandlegislativebodiesaroundtheworldintheusattentionhasbeenfocusedondrugprice andprofitsandprogramsthatencouragedoctorstowriteprescriptionsforparticulardrugsortorecommenduseor purchaseparticularmedicaldevicespayershavebecomeamorepotentforceinthemarketplaceandincreasedattention isbeingpaidtodrugandmedicaldevicepricingappropriatedrugandmedicaldeviceutilizationandthequalityandcost ofhealthcaregenerally usgovernmentagenciescontinuetoimplementtheextensiverequirementsofthepatientprotectionandaffordablecare acttheacathesehavebothpositiveandnegativeimpactsontheushealthcareindustrywithmuchremaine uncertainastohowvariousprovisionsoftheacaandpotentialmodificationorrepealofacaprovisionswillultimately affecttheindustry theregulatoryagenciesunderwhosepurviewthecompanyoperateshaveadministrativepowersthatmaysubjectitto actionssuchasproductwithdrawalsrecallsseizureofproductsandothercivilandcriminalsanctionsinsomecasesthe companyssubsidiariesmaydeemitadvisabletoinitiateproductrecall inadditionbusinesspracticesinthehealthcareindustryhavecomeunderincreasedscrutinyparticularlyintheunite statesbygovernmentagenciesandstateattorneysgeneralandresultinginvestigationsandprosecutionscarrytheriskof significantcivilandcriminalpenalties furtherthecompanyreliesonglobalsupplychainsandproductionanddistributionprocessesthatarecomplexare subjecttoincreasingregulatoryrequirementsthatmayaffectsourcingsupplyandpricingofmaterialsusedinthe companysproductstheseprocessesalsoaresubjecttolengthyregulatoryapproval available information thecompanysmaincorporatewebsiteaddressiswwwjnjcomcopiesofthecompanysquarterlyreportson formqannualreportonformkandcurrentreportsonformkfiledorfurnishedtotheussecuritiesand exchangecommissionthesecandanyamendmentstotheforegoingwillbeprovidedwithoutchargetoany shareholdersubmittingawrittenrequesttothesecretaryattheprincipalexecutiveofficesofthecompanyorbycalle allofthecompanyssecfilingsarealsoavailableonthecompanyswebsiteatwwwinvestorjnjcom seccfmassoonasreasonablypracticableafterhavingbeenelectronicallyfiledorfurnishedtothesecallsecfiling johnsonjohnsonannualreportarealsoavailableatthesecswebsiteatwwwsecgovinadditionthewrittenchartersoftheauditcommitteethe compensationbenefitscommitteethenominatingcorporategovernancecommitteetheregulatorycompliance governmentaffairscommitteeandthesciencetechnologysustainabilitycommitteeoftheboardofdirectorsandthe companysprinciplesofcorporategovernancecodeofbusinessconductforemployeescodeofbusiness conductethicsformembersoftheboardofdirectorsandexecutiveofficersandothercorporategovernance materialsareavailableatwwwinvestorjnjcomgovcfmonthecompanyswebsiteandwillbeprovidedwithoutchargeto anyshareholdersubmittingawrittenrequestasprovidedabovetheinformationonthecompanyswebsiteisnotand willnotbedeemedapartofthisreportorincorporatedintoanyotherfilingsthecompanymakeswiththesec item risk factor thecompanyfacesanumberofuncertaintiesandrisksthataredifficulttopredictandmanyofwhichareoutsideofthe companyscontrolinadditiontotheotherinformationinthisreportandthecompanysotherfilingswiththesec investorsshouldconsidercarefullythefactorssetforthbelowinvestorsshouldbeawarethatitisnotpossibletopredict oridentifyallsuchfactorsandthatthefollowingisnotmeanttobeacompletediscussionofallpotentialrisksor uncertaintiesifknownorunknownrisksoruncertaintiesmaterializethecompanysbusinessresultsofoperationsor financialconditioncouldbeadverselyaffectedpotentiallyinamaterialway oneofthecompanyskeyproductsremicadeinfliximabisexperiencingbiosimilarcompetitionwhich willresultinareductioninussalesofremicade thecompanyhasexperiencedsignificantchallengestopatentscoveringitslargestproductremicadeinfliximab accountingforapproximatelyofthecompanystotalrevenuesforfiscalandcontinuestoassertcertain patentsrelatedtotheproductinaprilthefdaapprovedforsaleintheunitedstatesaninfliximabbiosimilartobe marketedbyasubsidiaryofpfizerincinoctoberthenoticeoflaunchperiodundertheusbiologicsprice competitionandinnovationactthebpciapassedandinnovemberpfizerbeganshipmentofaninfliximab biosimilartowholesalersintheunitedstatessalesofaninfliximabbiosimilarintheusmarketwillresultinareductionin ussalesofremicade globalsalesinthecompanyspharmaceuticalandmedicaldevicessegmentsmaybenegativelyimpacted byhealthcarereformsandincreasingpricingpressures salesofthecompanyspharmaceuticalandmedicaldeviceproductsaresignificantlyaffectedbyreimbursementsby thirdpartypayerssuchasgovernmenthealthcareprogramsprivateinsuranceplansandmanagedcareorganizationsas partofvariouseffortstocontainhealthcarecoststhesepayersareputtingdownwardpressureonpricesatwhich productswillbereimbursedintheunitedstatesincreasedpurchasingpowerofentitiesthatnegotiateonbehalfof medicaremedicaidandprivatesectorbeneficiariesinpartduetocontinuedconsolidationamonghealthcareprovider couldresultinfurtherpricingpressuresoutsidetheunitedstatesnumerousmajormarketsincludingtheeuandjapan havepervasivegovernmentinvolvementinfundinghealthcareandinthatregarddirectlyorindirectlyimposeprice controlslimitaccesstoorreimbursementforthecompanysproductsorreducethevalueofitsintellectualproperty protection thecompanyissubjecttosignificantlegalproceedingsthatcanresultinsignificantexpensesfinesand reputationaldamage intheordinarycourseofbusinessjohnsonjohnsonanditssubsidiariesaresubjecttonumerousclaimsandlawsuit involvingvariousissuessuchaspatentdisputesproductliabilityandclaimsthattheirproductsalesmarketingandprice practicesviolatevariousantitrustunfairtradepracticesandorconsumerprotectionlawsthemostsignificantofthese proceedingsaredescribedinnotelegalproceedingsundernotestotheconsolidatedfinancialstatement includedinitemofthisreportwhilethecompanybelievesithassubstantialdefensesinthesemattersitisnotfeasible topredicttheultimateoutcomeoflitigationthecompanycouldinthefutureberequiredtopaysignificantamountsasa resultofsettlementsorjudgmentsinthesematterspotentiallyinexcessofaccrualstheresolutionoforincreasein accrualsforoneormoreofthesemattersinanyreportingperiodcouldhaveamaterialadverseeffectonthecompany resultsofoperationsandcashflowsforthatperiodfurthermoreasaresultofcostandavailabilityfactorseffective novemberthecompanyceasedpurchasingthirdpartyproductliabilityinsurance productreliabilitysafetyandeffectivenessconcernscanhavesignificantnegativeimpactsonsalesand resultsofoperationsleadtolitigationandcausereputationaldamage concernsaboutproductsafetywhetherraisedinternallyorbyregulatorsorconsumeradvocatesandwhetherornot basedonscientificevidencecanresultinsafetyalertsproductrecallsgovernmentalinvestigationsregulatoryactionon johnsonjohnsonannualreport thepartofthefdaoritscounterpartinothercountriesprivateclaimsandlawsuitspaymentoffinesandsettlements decliningsalesandreputationaldamagethesecircumstancescanalsoresultindamagetobrandimagebrandequity andconsumertrustinthecompanysproductsproductrecallshaveinthepastandcouldinthefutureprompt governmentinvestigationsandinspectionstheshutdownofmanufacturingfacilitiescontinuedproductshortagesand relatedsalesdeclinessignificantremediationcostsreputationaldamagepossiblecivilpenaltiesandcriminalprosecution changesintaxlawsorexposurestoadditionaltaxliabilitiescouldnegativelyimpactthecompanys operatingresult changesintaxlawsorregulationsincludingtaxreformproposalsintheusbelgiumandswitzerlandcouldnegatively impactthecompanyseffectivetaxrateandresultsofoperationsachangeinstatutorytaxratemayresultinthe revaluationofthecompanysdeferredtaxassetsandliabilitiesrelatedtotherelevantjurisdictionintheperiodinwhichthe newtaxlawisenactedpotentiallyresultinginamaterialexpenseorbenefitrecordedtothecompanysconsolidate statementofearningsforthatperiodforadiscussionofrisksofchangesintaxratesinothercountriesincluding belgiumpleaseseemanagementsdiscussionandanalysisofresultsofoperationsandfinancialconditionother informationeconomicandmarketfactorsinitemofthisreport thecompanyconductsbusinessandfilestaxreturnsinnumerouscountriesandcurrentlyhastaxauditsinprogresswith manytaxauthoritiesinconnectionwiththeorganizationforeconomiccooperationanddevelopmentbaseerosionand profitshiftingbepsprojectstartingincompaniesarerequiredtodisclosemoreinformationtotaxauthoritieson operationsaroundtheworldwhichmayleadtogreaterauditscrutinyofprofitsearnedinothercountriesthecompany regularlyassessesthelikelyoutcomesofitstaxauditstodeterminetheappropriatenessofitstaxreserveshoweverany taxauthoritycouldtakeapositionontaxtreatmentthatiscontrarytothecompanysexpectationswhichcouldresultintax liabilitiesinexcessofreserve thecompanymaynotbeabletosuccessfullysecureanddefendintellectualpropertyrightsessentialto thecompanysbusinesse thecompanyownsorlicensesasignificantnumberofpatentsandotherproprietaryrightsdeterminedbypatentoffice courtsandlawmakersinvariouscountriesrelatingtoitsproductsandmanufacturingprocessestheserightsareessential tothecompanysbusinessesandmateriallyimportanttothecompanysresultsofoperationspublicpolicybothwithin andoutsidetheushasbecomeincreasinglyunfavorabletowardintellectualpropertyrightsthecompanycannotbe certainthatitwillobtainadequatepatentprotectionfornewproductsandtechnologiesintheusandotherimportant marketsorthatsuchprotectionsoncegrantedwilllastaslongasoriginallyanticipate competitorsroutinelychallengethevalidityorextentofthecompanysownedorlicensedpatentsandproprietaryright throughlitigationinterferencesoppositionsandotherproceedingstheseproceedingsabsorbresourcesandcanbe protractedaswellasunpredictableinadditionchallengesthatthecompanysproductsinfringethepatentsofthird partiescouldresultintheneedtopaypastdamagesandfutureroyaltiesandadverselyaffectthecompetitivepositionand salesoftheproductsinquestion thecompanyhasfacedincreasingpatentchallengesfromthirdpartiesseekingtomanufactureandmarketgenericand biosimilarversionsofthecompanyskeypharmaceuticalproductspriortoexpirationoftheapplicablepatentscovering thoseproductsintheunitedstatesmanufacturersofgenericversionsofinnovativehumanpharmaceuticalproductsmay challengethevalidityorclaimnoninfringementofinnovatorproductsthroughtheabbreviatednewdrugapplicationor andaprocesswiththefdathebpciaenactedinwhichcreatedanewregulatorypathwayfortheapprovalby thefdaofbiosimilaralternativestoinnovatordevelopedbiologicalproductsalsocreatedmechanismsforbiosimilar applicantstochallengethepatentsontheinnovatorbiologicstheinterpartesreviewiprprocesswiththeuspto createdundertheamericainventsactisalsobeingusedbycompetitorstochallengepatentsheldbythe companyssubsidiariesforexampleakeypatentforzytigaiscurrentlysubjecttopatentlitigationandseveralipr proceedingsbroughtbygenericcompaniesseekingtoinvalidatethepatent intheeventthecompanyisnotsuccessfulindefendingitspatentsagainstsuchchallengesorupontheatrisklaunch despitependingpatentinfringementlitigationbythegenericorbiosimilarfirmofitsproductthecompanycanlosea majorportionofrevenuesforthereferencedproductinaveryshortperiodoftimecurrentlegalproceedingsinvolvingthe companyspatentsandotherintellectualpropertyrightsaredescribedinnotelegalproceedingsintellectual propertyofthenotestotheconsolidatedfinancialstatementsincludedinitemofthisreport johnsonjohnsonannualreportthecompanysbusinessesoperateinhighlycompetitiveproductmarketsandcompetitivepressurescould adverselyaffectthecompanysearning thecompanyfacessubstantialcompetitioninallthreeoperatingsegmentsandinallgeographicmarketsthecompanys businessescompetewithcompaniesofallsizesonthebasisofcosteffectivenesstechnologicalinnovationsintellectual propertyrightsproductperformancerealorperceivedproductadvantagespricingandavailabilityandrateof reimbursementthecompanyalsocompeteswithothermarketparticipantsinsecuringrightstoacquisition collaborationsandlicensingagreementswiththirdpartiescompetitionforrightstoproductcandidatesandtechnologie mayresultinsignificantinvestmentandacquisitioncostsandonerousagreementtermsforthecompanycompetitor developmentofmoreeffectiveorlesscostlyproductsandortheirabilitytosecurepatentandotherintellectualproperty rightsandsuccessfullymarketproductsaheadofuscouldnegativelyimpactsalesofthecompanysexistingproductsas wellasitsabilitytobringnewproductstomarketdespitesignificantpriorinvestmentintherelatedproductdevelopment forthecompanyspharmaceuticalbusinesseslossofpatentexclusivityforaproductoftenisfollowedbyasubstantial reductioninsalesascompetitorsgainregulatoryapprovalforgenericandothercompetingproductsandenterthemarket similarcompetitioncanbetriggeredbythelossofexclusivityforabiologicalproductforthecompanysmedicaldevice businessestechnologicalinnovationproductqualityreputationandcustomerserviceareespeciallyimportantto competitivenessdevelopmentbyothercompaniesofneworimprovedproductsprocessesandtechnologiescould threatentomakethecompanysproductsortechnologieslessdesirablelesseconomicalorobsoletethecompany consumerbusinessesfaceintensecompetitionfromotherbrandedproductsandretailersprivatelabelbrandsifthe companyfailstosufficientlydifferentiateandmarketitsbrandnameconsumerproductsthiscouldadverselyaffect revenuesandprofitabilityofthoseproduct significantchallengesordelaysinthecompanysinnovationanddevelopmentofnewproduct technologiesandindicationscouldhaveanadverseimpactonthecompanyslongtermsuccess thecompanyscontinuedgrowthandsuccessdependsonitsabilitytoinnovateanddevelopnewanddifferentiate productsandservicesthataddresstheevolvinghealthcareneedsofpatientsprovidersandconsumersdevelopmentof successfulproductsandtechnologiesisalsonecessarytooffsetrevenuelosseswhenthecompanysexistingproduct losemarketshareduetovariousfactorssuchascompetitionandlossofpatentexclusivitynewproductsintroduce withinthepastfiveyearsaccountedforapproximatelyofsalesthecompanycannotbecertainwhenor whetheritwillbeabletodeveloplicenseorotherwiseacquirecompaniesproductsandtechnologieswhetherparticular productcandidateswillbegrantedregulatoryapprovalandifapprovedwhethertheproductswillbecommercially successful thecompanypursuesproductdevelopmentthroughinternalresearchanddevelopmentaswellasthroughcollaboration acquisitionsjointventuresandlicensingorotherarrangementswiththirdpartiesinallofthesecontextsdevelopingnew productsparticularlypharmaceuticalandbiotechnologyproductsandmedicaldevicesrequiressignificantinvestmentof resourcesovermanyyearsonlyaveryfewbiopharmaceuticalresearchanddevelopmentprogramsresultincommercially viableproductstheprocessdependsonmanyfactorsincludingtheabilitytodiscernpatientsandhealthcareproviders futureneedsdeveloppromisingnewcompoundsstrategiesandtechnologiesachievesuccessfulclinicaltrialresults secureeffectiveintellectualpropertyprotectionobtainregulatoryapprovalsonatimelybasisandifandwhentheyreach themarketsuccessfullydifferentiatethecompanysproductsfromcompetingproductsandapproachestotreatment newproductsorenhancementstoexistingproductsmaynotbeacceptedquicklyorsignificantlyinthemarketplacedue toproductandpricecompetitionchangesincustomerpreferencesorhealthcarepurchasingpatternsresistanceby healthcareprovidersoruncertaintyoverthirdpartyreimbursementevenfollowinginitialregulatoryapprovalthesuccess ofaproductcanbeadverselyimpactedbysafetyandefficacyfindingsinlargerrealworldpatientpopulationsaswellas marketentryofcompetitiveproduct thecompanyfacesincreasingregulatoryscrutinywhichimposessignificantcompliancecostsandexpose thecompanytogovernmentinvestigationslegalactionsandpenaltie likeothercompaniesinthehealthcareindustrythecompanyissubjecttoextensiveregulationinvestigationsandlegal actionbynationalstateandlocalgovernmentagenciesintheunitedstatesandothercountriesinwhichtheyoperate regulatoryissuesregardingcompliancewithgoodmanufacturingpracticescgmpandcomparablequalityregulation inforeigncountriesbymanufacturersofdrugsdevicesandconsumerproductscanleadtofinesandpenaltiesproduct recallsproductshortagesinterruptionsinproductiondelaysinnewproductapprovalsandlitigationinadditionthe marketingpricingandsaleofthecompanysproductsaresubjecttoregulationinvestigationsandlegalactionsinclude underthefederalfooddrugandcosmeticactthemedicaidrebateprogramfederalandstatefalseclaimsactsstate unfairtradepracticesactsandconsumerprotectionlawsincreasedscrutinyofhealthcareindustrybusinesspracticesin johnsonjohnsonannualreport recentyearsbygovernmentagenciesandstateattorneysgeneralintheusandanyresultinginvestigationsand prosecutionscarryriskofsignificantcivilandcriminalpenaltiesincludingbutnotlimitedtodebarmentfromparticipation ingovernmenthealthcareprogramsanysuchdebarmentcouldhaveamaterialadverseeffectonthecompanysbusiness andresultsofoperationsthemostsignificantcurrentinvestigationsandlitigationbroughtbygovernmentagenciesare describedinnotelegalproceedingsgovernmentproceedingsundernotestotheconsolidatedfinancial statementsincludedinitemofthisreport thecompanyfacesavarietyofrisksassociatedwithconductingbusinessinternationally thecompanysextensiveoperationsandbusinessactivityoutsidetheusareaccompaniedbycertainfinancial economicandpoliticalrisksincludingthoselistedbelow foreigncurrencyexchangeinfiscalapproximatelyofthecompanyssalesoccurredoutsideoftheuswith approximatelyineuropeinthewesternhemisphereexcludingtheusandintheasiapacificandafrica regionchangesinnonuscurrenciesrelativetotheusdollarimpactthecompanysrevenuesandexpenseswhile thecompanyusesfinancialinstrumentstomitigatetheimpactoffluctuationsincurrencyexchangeratesonitscashflow unhedgedexposurescontinuetobesubjecttocurrencyfluctuationsinadditiontheweakeningorstrengtheningofthe usdollarmayresultinsignificantfavorableorunfavorabletranslationeffectswhentheoperatingresultsofthe companysnonusbusinessactivityaretranslatedintousdollar inflationandcurrencydevaluationrisksthecompanyfaceschallengesinmaintainingprofitabilityofoperationsin economiesexperiencinghighinflationratesthecompanyhasaccountedforoperationsinvenezuelaashighly inflationaryasthepriorthreeyearcumulativeinflationratesurpassedwhilethecompanystrivestomaintainprofit marginsintheseareasthroughcostreductionprogramsproductivityimprovementsandperiodicpriceincreasesitmight experienceoperatinglossesasaresultofcontinuedinflationinadditiontheimpactofcurrencydevaluationsincountrie experiencinghighinflationratesorsignificantcurrencyexchangefluctuationscouldnegativelyimpactthecompanys operatingresult illegalimportationofpharmaceuticalproductstheillegalimportationofpharmaceuticalproductsfromcountrieswhere governmentpricecontrolsorothermarketdynamicsresultinlowerpricesmayadverselyaffectthecompanyssalesand profitabilityintheusandothercountriesinwhichthecompanyoperateswiththeexceptionoflimitedquantitiesof prescriptiondrugsforpersonaluseforeignimportsofpharmaceuticalproductsareillegalundercurrentuslaw howeverthevolumeofillegalimportscontinuestoriseastheabilityofpatientsandothercustomerstoobtainthelower pricedimportshasgrownsignificantly antibriberyandotherregulationsthecompanyissubjecttovariousfederalandforeignlawsthatgovernit internationalbusinesspracticeswithrespecttopaymentstogovernmentofficialsthoselawsincludetheusforeign corruptpracticesactfcpawhichprohibitsuspubliclytradedcompaniesfrompromisingofferingorgivinganythe ofvaluetoforeignofficialswiththecorruptintentofinfluencingtheforeignofficialforthepurposeofhelpingthecompany obtainorretainbusinessorgainanyimproperadvantagethecompanysbusinessisheavilyregulatedandtherefore involvessignificantinteractionwithforeignofficialsalsoinmanycountriesoutsidetheusthehealthcareproviderswho prescribehumanpharmaceuticalsareemployedbythegovernmentandthepurchasersofhumanpharmaceuticalsare governmententitiesthereforethecompanysinteractionswiththeseprescribersandpurchasersaresubjecttoregulation underthefcpainadditiontotheusapplicationandenforcementofthefcpavariousjurisdictionsinwhichthe companyoperateshavelawsandregulationsincludingtheukbriberyactaimedatpreventingandpenalize corruptandanticompetitivebehaviorenforcementactivitiesundertheselawscouldsubjectthecompanytoadditional administrativeandlegalproceedingsandactionswhichcouldincludeclaimsforcivilpenaltiescriminalsanctionsand administrativeremediesincludingexclusionfromhealthcareprograms otherlegalsocialandpoliticalrisksotherrisksinherentinconductingbusinessgloballyinclude protectiveeconomicpoliciestakenbygovernmentssuchastradeprotectionmeasuresandimportexportlicensing requirement compliancewithlocalregulationsandlawsincludinginsomecountriesregulatoryrequirementsrestrictingthe companysabilitytomanufactureorsellitsproductsintherelevantmarket diminishedprotectionofintellectualpropertyandcontractualrightsincertainjurisdiction potentialnationalizationorexpropriationofthecompanysforeignassetsand disruptionstomarketsduetowararmedconflictterrorismsocialupheavalsorpandemic johnsonjohnsonannualreportinterruptionsanddelaysinmanufacturingoperationscouldadverselyaffectthecompanysbusinesssale andreputation thecompanysmanufactureofproductsrequiresthetimelydeliveryofsufficientamountsofcomplexhighquality componentsandmaterialsthesesubsidiariesoperatemanufacturingfacilitiesaswellassourcingfromhundredsof suppliersaroundtheworldthecompanyhasinthepastandmayinthefuturefaceunanticipatedinterruptionsand delaysinmanufacturingthroughitsinternalorexternalsupplychainmanufacturingdisruptionscanoccurformanyreason includingregulatoryactionproductionqualitydeviationsorsafetyissueslabordisputessitespecificincidentssucha firesnaturaldisastersrawmaterialshortagespoliticalunrestandterroristattackssuchdelaysanddifficultiesin manufacturingcanresultinproductshortagesdeclinesinsalesandreputationalimpactaswellassignificantremediation andrelatedcostsassociatedwithaddressingtheshortage aninformationsecurityincidentincludingacybersecuritybreachcouldhaveanegativeimpacttothe companysbusinessorreputation tomeetbusinessobjectivesthecompanyreliesonbothinternalinformationtechnologyitsystemsandnetworksand thoseofthirdpartiesandtheirvendorstoprocessandstoresensitivedataincludingconfidentialresearchbusiness plansfinancialinformationintellectualpropertyandpersonaldatatheextensiveinformationsecurityandcybersecurity threatswhichaffectcompaniesgloballyposearisktothesecurityandavailabilityoftheseitsystemsandnetworksand theconfidentialityintegrityandavailabilityofthecompanyssensitivedatathecompanycontinuallyassessesthese threatsandmakesinvestmentstoincreaseinternalprotectiondetectionandresponsecapabilitiesaswellasensurethe companysthirdpartyprovidershaverequiredcapabilitiesandcontrolstoaddressthisrisktodatethecompanyha notexperiencedanymaterialimpacttoourbusinessoroperationsresultingfrominformationorcybersecurityattacks howeverbecauseofthefrequentlychangingattacktechniquesalongwiththeincreasedvolumeandsophisticationofthe attacksthereisthepotentialforthecompanytobeadverselyimpactedthisimpactcouldresultinreputational competitiveoperationalorotherbusinessharmaswellasfinancialcostsandregulatoryaction item b unresolved staff comment notapplicable item property thecompanyssubsidiariesoperatemanufacturingfacilitiesoccupyingapproximatelymillionsquarefeetoffloor spacethemanufacturingfacilitiesareusedbytheindustrysegmentsofthecompanysbusinessapproximatelyas follow squarefeet segment inthousand consumer pharmaceutical medicaldevice worldwidetotal withintheunitedstatessevenfacilitiesareusedbytheconsumersegmentsevenbythepharmaceuticalsegmentand bythemedicaldevicessegmentoutsideoftheunitedstatesfacilitiesareusedbytheconsumersegmentby thepharmaceuticalsegmentandbythemedicaldevicessegment thelocationsofthemanufacturingfacilitiesbymajorgeographicareasoftheworldareasfollow squarefeet geographicarea numberoffacilitie inthousand unitedstate europe westernhemisphereexcludingus africaasiaandpacific worldwidetotal johnsonjohnsonannualreport inadditiontothemanufacturingfacilitiesdiscussedabovethecompanymaintainsnumerousofficeandwarehouse facilitiesthroughouttheworldresearchfacilitiesarealsodiscussedinitemofthisreportunderbusinessresearch anddevelopment thecompanyssubsidiariesgenerallyseektoowntheirmanufacturingfacilitiesalthoughsomeprincipallyinnonus locationsareleasedofficeandwarehousefacilitiesareoftenleasedthecompanyalsoengagescontract manufacturer thecompanyiscommittedtomaintainingallofitspropertiesingoodoperatingconditionandrepairandthefacilitiesare wellutilize mcneilppcincnowjohnsonjohnsonconsumerincmcneilppccontinuestooperateunderaconsentdecree signedinwiththefdawhichgovernscertainmcneilconsumerhealthcaremanufacturingoperationsandrequire mcneilppctoremediatethefacilitiesitoperatesinlancasterpennsylvaniafortwashingtonpennsylvaniaandlas piedraspuertoricotheconsentdecreethefortwashingtonfacilitywasvoluntarilyshutdowninapriland subsequentlymanyproductsweretransferredtoothermanufacturingsitesandsuccessfullyreintroducedtothemarket aftermcneilppcsuccessfullycompletedallrequirementscontainedintheconsentdecreeworkplansforthe lancasterandlaspiedrasmanufacturingsitesandcompletedthestepsrequiredforthirdpartycertificationofthefort washingtonplantathirdpartycgmpexpertsubmittedwrittencertificationstothefdaforallthreemanufacturingsite followingfdainspectionsinmcneilppcreceivednotificationsfromthefdathatallthreemanufacturingfacilitie areinconformitywithapplicablelawsandregulationscommercialproductioninfortwashingtonstartedasof september undertheconsentdecreeafterreceivingnoticefromthefdaofbeingincompliancewithapplicablelawsand regulationseachofthethreefacilitiesissubjecttoafiveyearauditperiodbyathirdpartycgmpexpertthusathird partyexpertwillcontinuetoreassessthesitesatvarioustimesforatleastfiveyearsadiscussionoflegalproceedings relatedtothismattercanbefoundinnotelegalproceedingsgovernmentproceedingsmcneilconsumer healthcareofthenotestoconsolidatedfinancialstatementsincludedinitemofthisreport forinformationregardingleaseobligationsseenoterentalexpenseandleasecommitmentsofthenotesto consolidatedfinancialstatementsincludedinitemofthisreportsegmentinformationonadditionstopropertyplant andequipmentiscontainedinnotesegmentsofbusinessandgeographicareasofthenotestoconsolidate financialstatementsincludedinitemofthisreport item legal proceeding theinformationcalledforbythisitemisincorporatedhereinbyreferencetotheinformationsetforthinnotelegal proceedingsofthenotestoconsolidatedfinancialstatementsincludedinitemofthisreport inadditionjohnsonjohnsonanditssubsidiariesarefromtimetotimepartytogovernmentinvestigationsinspectionsor otherproceedingsrelatingtoenvironmentalmattersincludingtheircompliancewithapplicableenvironmentallaw item safety disclosure notapplicable johnsonjohnsonannualreportexecutive officer registrant listedbelowaretheexecutiveofficersofthecompanytherearenofamilyrelationshipsbetweenanyoftheexecutive officersandthereisnoarrangementorunderstandingbetweenanyexecutiveofficerandanyotherpersonpursuantto whichtheexecutiveofficerwasselectedattheannualmeetingoftheboardofdirectorstheexecutiveofficersare electedbytheboardtoholdofficeforoneyearanduntiltheirrespectivesuccessorsareelectedandqualifiedoruntil earlierresignationorremoval informationwithregardtothedirectorsofthecompanyincludinginformationforalexgorskyisincorporatedhereinby referencetothematerialcaptioneditemelectionofdirectorsintheproxystatement age position dominicjcaruso memberexecutivecommitteeexecutivevicepresidentchieffinancial officera joaquinduato memberexecutivecommitteeexecutivevicepresidentworldwidechairman pharmaceuticalsb petermfasolo memberexecutivecommitteeexecutivevicepresidentchiefhuman resourcesofficerc alexgorsky chairmanboardofdirectorschairmanexecutivecommitteechiefexecutive officer jorgemesquita memberexecutivecommitteeexecutivevicepresidentworldwidechairman consumerd sandraepeterson memberexecutivecommitteeexecutivevicepresidentgroupworldwide chairmane garypruden memberexecutivecommitteeexecutivevicepresidentworldwidechairman medicaldevicesf paulusstoffel memberexecutivecommitteeexecutivevicepresidentchiefscientific officerg michaelhullmann memberexecutivecommitteeexecutivevicepresidentgeneralcounselh mrdjcarusojoinedthecompanyinwhenthecompanyacquiredcentocorincatthetimeofthatacquisitionhehadbeen seniorvicepresidentfinanceofcentocormrcarusowasnamedvicepresidentfinanceoforthomcneilpharmaceuticalinca subsidiaryofthecompanyinandvicepresidentgroupfinanceofthecompanysmedicaldevicesanddiagnosticsgroupin inmrcarusowasnamedvicepresidentofthecompanysgroupfinanceorganizationmrcarusobecameamember oftheexecutivecommitteeandvicepresidentfinanceandchieffinancialofficerininaprilhewasnamedexecutive vicepresidentchieffinancialofficer b mrjduatojoinedthecompanyinwithjanssenfarmaceuticasaspainandinbecamemanagingdirectorof janssencilagspaitalyinheledorthobiotecheuropebeforerelocatingtotheunitedstatesintoserveasvice presidentandinpresidentoforthobiotechincinhewasnamedcompanygroupchairmanorthoclinical diagnosticsandincompanygroupchairmanpharmaceuticalswhereheoversawpharmaceuticalproductlaunchesandthe majortherapeuticfranchisesincanadatheunitedstatesandlatinamericainhewasnamedworldwidechairman pharmaceuticalsresponsiblefortheglobalcommercialbusinessesofthejanssenpharmaceuticalcompaniesincludingfunctional supportfortheresearchdevelopmentorganizationsinaprilmrduatobecameamemberoftheexecutivecommitteeand wasnamedexecutivevicepresidentworldwidechairmanpharmaceutical c drpmfasolojoinedthecompanyinasvicepresidentworldwidehumanresourcesforcordiscorporationasubsidiary ofthecompanyhewasthennamedvicepresidentglobaltalentmanagementforthecompanyheleftjohnsonjohnsonin tojoinkohlbergkravisrobertscoaschieftalentofficerdrfasoloreturnedtothecompanyinasthevice presidentglobalhumanresourcesandinhebecameamemberoftheexecutivecommitteeinaprilhewasname executivevicepresidentchiefhumanresourcesofficer mrjmesquitajoinedthecompanyinasworldwidechairmanconsumerpriortojoiningthecompanyheservedinvarious marketingandleadershipcapacitiesacrosslatinamericaincludingrolesinoralcareandbeautyattheproctergamble companyfromtoinaprilmrmesquitabecameamemberoftheexecutivecommitteeandwasnameda executivevicepresidentworldwidechairmanconsumer e mssepetersonjoinedthecompanyinasgroupworldwidechairmanandamemberoftheexecutivecommitteeshe overseestheconsumerandconsumermedicaldevicebusinessesthecompanysoperatinginfrastructuresupplychain informationtechnologyglobalserviceshealthwellnessglobaldesignandhealthtechnologypriortojoiningthecompany mspetersonwaschairmanandchiefexecutiveofficerofbayercropscienceagingermanypreviouslyservingaspresidentand chiefexecutiveofficerofbayermedicalcareandpresidentofbayerhealthcareagsdiabetescaredivisionbeforejoiningbayer johnsonjohnsonannualreport inmspetersonheldanumberofleadershiprolesatmedcohealthsolutionspreviouslyknownasmerckmedcoinapril mspetersonwasnamedexecutivevicepresidentgroupworldwidechairmanofjohnsonjohnsoneffectivejune mspetersonwillassumeleadershipofthehospitalmedicaldevicebusinessinadditiontohercurrentresponsibilities f mrgprudenjoinedthecompanyinwithjanssenpharmaceuticaincandheldanumberofseniorpositionsinsale marketingandstrategicaccountmanagementinaprilhebecamepresidentofjanssenorthoincincanadainjanuary mrprudenwasappointedworldwidepresidentethiconproductsandinbecamecompanygroupchairmanethicon inhewasnamedworldwidechairmanglobalsurgerygroupandinworldwidechairmanmedicaldevicesinapril mrprudenbecameamemberoftheexecutivecommitteeandwasnamedexecutivevicepresidentworldwidechairman medicaldevicesmrprudenhasannouncedhisintentiontoretirefromthecompanyeffectivejune g drpstoffelsjoinedthecompanyinwiththeacquisitionoftibotecvirconvwherehewaschiefexecutiveofficerofvirco nvandchairmanoftibotecnvinhewasappointedcompanygroupchairmanglobalvirologyinheassumedthe roleofcompanygroupchairmanpharmaceuticalswithresponsibilityforworldwideresearchanddevelopmentforthecentral nervoussystemandinternalmedicinefranchisesdrstoffelswasappointedglobalheadresearchdevelopment pharmaceuticalsinandinbecameworldwidechairmanpharmaceuticalswithresponsibilityforthecompany therapeuticpipelinethroughglobalresearchanddevelopmentandstrategicbusinessdevelopmentindrstoffelswasalso appointedchiefscientificofficerwithresponsibilityforenterprisewideinnovationandproductsafetyandamemberofthe executivecommitteeinaprildrstoffelswasnamedexecutivevicepresidentchiefscientificofficer h mrmhullmannjoinedthecompanyinasacorporateattorneyinthelawdepartmenthewasappointedcorporate secretaryinandservedinthatroleuntilduringthattimehealsoheldvariousmanagementpositionsinthelaw departmentinhewasnamedgeneralcounselmedicaldevicesanddiagnosticsandwasappointedvicepresidentgeneral counselandamemberoftheexecutivecommitteeininaprilmrullmannwasnamedexecutivevicepresident generalcounsel johnsonjohnsonannualreportpart ii item market registrant common equity relate stockholder matter issuer purchase equity security asoffebruarytherewererecordholdersofcommonstockofthecompanyadditionalinformation calledforbythisitemisincorporatedhereinbyreferencetothefollowingsectionsofthisreportitemmanagement discussionandanalysisofresultsofoperationsandfinancialconditionliquidityandcapitalresourcesdividend andotherinformationcommonstockmarketpricesnotecommonstockstockoptionplansandstock compensationagreementsofthenotestoconsolidatedfinancialstatementsincludedinitemanditemsecurity ownershipofcertainbeneficialownersandmanagementandrelatedstockholdermattersequitycompensationplan information issuer purchase equity security onoctoberthecompanyannouncedthatitsboardofdirectorsapprovedasharerepurchaseprogram authorizingthecompanytopurchaseuptobillionofthecompanyscommonstocksharerepurchasestakeplace ontheopenmarketfromtimetotimebasedonmarketconditionstherepurchaseprogramhasnotimelimitandmaybe delayedorsuspendedforperiodsordiscontinuedatanytime thefollowingtableprovidesinformationwithrespecttocommonstockpurchasesbythecompanyduringthefiscalfourth quarterofcommonstockpurchasesontheopenmarketaremadeaspartofasystematicplantomeettheneed ofthecompanyscompensationprogramstherepurchasesbelowalsoincludethestockforstockoptionexercisesthat settledinthefiscalfourthquarter totalnumberof maximumnumberor sharesorunit approximatedollar purchasedaspart valueofsharesorunit totalnumber ofpublicly thatmayyetbe ofshare avgprice announcedplans purchasedundertheplans period purchase paidpershare orprograms orprograms octoberthrough october octoberthrough november novemberthrough january total duringthefiscalfourthquarterofthecompanyrepurchasedanaggregateofsharesofjohnsonjohnson commonstockinopenmarkettransactionsofwhichshareswerepurchasedpursuanttotherepurchaseprogramthat waspubliclyannouncedonoctoberandofwhichshareswerepurchasedinopenmarkettransactionsaspart ofasystematicplantomeettheneedsofthecompanyscompensationprogram asofjanuaryanaggregateofshareswerepurchasedforatotalofbillionsincetheinceptionofthe repurchaseprogramannouncedonoctober asofjanuarythemaximumnumberofsharesthatmayyetbepurchasedundertheplanisbasedontheclose priceofjohnsonjohnsoncommonstockonthenewyorkstockexchangeondecemberofpershare johnsonjohnsonannualreport item select financial datum summary operation statistical datum dollarsinmillionsexcept pershareamount salestocustomersus salestocustomer international totalsale costofproductssold sellingmarketingand administrativeexpense researchanddevelopment expense inprocessresearchand development interestincome interestexpensenetof portioncapitalize otherincomeexpensenet restructure earningsbeforeprovisionfor taxesonincome provisionfortaxesonincome netearning addnetlossattributableto noncontrollinginterest netearningsattributable tojohnsonjohnson percentofsalestocustomer dilutednetearningspershare ofcommonstock percentreturnonaverage shareholdersequity percentincrease decreaseoverprevious year salestocustomer dilutednetearningspershare supplementarybalance sheetdata propertyplantand equipmentnet additionstopropertyplant andequipment totalasset longtermdebt operatingcashflow commonstock information dividendspaidpershare shareholdersequityper share marketpricepershareyear endclose averagesharesoutstande millions basic diluted employeesthousand attributabletojohnsonjohnson amountshavebeenreclassifiedtoconformtocurrentyearpresentation johnsonjohnsonannualreportitem management discussion analysis result operation financial condition organization business segment descriptionofthecompanyandbusinesssegment johnsonjohnsonanditssubsidiariesthecompanyhaveapproximatelyemployeesworldwideengagedinthe researchanddevelopmentmanufactureandsaleofabroadrangeofproductsinthehealthcarefieldthecompany conductsbusinessinvirtuallyallcountriesoftheworldwiththeprimaryfocusonproductsrelatedtohumanhealthand wellbee thecompanyisorganizedintothreebusinesssegmentsconsumerpharmaceuticalandmedicaldevicesthe consumersegmentincludesabroadrangeofproductsusedinthebabycareoralcarebeautypreviouslyreferredtoas skincareoverthecounterpharmaceuticalwomenshealthandwoundcaremarketstheseproductsaremarketedto thegeneralpublicandsoldbothtoretailoutletsanddistributorsthroughouttheworldthepharmaceuticalsegmentis focusedonfivetherapeuticareasincludingimmunologyinfectiousdiseasesneuroscienceoncologyandcardiovascular andmetabolicdiseasesproductsinthissegmentaredistributeddirectlytoretailerswholesalershospitalsandhealth careprofessionalsforprescriptionusethemedicaldevicessegmentincludesabroadrangeofproductsusedinthe orthopaedicsurgerycardiovasculardiabetescareandvisioncarefieldswhicharedistributedtowholesalershospital andretailersandusedprincipallyintheprofessionalfieldsbyphysiciansnurseshospitalseyecareprofessionalsand clinic theexecutivecommitteeofjohnsonjohnsonistheprincipalmanagementgroupresponsibleforthestrategic operationsandallocationoftheresourcesofthecompanythiscommitteeoverseesandcoordinatestheactivitiesofthe consumerpharmaceuticalandmedicaldevicesbusinesssegment inallofitsproductlinesthecompanycompeteswithcompaniesbothlocallyandgloballythroughouttheworld competitionexistsinallproductlineswithoutregardtothenumberandsizeofthecompetingcompaniesinvolve competitioninresearchinvolvingthedevelopmentandtheimprovementofnewandexistingproductsandprocessesis particularlysignificantthedevelopmentofnewandinnovativeproductsaswellasprotectingtheunderlyingintellectual propertyofthecompanysproductportfolioisimportanttothecompanyssuccessinallareasofitsbusinessthe competitiveenvironmentrequiressubstantialinvestmentsincontinuingresearchinadditionthedevelopmentand maintenanceofcustomerdemandforthecompanysconsumerproductsinvolvessignificantexpendituresforadvertising andpromotion managementsobjective thecompanymanageswithinastrategicframeworkwithourcredoasthefoundationthecompanybelievesthatour strategicoperatingprinciplesbeingbroadlybasedinhumanhealthcaremanagingthebusinessforthelongtermhaving adecentralizedmanagementapproachandbeingcommittedtoourpeopleandvaluesarecrucialtosuccessfullymeeting thedemandsoftherapidlyevolvingmarketsinwhichwecompetetothisendmanagementisfocusedonourlongterm strategicgrowthdriverscreatingvaluethroughinnovationexpandingourglobalreachwithalocalfocusexcellencein executionandleadingwithpurpose thecompanyisbroadlybasedinhumanhealthcareandiscommittedtocreatingvaluebydevelopingaccessiblehigh qualityinnovativeproductsandservicesnewproductsintroducedwithinthepastfiveyearsaccountedforapproximately ofsalesinbillionorofsaleswasinvestedinresearchanddevelopmentreflecte managementscommitmenttodeliveringnewanddifferentiatedproductsandservicestomeetevolvinghealthcareneed andsustainthecompanyslongtermgrowth ourdiversebusinesseswithmorethanoperatingcompanieslocatedincountriesarethekeydriversofthe companyssuccessmaintainingthecompanysdecentralizedmanagementapproachwhileatthesametimeleveraging theextensiveresourcesoftheenterprisepositionsthecompanywelltoinnovateexecutestrategicplansandreach marketsgloballyaswellasaddresstheneedsandchallengesofthelocalmarket inordertoremainaleaderinhealthcarethecompanystrivestomaintainapurposedrivenorganizationandiscommitte todevelopingglobalbusinessleaderswhocanachievethesegrowthobjectivesbusinessesaremanagedforthelong terminordertosustainmarketleadershippositionsandenablegrowthwhichprovidesanenduringsourceofvaluetoour shareholder johnsonjohnsonannualreport ourcredounifiesalljohnsonjohnsonemployeesinachievingtheseobjectivesandprovidesacommonsetofvalue thatserveasthefoundationofthecompanysresponsibilitiestopatientsconsumersandhealthcareprofessional employeescommunitiesandshareholdersthecompanybelievesthatthesefoundationalvaluesitsstrategicframework andlongtermgrowthdriversalongwithitsoverallmissionofimprovingthequalityoflifeforpeoplearoundtheworldwill enablejohnsonjohnsontocontinuetobealeaderinthehealthcareindustry result operation analysisofconsolidatedsale inworldwidesalesincreasedtobillioncomparedtoadecreaseofinandanincreaseof inthesesaleschangesconsistedofthefollowe salesincreasedecreasedueto volume price currency total inacquisitionsanddivestitureshadanegativeimpactofontheworldwideoperationalsalesgrowthand competitiveproductstothecompanyshepatitiscproductsolysiosovriadsimeprevirandincivo telaprevirhadanegativeimpactofontheworldwideoperationalsalesgrowthoperationsinvenezuelanegatively impactedtheworldwideoperationalsalesgrowth intheintroductionofcompetitiveproductstothecompanyshepatitiscproductsolysiosovriad simeprevirandincivotelaprevirhadanegativeimpactofontheworldwideoperationalsalesgrowthin theimpactofacquisitionsanddivestituresontheworldwideoperationalsalesgrowthwasnegative insalesofthecompanyshepatitiscproductsolysiosovriadsimeprevirandincivotelaprevirhad apositiveimpactofandthedivestitureoftheorthoclinicaldiagnosticsbusinesshadanegativeimpactofon theworldwideoperationalgrowth salesbyuscompanieswerebillioninbillioninandbillioninthisrepresent increasesofininandinsalesbyinternationalcompanieswerebillionin billioninandbillioninthisrepresentsdecreasesofinandinandan increaseofin thefiveyearcompoundannualgrowthratesforworldwideusandinternationalsaleswereand respectivelythetenyearcompoundannualgrowthratesforworldwideusandinternationalsaleswereand respectively salesbycompaniesineuropeexperiencedadeclineofascomparedtotheprioryearincludingoperationalgrowth ofoffsetbyanegativecurrencyimpactofsalesbycompaniesinthewesternhemisphereexcludingthe usexperiencedadeclineofascomparedtotheprioryearincludingoperationalgrowthofoffsetbya negativecurrencyimpactofsalesbycompaniesintheasiapacificafricaregionachievedgrowthofas comparedtotheprioryearincludingoperationalgrowthofandapositivecurrencyimpactof thesalesgrowthpercentageascomparedtotheprioryearwasnegativelyimpactedbyapproximatelyfrom additionalshippingdaysinseenotetotheconsolidatedfinancialstatementsforannualclosingdatedetails whiletheadditionalweekinaddedafewdaystosalesitalsoaddedafullweeksworthofoperatingcosts thereforethenetearningsimpactwasnegligible inthecompanyhadtwowholesalersdistributingproductsforallthreesegmentsthatrepresentedapproximately andofthetotalconsolidatedrevenuesinandthecompanyhadonewholesalerdistribute productsforallthreesegmentsthatrepresentedapproximatelyandrespectivelyofthetotalconsolidate revenue johnsonjohnsonannualreportanalysis sale business segment consumersegment consumersegmentsalesinwerebillionadecreaseoffromwhichincludedoperational growthoffsetbyanegativecurrencyimpactofusconsumersegmentsaleswerebillionanincreaseof internationalsaleswerebillionadecreaseofwhichincludedoperationalgrowthoffsetbya negativecurrencyimpactofintheimpactofacquisitionsanddivestituresontheconsumersegment operationalsalesgrowthwasnegativeintheconsumersegmentoperationalsalesgrowthwasnegatively impactedbyoperationsinvenezuelaandnegativelyimpactedbyduetoadditionalshippingdaysin majorconsumerfranchisesale change dollarsinmillion vs vs otc beauty babycare oralcare womenshealth woundcareother totalconsumersale prioryearamountshavebeenreclassifiedtoconformtocurrentyearproductdisclosure formerlyskincare theoverthecounterotcfranchisesalesofbillionincreasedascomparedtotheprioryearwhichinclude operationalgrowthandanegativecurrencyimpactofoperationalgrowthwasprimarilydrivenbyanalgesic antismokingaidsanddigestivehealthproduct thebeautyfranchisesalesofbillionincreasedascomparedtotheprioryearwhichincludedoperational growthandanegativecurrencyimpactofoperationalgrowthwasprimarilyduetosalesfromtherecent acquisitionsofvogueinternationalllcwhichcontributedapproximatelyandneostratacompanyincaswellas salesgrowthofneutrogenaaveenoadultproductsanddabaoproducts thebabycarefranchisesaleswerebillioninadecreaseofcomparedtotheprioryearprimarilydueto competitivepressurepartiallyoffsetbysalesgrowthofaveenobabyproduct theoralcarefranchisesaleswerebillioninadecreaseofascomparedtotheprioryearwhich includedoperationalgrowthandanegativecurrencyimpactofoperationalgrowthwasdrivenbyincrease salesoflisterineproductsattributabletonewproductlaunchesandsuccessfulmarketingcampaign thewomenshealthfranchisesaleswerebillioninadecreaseofascomparedtotheprioryear primarilyduetooperationsinvenezuelaandtheusdivestitureoftuck thewoundcareotherfranchisesaleswerebillioninadecreaseoffromprimarilyduetothe splendadivestiture consumersegmentsalesinwerebillionadecreaseoffromwhichincludedoperational growthoffsetbyanegativecurrencyimpactofusconsumersegmentsaleswerebillionanincreaseof internationalsaleswerebillionadecreaseofwhichincludedoperationalgrowthoffsetbya negativecurrencyimpactofindivestitureshadanegativeimpactofontheworldwideconsumer segmentoperationalgrowth johnsonjohnsonannualreport pharmaceutical segment pharmaceuticalsegmentsalesinwerebillionanincreaseoffromwhichincludedoperational growthofpartiallyoffsetbyanegativecurrencyimpactofussaleswerebillionanincreaseof internationalsaleswerebillionanincreaseofwhichincludedoperationalgrowthpartiallyoffsetbya negativecurrencyimpactofinacquisitionsdivestituresandcompetitiveproductstothecompanyshepatitis cproductsolysiosovriadsimeprevirandincivotelaprevirhadanegativeimpactofonthe operationalgrowthofthepharmaceuticalsegmentinthepharmaceuticalsegmentoperationalgrowthwa negativelyimpactedbyduetoadditionalshippingdaysinthepharmaceuticalsegmentoperationalgrowthfor ascomparedtotheprioryearwasnotimpactedbyadjustmentstopreviousreserveestimatesasbothperiod includedapproximatelybillionofadjustment majorpharmaceutical therapeuticareasale change dollarsinmillion vs vs totalimmunology remicade simponisimponiaria stelara otherimmunology totalinfectiousdisease edurantrilpivirine olysiosovriad prezistaprezcobixrezolsta otherinfectiousdisease totalneuroscience concertamethylphenidate invegapaliperidone invegasustennaxepliontrinza risperdalconsta otherneuroscience totaloncology darzalex imbruvica velcade zytiga otheroncology cardiovascularmetabolismother xarelto invokanainvokamet procriteprex totalpharmaceuticalsale prioryearamountshavebeenreclassifiedtoconformtocurrentyearpresentation percentagegreaterthan johnsonjohnsonannualreportimmunologyproductsachievedsalesofbillioninrepresentinganincreaseofascomparedtotheprior yearimmunologyproductsgrowthofincludedoperationalgrowthofandanegativecurrencyimpactof thestronggrowthofremicadeinfliximabstelaraustekinumabandsimponisimponiaria golimumabwasprimarilydrivenbyimmunologymarketgrowthandincreasedpenetrationforbothstelara ustekinumabandsimponisimponiariagolimumab thepatentsforremicadeinfliximabincertaincountriesineuropeexpiredinfebruarybiosimilarversionsof remicadehavebeenintroducedincertainmarketsoutsidetheunitedstatesresultinginareductioninsalesof remicadeinthosemarketsadditionalbiosimilarcompetitionwilllikelyresultinafurtherreductioninremicade salesinmarketsoutsidetheunitedstatestheintroductionofabiosimilarversionofremicadeintheunitedstatesis subjecttoenforcementofpatentrightsapprovalbytheusfoodanddrugadministrationfdaandcompliancewith thedaynoticeprovisionsofthebiologicspricecompetitionandinnovationactthebpciainaprilthefda approvedforsaleintheunitedstatesaninfliximabbiosimilartobemarketedbyasubsidiaryofpfizerincinoctober theperiodfornoticeoflaunchunderthebpciapassedandpfizerincbeganshipmentofaninfliximabbiosimilarto wholesalersintheunitedstatesinlatenovembersalesofaninfliximabbiosimilarintheusmarketwillresultina reductioninussalesofremicadethecompanycontinuestoassertremicaderelatedpatentrightssee notetotheconsolidatedfinancialstatementsforadescriptionoflegalmattersregardingtheremicadepatent infectiousdiseaseproductssaleswerebillionadeclineoffromwhichincludedanoperational decreaseofandanegativecurrencyimpactofcompetitiveproductstothecompanyshepatitisc productsolysiosovriadsimeprevirandincivotelaprevirhadasignificantnegativeimpactonsalesthe declineofhepatitiscsaleswaspartiallyoffsetbysalesgrowthofedurantrilpivirineandprezcobixdarunavir cobicistat neuroscienceproductssaleswerebillionadecreaseoffromwhichincludedanoperationaldecreaseof andanegativecurrencyimpactofstrongsalesofinvegasustennaxepliontrinzapaliperidone palmitatewereoffsetbylowersalesofinvegapaliperidoneduetogenericcompetitionrisperdalconsta risperidoneandtheimpactofdivestituressalesgrowthofconcertamethylphenidatewasprimarilyduetoa therapeuticequivalencereclassificationofgenericcompetitor oncologyproductsachievedsalesofbillioninrepresentinganincreaseofascomparedtotheprior yearoncologyproductsgrowthofincludedoperationalgrowthofandanegativecurrencyimpactof contributorstothegrowthofoncologyproductswerestrongsalesofimbruvicaibrutinibanddarzalex daratumumabduetopatientuptakeadditionalcountrylaunchesandadditionalindicationsforimbruvicageneric competitionnegativelyimpactedthesalesgrowthofvelcadebortezomibsalesgrowthofzytigaabiraterone acetateintheasiapacificregionprimarilyduetothelaunchinchinaearlierthisyearwaspartiallyoffsetbylowersale ineuropeduetocompetition cardiovascularmetabolismotherproductssaleswerebillionadeclineoffromwhichincludedan operationalincreaseofandanegativecurrencyimpactofcontributorstothegrowthwerestrongsalesof xareltorivaroxabanduetomarketsharegrowthandinvokanainvokametcanagliflozinduetomarket growthandcontinueduptakeintheeuropeanunionandcanadasalesofhormonalcontraceptiveswerenegatively impactedbygenericcompetitionandahigheradjustmenttopreviousreserveestimatesinascomparedto whichnegativelyimpactedcardiovascularmetabolismotherbyapproximately johnsonjohnsonannualreport duringthecompanyadvanceditspipelinewithseveralregulatorysubmissionsandapprovalsfornewdrugsand additionalindicationsforexistingdrugsasfollow productnamechemical eu eu indication approv approv filing filing darzalexdaratumumab incombinationwithlenalidomideanddexamethasoneor bortezomibanddexamethasoneforthetreatmentofpatientswith multiplemyelomawhohavereceivedatleastonepriortherapy forthetreatmentofdoublerefractorymultiplemyeloma darunavirstr singletabletregimenforhivintreatmentnaivepatientsand treatmentexperiencedpatients guselkumab treatmentofadultslivingwithmoderatetosevereplaque psoriasis imbruvicaibrutinib additionalindicationforfirstlinetreatmentofchroniclymphocytic leukemia expandedlabeltoincludeoverallsurvivalandcombinationdatain chroniclymphocyticleukemiasmalllymphocyticlymphomacll sll expandedlabeltoincludetreatmentforpatientswithrelapsedor refractorychroniclymphocyticleukemiacllorsmall lymphocyticlymphomaincombinationwithbendamustineand rituximab invokametcanagliflozin initialtherapyfdcwithmetforminimmediaterelease invokametxrcanagliflozin aoncedailytherapycombiningfixeddosesofcanagliflozinand metforminhydrochlorideextendedreleaseforthetreatmentof adultswithtypediabete simponigolimumab treatmentofpolyarticularjuvenileidiopathicarthritis simponiariagolimumab treatmentofadultslivingwithactivepsoriaticarthritisandthe treatmentofadultslivingwithactiveankylosingspondylitis sirukumab treatmentofrheumatoidarthritis stelaraustekinumab treatmentofadultswithmoderatelytoseverelyactivecrohns disease treatmentofadolescentstoyearsofagewithmoderate tosevereplaquepsoriasis trevictapaliperidone maintenancetreatmentofschizophreniainadultpatient palmitateamonthlyinjection pharmaceuticalsegmentsalesinwerebillionadecreaseoffromwhichincludedoperational growthofoffsetbyanegativecurrencyimpactofussaleswerebillionanincreaseof internationalsaleswerebillionadecreaseofwhichincludedoperationalgrowthoffsetbyanegative currencyimpactofthepharmaceuticalsegmentoperationalgrowthwasnegativelyimpactedbyduetothe introductionofcompetitiveproductstothecompanyshepatitiscproductsolysiosovriadsimeprevirand incivotelaprevirandpositivelyimpactedbyduetoanadjustmenttopreviousreserveestimatesincluding managedmedicaidrebatesprimarilyinthecardiovascularmetabolismothertherapeuticareaindivestitureshada negativeimpactofontheworldwidepharmaceuticalsegmentoperationalgrowth medicaldevicessegment themedicaldevicessegmentsalesinwerebillionadecreaseoffromwhichincludedan operationalincreaseofandanegativecurrencyimpactofussaleswerebillionanincreaseof ascomparedtotheprioryearinternationalsaleswerebillionadecreaseofascomparedtotheprioryear withanoperationalincreaseofandanegativecurrencyimpactofinacquisitionsanddivestitureshada negativeimpactofontheworldwideoperationalgrowthofthemedicaldevicessegmentascomparedtoin themedicaldevicessegmentoperationalgrowthwasnegativelyimpactedbyduetoadditionalshippingday johnsonjohnsonannualreportmajormedicaldevicesfranchisesale change dollarsinmillion vs vs orthopaedic hip knee trauma spineother surgery advanced general specialty visioncare cardiovascular diabetescare diagnostic totalmedicaldevicessale onjunethecompanydivestedtheorthoclinicaldiagnosticsbusinessthediagnosticsfranchise theorthopaedicsfranchisesaleswerebillioninanincreaseoffromwhichincludedoperational growthofandanegativecurrencyimpactofsalesgrowthwasprimarilydrivenbymarketgrowthussalesof thetraumatfnanailingsystemworldwidesalesofthehipprimarystemplatformandtheattunekneesystem growthwasnegativelyimpactedbycontinuedpricingpressure thesurgeryfranchisesaleswerebillioninanincreaseoffromwhichincludedoperationalgrowth ofandanegativecurrencyimpactofoperationalgrowthinadvancedsurgerywasdrivenbyendocutter energyandbiosurgeryproductsprimarilyattributabletomarketgrowthincreasedpenetrationincertainmarketsandnew productlaunchestheacquisitionofneuwavemedicalincalsocontributedtogrowththeoperationaldeclinein generalsurgerywasduetolowersalesofwomenshealthandurologyproductsandpricingpressurespartiallyoffsetby growthofsuturestheoperationaldeclineinspecialtysurgerywasprimarilyduetolowersalesofacclarentproductsand advancedsterilizationproductsoutsidetheusdivestituresandcompetitivepressuresinsterilmedpartiallyoffsetby growthofmentorproductsoutsidetheus thevisioncarefranchiseachievedsalesofbillioninanincreaseoffromwhichinclude operationalgrowthofandapositivecurrencyimpactofgrowthinallthemajorregionswasprimarilydrivenby newproductlaunches thecardiovascularfranchisesaleswerebillionadecreaseoffromwhichrepresentedanoperational declineofstrongoperationalgrowthintheelectrophysiologybusinessdrivenbymarketgrowthsharegrowthand newproductlauncheswasmorethanoffsetbytheimpactofdivestingthecordisbusinessthecompanycompletedthe divestitureofthecordisbusinesstocardinalhealthonoctoberforadditionaldetailsseenotetothe consolidatedfinancialstatements thediabetescarefranchisesaleswerebillionadecreaseoffromwhichrepresentedanoperational declineofandanegativecurrencyimpactoftheoperationaldeclinewasprimarilyduetopricedeclinesand competitivepressuresonjanuarysubsequenttoyearendthecompanyannounceditisengagingina processtoevaluatepotentialstrategicoptionsforthediabetescarefranchise themedicaldevicessegmentsalesinwerebillionadecreaseoffromwhichincludedan operationaldeclineofandanegativecurrencyimpactofussaleswerebillionadecreaseofas comparedtotheprioryearinternationalsaleswerebillionadecreaseofascomparedtotheprioryearwith anoperationaldecreaseofandanegativecurrencyimpactofthedivestituresoftheorthoclinical diagnosticsandthecordisbusinesseshadanegativeimpactofandrespectivelyontheworldwide operationalgrowthofthemedicaldevicessegmentascomparedto johnsonjohnsonannualreport analysis consolidate earning provision taxis income consolidatedearningsbeforeprovisionfortaxesonincomeincreasedtobillioninascomparedto billioninanincreaseoftheincreasewasprimarilyattributabletohighersalesvolumefavorablemixin thebusinessandlowersellingmarketingandadministrativecoststhiswaspartiallyoffsetbyhighernetlitigationexpense ofbillionandahigherrestructuringchargeofbillionascomparedtoadditionallythefiscalyear includedhighergainsonthesaleofassetsbusinessesascomparedtothefiscalyearofincludedgainsof billionfromthedivestituresofthecontrolledsubstancerawmaterialandapibusinesscertainanestheticproductsin europeandcertainnonstrategicconsumerbrandsversusgainsofbillionrecordedinprimarilyfromthe divestitureofthecordisbusinesstheusdivestitureofnucyntaandthesplendabrandthiswaspartiallyoffset byabillionintangibleassetwritedownrelatedtoacclarentincludedin consolidatedearningsbeforeprovisionfortaxesonincomedecreasedtobillioninascomparedto billioninadecreaseofthedecreasewasprimarilyattributabletosignificantlylowersalesofolysio sovriadsimeprevirnegativecurrencyimpactsarestructuringchargeofbillionandhigherintangibleasset writedownsofbillioninascomparedtothedecreasewaspartiallyoffsetbylowernetlitigation expenseofbillionlowersynthesintegrationcostsofbillionapositiveadjustmentofbilliontoprevious reserveestimatesincludingmanagedmedicaidrebatesandhighergainsofbillionfromdivestituresascomparedto theprioryearthefiscalyearincludedhighergainsofbillionprimarilyfromthedivestituresofthecordis businessthesplendabrandandtheusdivestitureofnucyntaversusthegainsrecordedinfromthe divestituresoftheorthoclinicaldiagnosticsbusinessandthekybrandadditionallyincludedanadditionalyear ofthebrandedprescriptiondrugfeeofbillion asapercenttosalesconsolidatedearningsbeforeprovisionfortaxesonincomeinwasversusin costofproductssoldandsellingmarketingandadministrativeexpensescostofproductssoldandselle marketingandadministrativeexpensesasapercenttosaleswereasfollow ofsale costofproductssold percentpointincreasedecreaseovertheprioryear sellingmarketingandadministrativeexpense percentpointincreasedecreaseovertheprioryear incostofproductssoldasapercenttosalesdecreasedtofromascomparedtothesameperioda yearagofavorablemixinthebusinessandcostimprovementprogramswaspartiallyoffsetbytheunfavorableimpactof transactionalcurrencyintangibleassetamortizationexpenseofbillionwasincludedincostofproductssoldfor andtherewasadecreaseinthepercenttosalesofsellingmarketingandadministrativeexpensesin comparedtotheprioryearprimarilyduetocostmanagementinallthesegmentsandfavorablemix incostofproductssoldasapercenttosalesincreasedslightlyascomparedtotheprioryearfavorablemix betweenthesegmentswasoffsetbymillionassociatedwiththerestructuringactivityinthemedicaldevicessegment negativetransactionalcurrencyandlowersalesofolysiosovriadsimeprevirinintangibleasset amortizationexpenseincludedincostofproductssoldforandwasbillionandbillionrespectively therewasanincreaseinthepercenttosalesofsellingmarketingandadministrativeexpensesincomparedtothe prioryearprimarilyduetoincrementalinvestmentspendinginallthesegmentsandtheimpactfromlowersalesof olysiosovriadsimeprevirpartiallyoffsetbyfavorablemixandtheinclusionofanadditionalyearofthebrande prescriptiondrugfeeofbillionin johnsonjohnsonannualreportresearchanddevelopmentexpenseresearchanddevelopmentexpensebysegmentofbusinesswasasfollows dollarsinmillion ofsale ofsale ofsale consumer pharmaceutical medicaldevice totalresearchanddevelopmentexpense percentincreasedecreaseovertheprior year asapercenttosegmentsale researchanddevelopmentactivitiesrepresentasignificantpartofthecompanysbusinesstheseexpendituresrelateto theprocessesofdiscoveringtestinganddevelopingnewproductsupfrontpaymentsandmilestonesimprovingexisting productsaswellasensuringproductefficacyandregulatorycompliancepriortolaunchthecompanyremain committedtoinvestinginresearchanddevelopmentwiththeaimofdeliveringhighqualityandinnovativeproductsin worldwidecostsofresearchanddevelopmentactivitiesincreasedbycomparedtobutdecreasedasa percentofsalesthedecreaseasapercentofsaleswasattributabletohigheroverallsalesinthepharmaceutical segmenttheincreaseddollarspendinthepharmaceuticalsegmentwasforinvestmentspendingtoadvancethepipeline inworldwidecostsofresearchanddevelopmentactivitiesincreasedbycomparedtotheincreaseasa percenttosaleswasattributabletoincreasedinvestmentspendingprimarilyinthepharmaceuticalsegmentloweroverall salesandbusinessmix inprocessresearchanddevelopmentiprdinthecompanyrecordedaniprdchargeofmillion forthediscontinuationofadevelopmentprogramrelatedtocrucellinthecompanyrecordedaniprdchargeof billionprimarilyforthediscontinuationofcertaindevelopmentprojectsrelatedtocovageninthecompany recordedaniprdchargeofbillionfortheimpairmentofvariousiprdprojectsrelatedtorespivertcrucell mentorandsynthesforthedelayordiscontinuationofcertaindevelopmentproject otherincomeexpensenetotherincomeexpensenetistheaccountwherethecompanyrecordsgainsand lossesrelatedtothesaleandwritedownofcertaininvestmentsinequitysecuritiesheldbyjohnsonjohnson innovationjjdcincjjdcgainsandlossesondivestiturestransactionalcurrencygainsandlossesacquisition relatedcostslitigationaccrualsandsettlementsaswellasroyaltyincomethechangeinotherincomeexpensenetfor thefiscalyearwasanunfavorablechangeofbillionascomparedtotheprioryearprimarilyduetohighergain onthesaleofassetsbusinessesinthefiscalyearascomparedtothefiscalyearofincludedgainsof billionfromthedivestituresofthecontrolledsubstancerawmaterialandapibusinesscertainanestheticproductsin europeandcertainnonstrategicconsumerbrandsversusgainsofbillionrecordedinprimarilyfromthe divestitureofthecordisbusinesstheusdivestitureofnucyntaandthesplendabrandadditionallythefiscal yearofincludedhigherlitigationexpenseofbillionascomparedtothiswaspartiallyoffsetbya billionintangibleassetwritedownrelatedtoacclarentincludedinthefiscalyear thechangeinotherincomeexpensenetforthefiscalyearwasafavorablechangeofbillionascomparedto theprioryearprimarilyduetolowerlitigationexpenseofbillionlowersynthesintegrationcostsofbillionand higherjjdcportfoliogainsofbillionascomparedtotheprioryearadditionallythefiscalyearincludedhigher gainsofbillionprimarilyfromthedivestituresofthecordisbusinessthesplendabrandandtheusdivestiture ofnucyntaversusthegainsrecordedinfromthedivestituresoftheorthoclinicaldiagnosticsbusinessandthe kybrandthiswaspartiallyoffsetbyhigherintangibleassetwritedownsofbillionin interestincomeexpenseinterestincomeinincreasedbymillionascomparedtoduetoahigher averagebalanceofcashcashequivalentsandmarketablesecuritiesandhigherinterestratescashcashequivalentsand marketablesecuritiestotaledbillionattheendofandaveragedbillionascomparedtothe billionaveragecashbalancein interestexpenseinwashigherascomparedtotheaveragedebtbalancewasbillioninversus billioninthetotaldebtbalanceattheendofwasbillionascomparedtobillionattheend ofthehigherdebtbalanceofapproximatelybillionwasprimarilyduetoincreasedborrowingsinfebruaryand mayofthecompanyincreasedborrowingscapitalizingonfavorabletermsinthecapitalmarketstheproceedsof theborrowingswereusedforgeneralcorporatepurposesprimarilythestockrepurchaseprogram johnsonjohnsonannualreport interestincomeinincreasedbymillionascomparedtoduetoahigheraveragebalanceofcashcash equivalentsandmarketablesecuritiesandhigherinterestratescashcashequivalentsandmarketablesecuritiestotale billionattheendofandaveragedbillionascomparedtothebillionaveragecashbalancein theincreaseintheyearendcashbalancewasprimarilyduetocashgeneratedfromoperatingactivitie interestexpenseinincreasedslightlyascomparedtotheaveragedebtbalancewasbillionin versusbillioninthetotaldebtbalanceattheendofwasbillionascomparedtobillionat theendofthehigherdebtbalanceofapproximatelybillionwasanincreaseincommercialpaperforgeneral corporatepurposesprimarilythestockrepurchaseprogram incomebeforetaxbysegment incomebeforetaxbysegmentofbusinesswereasfollow percentof incomebeforetax segmentsale segmentsale dollarsinmillion consumer pharmaceutical medicaldevice total lessexpensesnotallocatedtosegment earningsbeforeprovisionfortaxesonincome seenotetotheconsolidatedfinancialstatementsformoredetail amountsnotallocatedtosegmentsincludeinterestincomeexpenseandgeneralcorporateincomeexpense consumersegmentintheconsumersegmentincomebeforetaxasapercenttosaleswasversus inprimarilydrivenbyfavorablesellingmarketingandadministrativeexpensesduetocostmanagementand highergrossprofitmarginsfromcostimprovementprojectsandfavorablemixthiswaspartiallyoffsetbyhighergainsin relatedtodivestituresprimarilythedivestitureofthesplendabrandadditionallyoperationsinvenezuela negativelyimpactedtheconsumersegmentincomebeforetaxinascomparedto intheconsumersegmentincomebeforetaxasapercenttosaleswasversusinprimarilydue tolowerdivestituregainsinversusintheconsumersegmenttaxincludedagainofbillionfrom divestituresprimarilythedivestitureofthesplendabrandintheconsumersegmentincludedagainbillion fromdivestituresprimarilythedivestitureofthekybrand pharmaceuticalsegmentinthepharmaceuticalsegmentincomebeforetaxasapercenttosaleswa versusintheincreaseinincomebeforetaxwasprimarilyduetostrongsalesvolumegrowthandfavorable sellingmarketingandadministrativeexpensesduetocostmanagementadditionallythefiscalyearhadhigher gainsofbillionrelatedtodivestiturespartiallyoffsetbyahigheriprdchargeofbillionascomparedto thefiscalyearofincludedthegainsfromthedivestituresofthecontrolledsubstancerawmaterialandapibusiness andcertainanestheticproductsineuropeversusthegainsrecordedinfromtheusdivestitureofnucynta inthepharmaceuticalsegmentincomebeforetaxasapercenttosaleswasversusinthe favorableincomebeforetaxwasprimarilyduetohighergainsrecognizedinpartiallyoffsetbyasalesdeclineof olysiosovriadsimeprevirincreasedinvestmentspendingandnegativecurrencyimpactsascomparedto includedinwasagainofbillionontheusdivestitureofnucyntaaswellasreceiptofacontingent paymentandapositiveadjustmenttopreviousreserveestimatesincludingmanagedmedicaidrebatesadditionallythe pharmaceuticalsegmentincomebeforetaxinwasnegativelyimpactedbybillionforanadditionalyearofthe brandedprescriptiondrugfeeandhigherintangibleassetamortizationexpenseofbillionprimarilyrelatedtothe writedownofincivotelaprevir medicaldevicessegmentinthemedicaldevicessegmentincomebeforetaxasapercenttosaleswa versusinthedecreaseintheincomebeforetaxasapercenttosaleswasprimarilyduetolowergainsof billionrelatedtodivestitureshigherlitigationexpenseofbillionandahigherrestructuringchargeofbillion ascomparedtothiswaspartiallyoffsetbyanintangibleassetwritedownofbillionrelatedtoacclarentin andfavorablesellingmarketingandadministrativeexpensesin johnsonjohnsonannualreportinthemedicaldevicessegmentincomebeforetaxasapercenttosaleswasversusin primarilyduetoarestructuringchargeofbillionanintangibleassetwritedownofbillionrelatedtoacclarent andlowergainsofbillionondivestituresascomparedtointhemedicaldevicessegmentinclude gainsofbillionprimarilyforthedivestitureofthecordisbusinessversusagainofbillionrecordedinfor thedivestitureoftheorthoclinicaldiagnosticsbusinesstheincomebeforetaxwasfavorablyimpactedbylower netlitigationexpenseofbillionwhichincludedagainfromthelitigationsettlementagreementofbillionwith guidantandlowersynthesintegrationcostsofbillioninascomparedto restructuringthecompanyannouncedrestructuringactionsinitsmedicaldevicessegmentthatareexpectedtoresult inannualizedpretaxcostsavingsofmilliontobillionthemajorityofwhichisexpectedtoberealizedbythe endofapproximatelymillioninsavingswererealizedinthesavingswillprovidethecompanywith addedflexibilityandresourcestofundinvestmentinnewgrowthopportunitiesandinnovativesolutionsforcustomersand patientsthecompanyestimatesthatinconnectionwithitsplansitwillrecordpretaxrestructuringrelatedchargesof approximatelybilliontobillionmostofwhichareexpectedtobeincurredbytheendofinthe companyrecordedapretaxchargeofmillionofwhichmillionisincludedincostofproductssoldand millionisincludedinotherincomeexpenseinthecompanyrecordedapretaxchargeofmillionof whichmillionwasincludedincostofproductssoldrestructuringchargesofbillionhavebeenrecorde sincetherestructuringwasannouncedseenotetotheconsolidatedfinancialstatementsforadditionaldetail relatedtotherestructure provisionfortaxesonincometheworldwideeffectiveincometaxratewasininand intheeffectivetaxratedecreasedbyascomparedtoasdescribedinnotetothe consolidatedfinancialstatementsthecompanyadoptedanewaccountingstandardforthereportingofadditionaltax benefitsonsharebasedcompensationthatvestedorwereexercisedduringthefiscalyeartheadoptionofthisnew standardreducedtheeffectivetaxrateforthefiscalbyversustheremainderofthechangeinthe effectivetaxratewasprimarilyrelatedtothelowerearningsbeforetaxesintheunitedstatesandthesettlementofseveral uncertaintaxpositionsinversus thedecreaseintheeffectivetaxrateascomparedtowasprimarilyattributabletotheincreasesintaxable incomeinlowertaxjurisdictionsrelativetohighertaxjurisdictionsandataxbenefitresultingfromarestructuringof internationalaffiliatesadditionallytheeffectivetaxratewasaffectedbytheitemsmentionedbelow theincreaseintheeffectivetaxrateascomparedtowasattributabletothefollowingthedivestitureofthe orthoclinicaldiagnosticsbusinessatanapproximateeffectivetaxratelitigationaccrualsatlowtaxratesthemixof earningsintohighertaxjurisdictionsprimarilytheustheaccrualofanadditionalyearofthebrandedprescriptiondrug feewhichisnottaxdeductibleandadditionalustaxexpenserelatedtoaplannedincreaseindividendsfromcurrent yearforeignearningsascomparedtotheprioryeartheseincreasestotheeffectivetaxratewerepartiallyoffsetby ataxbenefitofbillionassociatedwiththeconormedsystemsdivestiture theeffectivetaxratewasalsoreducedasthecompanyadjusteditsunrecognizedtaxbenefitsasaresultofithe federalappealscourtsdecisioninomjpharmaceuticalsincslitigationregardingcreditsunderformersectionof theinternalrevenuecodeandiiasettlementofsubstantiallyallissuesrelatedtothecompanysusinternalrevenue serviceauditoftaxyear liquidity capital resource liquiditycashflow cashandcashequivalentswerebillionattheendofascomparedtobillionattheendofthe primarysourcesandusesofcashthatcontributedtothebillionincreasewereapproximatelybillionofcash generatedfromoperatingactivitiesoffsetbybillionnetcashusedbyinvestingactivitiesandbillionnetcash usedbyfinancingactivitiesandbillionduetotheeffectonexchangeratechangesoncashandcashequivalentsin additionthecompanyhadbillioninmarketablesecuritiesattheendofandbillionattheendof seenotetotheconsolidatedfinancialstatementsforadditionaldetailsoncashcashequivalentsandmarketable security cashflowfromoperationsofbillionwastheresultofbillionofnetearningsandbillionofnoncash expensesandotheradjustmentsfordepreciationandamortizationstockbasedcompensationandassetswritedown reducedbybillionfromnetgainsonsaleofassetsbusinessesbillionrelatedtodeferredtaxesandbillion johnsonjohnsonannualreport relatedtoaccountsreceivableinventoriesandothercurrentandnoncurrentliabilitiesadditionalsourcesofoperate cashflowofbillionresultedfromanincreaseinaccountspayableandaccruedliabilitiesandadecreaseinother currentandnoncurrentasset investingactivitiesuseofbillionwasprimarilyforacquisitionsnetofcashacquiredofbillionandadditionsto propertyplantandequipmentofbillionthiswaspartiallyoffsetbyproceedsfromthenetsaleofinvestment primarilymarketablesecuritiesofbillionandbillionofproceedsfromthedisposalofassetsbusinesse financingactivitiesuseofbillionwasprimarilyfordividendstoshareholdersofbillionandbillionforthe repurchaseofcommonstockfinancingactivitiesalsoincludedasourceofbillionfromnetproceedsofshortand longtermdebtandbillionofproceedsfromstockoptionsexercisedemployeewithholdingtaxonstockawardsnet inthecompanyannouncedadefinitiveagreementtoacquireabbottmedicalopticsincforapproximately billionandonjanuarysubsequenttoyearendthecompanyannouncedadefinitivetransactionagreement toacquireactelionltdforapproximatelybillionabbottmedicalopticsclosedonfebruarythe companywillusecashheldbythecompanysforeignsubsidiariestopayfortheseacquisition onoctoberthecompanyannouncedthatitsboardofdirectorsapprovedasharerepurchaseprogram authorizingthecompanytopurchaseuptobillionofthecompanyssharesofcommonstockasofjanuary billionhasbeenrepurchasedundertheprogramtherepurchaseprogramhasnotimelimitandmaybe delayedorsuspendedforperiodsordiscontinuedatanytimeanysharesacquiredwillbeavailableforgeneralcorporate purposesthecompanyintendstofinancethesharerepurchaseprogramthroughavailablecashandaccesstothe capitalmarketstheprevioussharerepurchaseprogramapprovedonjulyauthorizingthecompanytopurchase uptobillionofthecompanyssharesofcommonstockwascompletedonapril inthecompanycontinuedtohaveaccesstoliquiditythroughthecommercialpapermarketthecompanyhada shelfregistrationwiththeussecuritiesandexchangecommissionthatexpiredonfebruarythecompany planstofileanewshelfregistrationonfebruarywhichwillenableittoissuedebtsecuritiesonatimelybasis foradditionaldetailsonborrowingsseenotetotheconsolidatedfinancialstatement thecompanyanticipatesthatoperatingcashflowsexistingcreditfacilitiesandaccesstothecapitalmarketswillprovide sufficientresourcestofundoperatingneedsin concentrationofcreditrisk globalconcentrationofcreditriskwithrespecttotradeaccountsreceivablescontinuestobelimitedduetothelarge numberofcustomersgloballyandadherencetointernalcreditpoliciesandcreditlimitseconomicchallengesinitaly spaingreeceandportugalthesoutherneuropeanregionhaveimpactedcertainpaymentpatternswhichhave historicallybeenlongerthanthoseexperiencedintheusandotherinternationalmarketsthetotalnettradeaccount receivablebalanceinthesoutherneuropeanregionwasapproximatelybillionasofjanuaryandbillion asofjanuaryapproximatelybillionasofjanuaryandapproximatelybillionasofjanuary ofthesoutherneuropeanregionnettradeaccountsreceivablebalancerelatedtothecompanysconsumer visioncareanddiabetescarebusinessesaswellascertainpharmaceuticalandmedicaldevicescustomerswhicharein linewithhistoricalcollectionpattern theremainingbalanceofnettradeaccountsreceivableinthesoutherneuropeanregionhasbeennegativelyimpacte bythetimingofpaymentsfromcertaingovernmentownedorsupportedhealthcarecustomersaswellascertain distributorsofthepharmaceuticalandmedicaldeviceslocalaffiliatesthetotalnettradeaccountsreceivablebalancefor thesecustomerswereapproximatelybillionatjanuaryandbillionatjanuarythecompany continuestoreceivepaymentsfromthesecustomersandinsomecaseslatepaymentswithinterestforcustomer wherepaymentisexpectedoverperiodsoftimelongerthanoneyearrevenueandtradereceivableshavebeen discountedovertheestimatedperiodoftimeforcollectionallowancesfordoubtfulaccountshavebeenincreasedfor thesecustomersbuthavebeenimmaterialtodatethecompanywillcontinuetoworkcloselywiththesecustomerson paymentplansmonitortheeconomicsituationandtakeappropriateactionsasnecessary financingandmarketrisk thecompanyusesfinancialinstrumentstomanagetheimpactofforeignexchangeratechangesoncashflow accordinglythecompanyentersintoforwardforeignexchangecontractstoprotectthevalueofcertainforeigncurrency assetsandliabilitiesandtohedgefutureforeigncurrencytransactionsprimarilyrelatedtoproductcostsgainsorlosse onthesecontractsareoffsetbythegainsorlossesontheunderlyingtransactionsaappreciationoftheusdollar johnsonjohnsonannualreportfromthejanuarymarketrateswouldincreasetheunrealizedvalueofthecompanysforwardcontractsby millionconverselyadepreciationoftheusdollarfromthejanuarymarketrateswoulddecreasethe unrealizedvalueofthecompanysforwardcontractsbymillionineitherscenariothegainorlossontheforward contractwouldbeoffsetbythegainorlossontheunderlyingtransactionandthereforewouldhavenoimpactonfuture anticipatedearningsandcashflow thecompanyhedgestheexposuretofluctuationsincurrencyexchangeratesandtheeffectoncertainassetsand liabilitiesinforeigncurrencybyenteringintocurrencyswapcontractsachangeinthespreadbetweenusand foreigninterestratesonthecompanysinterestratesensitivefinancialinstrumentswouldeitherincreaseordecreasethe unrealizedvalueofthecompanysswapcontractsbyapproximatelymillionineitherscenarioatmaturitythegainor lossontheswapcontractwouldbeoffsetbythegainorlossontheunderlyingtransactionandthereforewouldhaveno impactonfutureanticipatedcashflow thecompanydoesnotenterintofinancialinstrumentsfortradingorspeculativepurposesfurtherthecompanyhasa policyofonlyenteringintocontractswithpartiesthathaveatleastaninvestmentgradecreditratingthecounterpartie tothesecontractsaremajorfinancialinstitutionsandthereisnosignificantconcentrationofexposurewithanyone counterpartymanagementbelievestheriskoflossisremote thecompanyinvestsinbothfixedrateandfloatingrateinterestearningsecuritieswhichcarryadegreeofinterestrate riskthefairmarketvalueoffixedratesecuritiesmaybeadverselyimpactedduetoariseininterestrateswhilefloate ratesecuritiesmayproducelessincomethanpredictedifinterestratesfallabasispointschangeinspreadon thecompanysinterestratesensitiveinvestmentswouldeitherincreaseordecreasetheunrealizedvalueofcash equivalentsandcurrentmarketablesecuritiesbyapproximatelymillion thecompanyhasaccesstosubstantialsourcesoffundsatnumerousbanksworldwideinseptemberthe companysecuredanewdaycreditfacilitytotalcreditavailabletothecompanyapproximatesbillionwhich expiresonseptemberinterestchargedonborrowingsunderthecreditlineagreementisbasedoneitherbids providedbybankstheprimerateorlondoninterbankofferedratesliborplusapplicablemarginscommitmentfee undertheagreementarenotmaterial totalborrowingsattheendofandwerebillionandbillionrespectivelytheincreasein borrowingsbetweenandwasaresultoffinancingforthecompanyssharerepurchaseprogramandgeneral corporatepurposesinnetcashcashandcurrentmarketablesecuritiesnetofdebtwasbillioncompare tonetcashofbillionintotaldebtrepresentedoftotalcapitalshareholdersequityandtotaldebtin andoftotalcapitalinshareholdersequitypershareattheendofwascomparedto atyearendanincreaseof asummaryofborrowingscanbefoundinnotetotheconsolidatedfinancialstatement contractualobligationsandcommitment thecompanyscontractualobligationsareprimarilyforleasesdebtandunfundedretirementplanstherearenoother significantobligationstosatisfytheseobligationsthecompanywillusecashfromoperationsthefollowingtable summarizesthecompanyscontractualobligationsandtheiraggregatematuritiesasofjanuaryseenote andtotheconsolidatedfinancialstatementsforfurtherdetail intereston unfunded debt debt retirement operating dollarsinmillion obligation obligation plan lease total total fortaxmattersseenotetotheconsolidatedfinancialstatementsforotherretirementplanandpostemployment medicalbenefitinformationseenotetotheconsolidatedfinancialstatementsthetabledoesnotincludeactivity relatedtobusinesscombination johnsonjohnsonannualreport dividend thecompanyincreaseditsdividendinforthethconsecutiveyearcashdividendspaidwerepersharein comparedwithdividendsofpershareinandpershareinthedividendsweredistributed asfollow firstquarter secondquarter thirdquarter fourthquarter total onjanuarytheboardofdirectorsdeclaredaregularquarterlycashdividendofpersharepayableon marchtoshareholdersofrecordasoffebruarythecompanyexpectstocontinuethepracticeof payingregularcashdividend information criticalaccountingpoliciesandestimate managementsdiscussionandanalysisofresultsofoperationsandfinancialconditionarebasedonthecompany consolidatedfinancialstatementsthathavebeenpreparedinaccordancewithaccountingprinciplesgenerallyacceptedin theusgaapthepreparationofthesefinancialstatementsrequiresthatmanagementmakeestimatesand assumptionsthataffecttheamountsreportedforrevenuesexpensesassetsliabilitiesandotherrelateddisclosure actualresultsmayormaynotdifferfromtheseestimatesthecompanybelievesthattheunderstandingofcertainkey accountingpoliciesandestimatesareessentialinachievingmoreinsightintothecompanysoperatingresultsand financialconditionthesekeyaccountingpoliciesincluderevenuerecognitionincometaxeslegalandselfinsurance contingenciesvaluationoflonglivedassetsassumptionsusedtodeterminetheamountsrecordedforpensionsandother employeebenefitplansandaccountingforstockbasedawards revenuerecognitionthecompanyrecognizesrevenuefromproductsaleswhengoodsareshippedordeliveredand titleandriskoflosspasstothecustomerprovisionsforcertainrebatessalesincentivestradepromotionscoupon productreturnsanddiscountstocustomersareaccountedforasreductionsinsalesinthesameperiodtherelatedsale arerecorde productdiscountsgrantedarebasedonthetermsofarrangementswithdirectindirectandothermarketparticipantsas wellasmarketconditionsincludingpriceschargedbycompetitorsrebateswhichincludethemedicaidrebateprovision areestimatedbasedoncontractualtermshistoricalexperiencepatientoutcomestrendanalysisandprojectedmarket conditionsinthevariousmarketsservedthecompanyevaluatesmarketconditionsforproductsorgroupsofproduct primarilythroughtheanalysisofwholesalerandotherthirdpartysellthroughandmarketresearchdataaswellas internallygeneratedinformation salesreturnsareestimatedandrecordedbasedonhistoricalsalesandreturnsinformationproductsthatexhibitunusual salesorreturnpatternsduetodatingcompetitionorothermarketingmattersarespecificallyinvestigatedandanalyzedas partoftheaccountingforsalesreturnaccrual salesreturnsallowancesrepresentareserveforproductsthatmaybereturnedduetoexpirationdestructioninthefield orinspecificareasproductrecallthereturnsreserveisbasedonhistoricalreturntrendsbyproductandbymarketasa percenttogrosssalesinaccordancewiththecompanysaccountingpoliciesthecompanygenerallyissuescreditto customersforreturnedgoodsthecompanyssalesreturnsreservesareaccountedforinaccordancewiththe usgaapguidanceforrevenuerecognitionwhenrightofreturnexistssalesreturnsreservesarerecordedatfullsales valuesalesreturnsintheconsumerandpharmaceuticalsegmentsarealmostexclusivelynotresalablesalesreturnsfor certainfranchisesinthemedicaldevicessegmentaretypicallyresalablebutarenotmaterialthecompanyinfrequently exchangesproductsfrominventoryforreturnedproductsthesalesreturnsreserveforthetotalcompanyhasbeen approximatelyofannualnettradesalesduringthefiscalreportingyearsand johnsonjohnsonannualreportpromotionalprogramssuchasproductlistingallowancesandcooperativeadvertisingarrangementsarerecordedinthe yearincurredcontinuingpromotionalprogramsincludecouponsandvolumebasedsalesincentiveprogramsthe redemptioncostofconsumercouponsisbasedonhistoricalredemptionexperiencebyproductandvaluevolumebase incentiveprogramsarebasedonestimatedsalesvolumesfortheincentiveperiodandarerecordedasproductsaresold thecompanyalsoearnsservicerevenueforcopromotionofcertainproductsforallyearspresentedservicerevenue wereorlessofthetotalrevenuesandareincludedinsalestocustomersthesearrangementsareevaluatedto determinetheappropriateamountstobedeferredorrecordedasareductionofrevenue inadditionthecompanyentersintocollaborationarrangementsthatcontainmultiplerevenuegeneratingactivitie amountsduefromcollaborativepartnersforthesearrangementsarerecognizedaseachactivityisperformedordelivere basedontherelativesellingpriceupfrontfeesreceivedaspartofthesearrangementsaredeferredandrecognizedover theperformanceperiodseenotetotheconsolidatedfinancialstatementsforadditionaldisclosuresoncollaboration reasonablylikelychangestoassumptionsusedtocalculatetheaccrualsforrebatesreturnsandpromotionsarenot anticipatedtohaveamaterialeffectonthefinancialstatementsthecompanycurrentlydisclosestheimpactofchange toassumptionsinthequarterlyorannualfilinginwhichthereisamaterialfinancialstatementimpact belowaretablesthatshowtheprogressionofaccruedrebatesreturnspromotionsreservefordoubtfulaccountsand reserveforcashdiscountsbysegmentofbusinessforthefiscalyearsendedjanuaryandjanuary consumersegment balanceat balanceat beginning payment endof dollarsinmillion ofperiod accrual credit period accruedrebate accruedreturn accruedpromotions subtotal reservefordoubtfulaccount reserveforcashdiscount total accruedrebate accruedreturn accruedpromotions subtotal reservefordoubtfulaccount reserveforcashdiscount total includesreserveforcustomerrebatesofmillionatjanuaryandmillionatjanuaryrecordedasacontra asset johnsonjohnsonannualreport pharmaceutical segment balanceat balanceat beginningof payment endof dollarsinmillion period accrual credit period accruedrebate accruedreturn accruedpromotions subtotal reservefordoubtfulaccount reserveforcashdiscount total accruedrebate accruedreturn accruedpromotions subtotal reservefordoubtfulaccount reserveforcashdiscount total includesreserveforcustomerrebatesofmillionatjanuaryandmillionatjanuaryrecordedasacontra asset includesadjustment medicaldevicessegment balanceat balanceat beginningof payment endof dollarsinmillion period accrual credit period accruedrebate accruedreturn accruedpromotions subtotal reservefordoubtfulaccount reserveforcashdiscount total accruedrebate accruedreturn accruedpromotions subtotal reservefordoubtfulaccount reserveforcashdiscount total includesreserveforcustomerrebatesofmillionatjanuaryandmillionatjanuaryrecordedasacontra asset johnsonjohnsonannualreportincometaxesincometaxesarerecordedbasedonamountsrefundableorpayableforthecurrentyearandincludethe resultsofanydifferencebetweenusgaapaccountingandtaxreportingrecordedasdeferredtaxassetsorliabilitie thecompanyestimatesdeferredtaxassetsandliabilitiesbasedonenactedtaxregulationsandratesfuturechangesin taxlawsandratesmayaffectrecordeddeferredtaxassetsandliabilitie thecompanyhasunrecognizedtaxbenefitsforuncertaintaxpositionsthecompanyfollowsusgaapwhich prescribesarecognitionthresholdandmeasurementattributeforthefinancialstatementrecognitionandmeasurementof ataxpositiontakenorexpectedtobetakeninataxreturnmanagementbelievesthatchangesintheseestimateswould nothaveamaterialeffectonthecompanysresultsofoperationscashflowsorfinancialposition atjanuaryandjanuarythecumulativeamountsofundistributedinternationalearningswere approximatelybillionandbillionrespectivelyatjanuaryandjanuarythecompany foreignsubsidiariesheldbalancesofcashcashequivalentsandmarketablesecuritiesintheamountsofbillionand billionrespectivelythecompanyhasnotprovideddeferredtaxesontheundistributedearningsfromcertain internationalsubsidiarieswheretheearningsareconsideredtobeindefinitelyreinvestedthecompanyintendsto continuetoreinvesttheseearningsininternationaloperationsifthecompanydecidedatalaterdatetorepatriatethese earningstotheusthecompanywouldberequiredtoprovideforthenettaxeffectsontheseamountsthecompany doesnotdeterminethedeferredtaxliabilityassociatedwiththeseundistributedearningsassuchdeterminationisnot practical seenotetotheconsolidatedfinancialstatementsforfurtherinformationregardingincometaxe legalandselfinsurancecontingenciesthecompanyrecordsaccrualsforvariouscontingenciesincludinglegal proceedingsandproductliabilityclaimsastheseariseinthenormalcourseofbusinesstheaccrualsarebasedon managementsjudgmentastotheprobabilityoflossesandwhereapplicableactuariallydeterminedestimatesthe companyhasselfinsurancethroughawhollyownedcaptiveinsurancecompanyinadditiontoaccrualsintheself insuranceprogramclaimsthatexceedtheinsurancecoverageareaccruedwhenlossesareprobableandamountscanbe reasonablyestimatedadditionallythecompanyrecordsinsurancereceivableamountsfromthirdpartyinsurerswhen recoveryisprobableasappropriatereservesagainstthesereceivablesarerecordedforestimatedamountsthatmaynot becollectedfromthirdpartyinsurer thecompanyfollowstheprovisionsofusgaapwhenrecordinglitigationrelatedcontingenciesaliabilityisrecorde whenalossisprobableandcanbereasonablyestimatedthebestestimateofalosswithinarangeisaccruedhowever ifnoestimateintherangeisbetterthananyothertheminimumamountisaccrue seenotesandtotheconsolidatedfinancialstatementsforfurtherinformationregardingproductliabilityandlegal proceeding longlivedandintangibleassetsthecompanyassesseschangesineconomicconditionsandmakesassumption regardingestimatedfuturecashflowsinevaluatingthevalueofthecompanyspropertyplantandequipmentgoodwill andintangibleassetsastheseassumptionsandestimatesmaychangeovertimeitmayormaynotbenecessaryforthe companytorecordimpairmentcharges employeebenefitplansthecompanysponsorsvariousretirementandpensionplansincludingdefinedbenefit definedcontributionandterminationindemnityplanswhichcovermostemployeesworldwidetheseplansarebasedon assumptionsforthediscountrateexpectedreturnonplanassetsmortalityratesexpectedsalaryincreaseshealthcare costtrendratesandattritionratesseenotetotheconsolidatedfinancialstatementsforfurtherdetailsontheserate andtheeffectaratechangetothehealthcarecosttrendwouldhaveonthecompanysresultsofoperation stockbasedcompensationthecompanyrecognizescompensationexpenseassociatedwiththeissuanceofequity instrumentstoemployeesfortheirservicesbasedonthetypeofequityinstrumentthefairvalueisestimatedonthedate ofgrantusingeithertheblackscholesoptionvaluationmodeloracombinationofboththeblackscholesoption valuationmodelandmontecarlovaluationmodelandisexpensedinthefinancialstatementsovertheserviceperiodthe inputassumptionsusedindeterminingfairvaluearetheexpectedlifeexpectedvolatilityriskfreerateandexpected dividendyieldforperformanceshareunitsthefairmarketvalueiscalculatedforeachofthethreecomponentgoalsatthe dateofgrantthefairvaluesforthesalesandearningspersharegoalsofeachperformanceshareunitwereestimatedon thedateofgrantusingthefairmarketvalueofthesharesatthetimeoftheawarddiscountedfordividendswhicharenot paidontheperformanceshareunitsduringthevestingperiodthefairvaluefortherelativetotalshareholderreturngoalof eachperformanceshareunitwasestimatedonthedateofgrantusingthemontecarlovaluationmodelseenoteto theconsolidatedfinancialstatementsforadditionalinformation johnsonjohnsonannualreport newaccountingpronouncement refertonotetotheconsolidatedfinancialstatementsforrecentlyadoptedaccountingpronouncementsandrecently issuedaccountingpronouncementsnotyetadoptedasofjanuary economicandmarketfactor thecompanyisawarethatitsproductsareusedinanenvironmentwhereformorethanadecadepolicymaker consumersandbusinesseshaveexpressedconcernsabouttherisingcostofhealthcareinresponsetotheseconcern thecompanyhasalongstandingpolicyofpricingproductsresponsiblyfortheperiodintheunited statestheweightedaveragecompoundannualgrowthrateofthecompanysnetpriceincreasesforhealthcareproduct prescriptionandoverthecounterdrugshospitalandprofessionalproductswasbelowtheusconsumerpriceindex cpi thecompanyoperatesincertaincountrieswheretheeconomicconditionscontinuetopresentsignificantchallengesthe companycontinuestomonitorthesesituationsandtakeappropriateactionsinflationratescontinuetohaveaneffecton worldwideeconomiesandconsequentlyonthewaycompaniesoperatethecompanyhasaccountedforoperationsin venezuelaashighlyinflationaryasthepriorthreeyearcumulativeinflationratesurpassedinthefaceofincrease coststhecompanystrivestomaintainitsprofitmarginsthroughcostreductionprogramsproductivityimprovementsand periodicpriceincrease thevenezuelangovernmenthasestablishedalternativesystemsandofferingsofvariousforeigncurrencyexchange throughthefourthquarterofthenumberofthecompanystransactionsconductedattheofficialratedeclinedfrom priorquartersasaresultthecompanydeterminedthatitwasnolongerlikelythatalloutstandingnetmonetaryasset wouldbesettledattheofficialgovernmentrateofbolivaresfuertestooneusdollarthereforeinthe companyrecordedachargeofmilliontorevalueitsnetmonetaryassetsinvenezuelaatoneofthegovernments alternativeexchangeratessimadiandimpairitsnonmonetaryassetsaftertherevaluationasofjanuarythe companysvenezuelansubsidiariesrepresentedlessthanofthecompanysconsolidatedassetsandliabilities whilethecompanycontinuestodobusinessingreecethecompanycloselymonitorstheeconomicsituationasof januarythecompanysgreeksubsidiariesrepresentedandofthecompanysconsolidatedasset andrevenuesrespectively onjunetheunitedkingdomukheldareferenduminwhichvotersapprovedanexitfromtheeuropean unioneucommonlyreferredtoasbrexitgiventhelackofcomparableprecedentitisunclearwhatfinancialtrade regulatoryandlegalimplicationsthewithdrawaloftheukfromtheeuwillhavebrexitcreatesglobalpoliticaland economicuncertaintywhichmaycauseamongotherconsequencesvolatilityinexchangeratesandinterestrates additionalcostcontainmentbythirdpartypayorsandchangesinregulationshoweverthecompanycurrentlydoesnot believethattheseandotherrelatedeffectswillhaveamaterialimpactonthecompanysconsolidatedfinancialpositionor operatingresultsasofjanuarythebusinessofthecompanysuksubsidiariesrepresentedlessthanof boththecompanysconsolidatedassetsandfiscaltwelvemonthsrevenue thecompanyisexposedtofluctuationsincurrencyexchangeratesachangeinthevalueoftheusdollaras comparedtoallforeigncurrenciesinwhichthecompanyhadsalesincomeorexpenseinwouldhaveincreasedor decreasedthetranslationofforeignsalesbyapproximatelymillionandincomebymillion governmentsaroundtheworldincludingintheunitedstatesconsidervariousproposalstomakechangestotaxlaw whichmayincludeincreasingordecreasingexistingstatutorytaxratesachangeinstatutorytaxrateinanycountrywould resultintherevaluationofthecompanysdeferredtaxassetsandliabilitiesrelatedtothatparticularjurisdictioninthe periodinwhichthenewtaxlawisenactedthischangewouldresultinanexpenseorbenefitrecordedtothecompany consolidatedstatementofearningsthecompanycloselymonitorstheseproposalsastheyariseinthecountrieswhere itoperateschangestothestatutorytaxratemayoccuratanytimeandanyrelatedexpenseorbenefitrecordedmaybe materialtothefiscalquarterandyearinwhichthelawchangeisenacte thebelgiangovernmentiscurrentlyconsideringaproposedchangetoitscorporatetaxcodeincludingaproposalto loweritsstatutorytaxrateifenactedtheproposedchangewouldresultinrevaluationofthecompanysdeferredtax assetswithacorrespondingchargetotaxexpensethatmayhaveamaterialeffectonthecompanysresultsofoperation fortheperiodbasedonthedeferredtaxassetbalancesasofjanuarythecompanyestimatesforeverythat thestatutorytaxisloweredtherewillbeadditionalonetimetaxexpenseofapproximatelymillionasignificant portionofthedeferredtaxassetdescribedasinternationalrdcapitalizedfortaxinnotetotheconsolidate financialstatementsisrelatedtothecompanysoperationsinbelgium johnsonjohnsonannualreporttheusgovernmentiscurrentlyconsideringvariousproposalstochangesinitscorporatetaxcodetheseproposal includebutarenotlimitedtoloweringthestatutorytaxrateandtherulesonhowinternationalincomeearnedbythe companyistaxedintheustheimpactoftheseproposalsmayhaveamaterialeffectonthecompanysresultsof operationsfortheperiodandonfutureperiod asthebelgianorusgovernmentsarestillconsideringtheseproposalsitisnotcertainwhenoriftheywillbeenacte thecompanyfacesvariousworldwidehealthcarechangesthatmaycontinuetoresultinpricingpressuresthatinclude healthcarecostcontainmentandgovernmentlegislationrelatingtosalespromotionsandreimbursementofhealthcare product changesinthebehaviorandspendingpatternsofpurchasersofhealthcareproductsandservicesincludingdelaye medicalproceduresrationingprescriptionmedicationsreducingthefrequencyofphysicianvisitsandforegoinghealth careinsurancecoverageasaresultofthecurrentglobaleconomicdownturnmaycontinuetoimpactthecompany business thecompanyalsooperatesinanenvironmentincreasinglyhostiletointellectualpropertyrightsfirmshavefile abbreviatednewdrugapplicationsorbiosimilarbiologicalproductapplicationswiththefdaorotherwisechallenge thecoverageandorvalidityofthecompanyspatentsseekingtomarketgenericorbiosimilarformsofmanyofthe companyskeypharmaceuticalproductspriortoexpirationoftheapplicablepatentscoveringthoseproductsintheevent thecompanyisnotsuccessfulindefendingthepatentclaimschallengedintheresultinglawsuitsgenericorbiosimilar versionsoftheproductsatissuewillbeintroducedtothemarketresultinginthepotentialforsubstantialmarketshareand revenuelossesforthoseproductsandwhichmayresultinanoncashimpairmentchargeinanyassociatedintangible assetthereisalsoariskthatoneormorecompetitorscouldlaunchagenericorbiosimilarversionoftheproductatissue followingregulatoryapprovaleventhoughoneormorevalidpatentsareinplaceforfurtherinformationseethe discussiononremicaderelatedcasesandlitigationagainstfilersofabbreviatednewdrugapplicationsin notetotheconsolidatedfinancialstatement legalproceeding johnsonjohnsonandcertainofitssubsidiariesareinvolvedinvariouslawsuitsandclaimsregardingproductliability intellectualpropertycommercialandothermattersgovernmentalinvestigationsandotherlegalproceedingsthatarise fromtimetotimeintheordinarycourseofbusiness thecompanyrecordsaccrualsforlosscontingenciesassociatedwiththeselegalmatterswhenitisprobablethata liabilitywillbeincurredandtheamountofthelosscanbereasonablyestimatedthecompanyhasaccruedforcertain litigationmattersandcontinuestomonitoreachrelatedlegalissueandadjustaccrualsfornewinformationandfurther developmentsinaccordancewithaccountingstandardscodificationascfortheseandotherlitigation andregulatorymatterscurrentlydisclosedforwhichalossisprobableorreasonablypossiblethecompanyisunableto estimatethepossiblelossorrangeoflossbeyondtheamountsalreadyaccruedamountsaccruedforlegalcontingencies oftenresultfromacomplexseriesofjudgmentsaboutfutureeventsanduncertaintiesthatrelyheavilyonestimatesand assumptionstheabilitytomakesuchestimatesandjudgmentscanbeaffectedbyvariousfactorsincludingwhether damagessoughtintheproceedingsareunsubstantiatedorindeterminatescientificandlegaldiscoveryhasnot commencedorisnotcompleteproceedingsareinearlystagesmatterspresentlegaluncertaintiestherearesignificant factsindisputeortherearenumerouspartiesinvolve inthecompanysopinionbasedonitsexaminationofthesemattersitsexperiencetodateanddiscussionswithcounsel theultimateoutcomeoflegalproceedingsnetofliabilitiesaccruedinthecompanysbalancesheetisnotexpectedto haveamaterialadverseeffectonthecompanysfinancialpositionhowevertheresolutionoforincreaseinaccrualsfor oneormoreofthesemattersinanyreportingperiodmayhaveamaterialadverseeffectonthecompanysresultsof operationsandcashflowsforthatperiod seenotetotheconsolidatedfinancialstatementsforfurtherinformationregardinglegalproceeding johnsonjohnsonannualreport commonstockmarketprice thecompanyscommonstockislistedonthenewyorkstockexchangeunderthesymboljnjasoffebruary therewererecordholdersofcommonstockofthecompanythecompositemarketpricerangesfor johnsonjohnsoncommonstockduringandwere high low high low firstquarter secondquarter thirdquarter fourthquarter yearendclose johnsonjohnsonannualreportitem quantitative qualitative disclosure market risk theinformationcalledforbythisitemisincorporatedhereinbyreferencetoitemmanagementsdiscussionand analysisofresultsofoperationsandfinancialconditionliquidityandcapitalresourcesfinancingandmarketrisk ofthisreportandnotesummaryofsignificantaccountingpoliciesfinancialinstrumentsofthenotesto consolidatedfinancialstatementsincludedinitemofthisreport item financial statement supplementary data indextoauditedconsolidatedfinancialstatement consolidatedbalancesheet consolidatedstatementsofearning consolidatedstatementsofcomprehensiveincome consolidatedstatementsofequity consolidatedstatementsofcashflow notestoconsolidatedfinancialstatement reportofindependentregisteredpublicaccountingfirm managementsreportoninternalcontroloverfinancialreporte johnsonjohnsonannualreport johnson johnson subsidiaries consolidate balance sheet atjanuaryandjanuary dollarsinmillionsexceptshareandpershareamountsnote asset currentasset cashandcashequivalentsnotesand marketablesecuritiesnotesand accountsreceivabletradelessallowancesfordoubtfulaccount inventoriesnotesand prepaidexpensesandotherreceivable totalcurrentassets propertyplantandequipmentnetnotesand intangibleassetsnetnotesand goodwillnotesand deferredtaxesonincomenote otherasset totalasset liabilitiesandshareholdersequity currentliabilitie loansandnotespayablenote accountspayable accruedliabilitie accruedrebatesreturnsandpromotion accruedcompensationandemployeerelatedobligation accruedtaxesonincomenote totalcurrentliabilities longtermdebtnote deferredtaxesonincomenote employeerelatedobligationsnotesand otherliabilitie totalliabilitie shareholdersequity preferredstockwithoutparvalueauthorizedandunissuedshare commonstockparvaluepersharenoteauthorizedsharesissue share accumulatedothercomprehensiveincomenote retainedearning lesscommonstockheldintreasuryatcostnotesharesandshare totalshareholdersequity totalliabilitiesandshareholdersequity seenotestoconsolidatedfinancialstatement johnsonjohnsonannualreportjohnson johnson subsidiaries consolidate statement earning dollarsandsharesinmillionsexceptpershareamountsnote salestocustomer costofproductssold grossprofit sellingmarketingandadministrativeexpense researchanddevelopmentexpense inprocessresearchanddevelopment interestincome interestexpensenetofportioncapitalizednote otherincomeexpensenet restructuringnote earningsbeforeprovisionfortaxesonincome provisionfortaxesonincomenote netearning netearningspersharenotesand basic diluted cashdividendspershare averagesharesoutstandingnotesand basic diluted seenotestoconsolidatedfinancialstatement johnsonjohnsonannualreport johnson johnson subsidiaries consolidate statement comprehensive income dollarsinmillionsnote netearning othercomprehensiveincomelossnetoftax foreigncurrencytranslation security unrealizedholdinggainlossarisingduringperiod reclassificationstoearning netchange employeebenefitplans priorservicecreditcostnetofamortization gainlossnetofamortization effectofexchangerate netchange derivativeshedge unrealizedgainlossarisingduringperiod reclassificationstoearning netchange othercomprehensiveincomeloss comprehensiveincome thetaxeffectsinothercomprehensiveincomeforthefiscalyearsendedandrespectivelysecuritie millionmillionandmillionemployeebenefitplansmillionmillionandmillion derivativeshedgesmillionmillionandmillion seenotestoconsolidatedfinancialstatement johnsonjohnsonannualreportjohnson johnson subsidiaries consolidate statement equity dollarsinmillionsnote accumulate common stock treasury retain comprehensive issue stock total earning income balancedecember netearning cashdividendspaid employeecompensationandstockoptionplans repurchaseofcommonstock othercomprehensiveincomelossnetoftax balancedecember netearning cashdividendspaid employeecompensationandstockoptionplans repurchaseofcommonstock othercomprehensiveincomelossnetoftax balancejanuary netearning cashdividendspaid employeecompensationandstockoptionplans repurchaseofcommonstock othercomprehensiveincomelossnetoftax balancejanuary seenotestoconsolidatedfinancialstatement johnsonjohnsonannualreport johnson johnson subsidiaries consolidate statement cash flow dollarsinmillionsnote cashflowsfromoperatingactivitie netearning adjustmentstoreconcilenetearningstocashflowsfromoperatingactivitie depreciationandamortizationofpropertyandintangible stockbasedcompensation venezuelaadjustment assetwritedowns netgainonsaleofassetsbusinesse deferredtaxprovision accountsreceivableallowance changesinassetsandliabilitiesnetofeffectsfromacquisitionsanddivestiture increaseinaccountsreceivable increaseininventorie increaseinaccountspayableandaccruedliabilitie decreaseinothercurrentandnoncurrentasset decreaseincreaseinothercurrentandnoncurrentliabilitie netcashflowsfromoperatingactivitie cashflowsfrominvestingactivitie additionstopropertyplantandequipment proceedsfromthedisposalofassetsbusinessesnet acquisitionsnetofcashacquirednote purchasesofinvestment salesofinvestment otherprimarilyintangible netcashusedbyinvestingactivitie cashflowsfromfinancingactivitie dividendstoshareholder repurchaseofcommonstock proceedsfromshorttermdebt retirementofshorttermdebt proceedsfromlongtermdebt retirementoflongtermdebt proceedsfromtheexerciseofstockoptionsemployeewithholdingtaxonstockawardsnet netcashusedbyfinancingactivitie effectofexchangeratechangesoncashandcashequivalent increasedecreaseincashandcashequivalent cashandcashequivalentsbeginningofyearnote cashandcashequivalentsendofyearnote supplementalcashflowdata cashpaidduringtheyearfor interest interestnetofamountcapitalize incometaxe supplementalscheduleofnoncashinvestingandfinancingactivitie treasurystockissuedforemployeecompensationandstockoptionplansnetofcashproceedsemployee withholdingtaxonstockaward conversionofdebt acquisition fairvalueofassetsacquire fairvalueofliabilitiesassumedandnoncontrollinginterest netcashpaidforacquisition seenotestoconsolidatedfinancialstatement johnsonjohnsonannualreportnote consolidated financial statement summary significant accounting policy principlesofconsolidation theconsolidatedfinancialstatementsincludetheaccountsofjohnsonjohnsonanditssubsidiariesthecompany intercompanyaccountsandtransactionsareeliminate descriptionofthecompanyandbusinesssegment thecompanyhasapproximatelyemployeesworldwideengagedintheresearchanddevelopmentmanufacture andsaleofabroadrangeofproductsinthehealthcarefieldthecompanyconductsbusinessinvirtuallyallcountriesof theworldanditsprimaryfocusisonproductsrelatedtohumanhealthandwellbee thecompanyisorganizedintothreebusinesssegmentsconsumerpharmaceuticalandmedicaldevicesthe consumersegmentincludesabroadrangeofproductsusedinthebabycareoralcarebeautypreviouslyreferredtoas skincareoverthecounterpharmaceuticalwomenshealthandwoundcaremarketstheseproductsaremarketedto thegeneralpublicandsoldbothtoretailoutletsanddistributorsthroughouttheworldthepharmaceuticalsegmentis focusedonfivetherapeuticareasincludingimmunologyinfectiousdiseasesneuroscienceoncologyandcardiovascular andmetabolicdiseasesproductsinthissegmentaredistributeddirectlytoretailerswholesalershospitalsandhealth careprofessionalsforprescriptionusethemedicaldevicessegmentincludesabroadrangeofproductsusedinthe orthopaedicsurgerycardiovasculardiabetescareandvisioncarefieldswhicharedistributedtowholesalershospital andretailersandusedprincipallyintheprofessionalfieldsbyphysiciansnurseshospitalseyecareprofessionalsand clinic newaccountingpronouncement recentlyadoptedaccountingpronouncement duringthefiscalfirstquarterofthefinancialaccountingstandardsboardfasbissuedaccountingstandard updatecompensationstockcompensationimprovementstoemployeesharebasedpaymentaccounte theamendmentsintheupdateareeffectiveforannualperiodsbeginningafterdecemberandinterimperiod withinthoseannualperiodsearlyadoptionispermittedforanyentityinanyinterimorannualperiodduringthefiscal secondquarterofthecompanyelectedtoearlyadoptthisstandardtheupdaterequiresthefollowingchangesto presentationofthefinancialstatements allexcesstaxbenefitsanddeficienciestoberecognizedasareductionoranincreasetotheprovisionfortaxeson incomepreviouslythecompanyrecordedthesebenefitsdirectlytoretainedearningsthetaxbenefitforthe companywasmillionforthefiscalyearthestandarddoesnotpermitretroactivepresentationofthis benefittopriorfiscalyearsontheconsolidatedstatementofearning thetaxbenefitordeficiencyisrequiredtobeclassifiedandpresentedasacashflowtofromoperatingactivitiesitwa previouslyrequiredtobepresentedasacashflowtofromfinancingactivitiesontheconsolidatedstatementofcash flowsaspermittedinthestandardthecompanyhaselectedtoadoptthisreclassificationonaprospectivebasisand thereforepriorfiscalyearsfortheconsolidatedstatementofcashflowshavenotbeenrecastforthisprovision clarifiesthatallcashpaymentsmadetotaxingauthoritiesonemployeessharebasedcompensationshouldbe classifiedasacashoutflowfromfinancingactivitiesthisreclassificationisrequiredtoberecastretrospectivelyasa resultforthefiscalyearmillionwasclassifiedasacashoutflowfromfinancingactivitiesandmillion andmillionofcashoutflowwasreclassifiedfromanoperatingactivitytoafinancingactivityproceedsfromthe exerciseofstockoptionsemployeewithholdingtaxonstockawardsnetinthefiscalyearsand respectively inthedilutednetearningspersharecalculationwhenapplyingthetreasurystockmethodforsharesthatcouldbe repurchasedtheassumedproceedsnolongerincludetheamountofexcesstaxbenefitthisdidnothaveamaterial impactonthecompanysdilutednetearningspersharecalculation duringthefiscalsecondquarterofthefasbissuedaccountingstandardsupdatesimplifyingthe presentationofdebtissuancecoststhisupdaterequirescapitalizeddebtissuancecoststobepresentedasareduction johnsonjohnsonannualreport tothecarryingvalueofdebtinsteadofbeingclassifiedasadeferredchargethisupdateiseffectiveforthecompanyfor allannualandinterimperiodsbeginningafterdecemberandisrequiredtobeappliedretroactivelyforallperiod presentedthisupdatedidnothaveamaterialimpactonthepresentationofthecompanysfinancialposition duringthefiscalthirdquarterofthefasbissuedaccountingstandardsupdatebusinesscombination simplifyingtheaccountingformeasurementperiodadjustmentstheamendmentsinthisupdaterequirethatanacquirer recognizeadjustmentstoprovisionalamountsthatareidentifiedduringthemeasurementperiodinthereportingperiodin whichtheadjustmentamountsaredeterminedthisupdateiseffectiveforthecompanyforallannualandinterimperiod beginningafterdecembertheamendmentsinthisupdateshouldbeappliedprospectivelytoadjustmentsto provisionalamountsthatoccuraftertheeffectivedateofthisupdatewithearlierapplicationpermittedforfinancial statementsthathavenotbeenissuedthisupdatedidnothaveamaterialimpactonthecompanysconsolidatedfinancial statement duringthefiscalthirdquarterofthefasbissuedaccountingstandardsupdatenodisclosureof uncertaintiesaboutanentitysabilitytocontinueasagoingconcernthisstandardrequiresmanagementtoevaluate foreachannualandinterimreportingperiodwhetherthereareconditionsandeventsconsideredintheaggregatethat raisesubstantialdoubtaboutanentitysabilitytocontinueasagoingconcernwithinoneyearafterthedatethefinancial statementsareissuedorareavailabletobeissuedifsubstantialdoubtisraisedadditionaldisclosuresaround managementsplantoalleviatethesedoubtsarerequiredthisupdatebecomeseffectiveforallannualperiodsandinterim reportingperiodsendingafterdecembertheadoptionofthisstandarddidnothaveanyimpactonthe companyscurrentdisclosuresinthefinancialstatement recentlyissuedaccountingpronouncement notadoptedasofjanuary duringthefiscalfirstquarterofthefasbissuedaccountingstandardupdateclarifyingthedefinitionof abusinessthisupdatenarrowsthedefinitionofabusinessbyprovidingascreentodeterminewhenanintegratedsetof assetsandactivitiesisnotabusinessthescreenspecifiesthatanintegratedsetofassetsandactivitiesisnotabusiness ifsubstantiallyallofthefairvalueofthegrossassetsacquiredordisposedofisconcentratedinasingleoragroupof similaridentifiableassetsthisupdatewillbeeffectiveforthecompanyforannualperiodsbeginningafterdecember includinginterimperiodswithinthoseannualperiodsearlyadoptionispermittedthisupdateshouldbeapplie prospectivelythecompanyiscurrentlyassessingtheimpactofthefutureadoptionofthisstandardonitsfinancial statement duringthefiscalfirstquarterofthefasbissuedaccountingstandardupdatesimplifyingthetestfor goodwillimpairmentthisupdatesimplifieshowanentityisrequiredtotestgoodwillforimpairmentagoodwill impairmentwillnowbemeasuredbytheamountbywhichareportingunitscarryingvalueexceedsitsfairvaluenotto exceedthecarryingamountofgoodwillthisupdatewillbeeffectiveforthecompanyforitsannualoranyinterimgoodwill impairmenttestsinfiscalyearsbeginningafterdecemberearlyadoptionispermittedthisupdateshouldbe appliedprospectivelythecompanyiscurrentlyassessingtheimpactofthefutureadoptionofthisstandardonit financialstatements duringthefiscalfirstquarterofthefasbissuedaccountingstandardupdateotherincomegainsand lossesfromthederecognitionofnonfinancialassetsthisupdateclarifiesthescopeofassetderecognitionguidance addsguidanceforpartialsalesofnonfinancialassetsandclarifiesrecognizinggainsandlossesfromthetransferof nonfinancialassetsincontractswithnoncustomersthisupdatewillbeeffectiveforthecompanyforitsannualandinterim reportingperiodsbeginningafterdecemberthesametimeastheamendmentsinupdaterevenue fromcontractswithcustomersthisupdateallowsthecompanytochooseeitherafullretrospectivemethodormodifie retrospectivemethoduponadoptionthecompanyiscurrentlyassessingtheimpactofthefutureadoptionofthis standardonitsfinancialstatement duringthefiscalfirstquarterofthefasbissuedaccountingstandardsupdatefinancialinstrument recognitionandmeasurementoffinancialassetsandfinancialliabilitiestheamendmentsinthisupdatesupersedethe guidancetoclassifyequitysecuritieswithreadilydeterminablefairvaluesintodifferentcategoriesthatistradingor availableforsaleandrequireequitysecuritiestobemeasuredatfairvaluewithchangesinthefairvaluerecognize throughnetincomethestandardamendsfinancialreportingbyprovidingrelevantinformationaboutanentitysequity investmentsandreducingthenumberofitemsthatarerecognizedinothercomprehensiveincomethisupdatewillbe effectiveforthecompanyforannualperiodsbeginningafterdecemberandinterimperiodswithinthoseannual periodsthecompanyisunabletoestimatetheimpactofthefutureadoptionofthisstandardonitsfinancialstatement asitwilldependontheequityinvestmentsasoftheadoptiondate johnsonjohnsonannualreportduringthefiscalfirstquarterofthefasbissuedaccountingstandardsupdateleasestopicthis updaterequirestherecognitionofleaseassetsandleaseliabilitiesonthebalancesheetforallleaseobligationsand disclosingkeyinformationaboutleasingarrangementsthisupdaterequirestherecognitionofleaseassetsandlease liabilitiesbylesseesforthoseleasesclassifiedasoperatingleasesundercurrentgenerallyacceptedaccountingprinciple thisupdatewillbeeffectiveforthecompanyforallannualandinterimperiodsbeginningafterdecember includinginterimperiodswithinthosefiscalyearsearlyapplicationispermittedtheupdateisrequiredtobeadopteduse amodifiedretrospectiveapproachthecompanyanticipatesthatmostofitsoperatingleaseswillresultintherecognitionof additionalassetsandthecorrespondingliabilitiesonitsconsolidatedbalancesheetshoweverdoesnotexpecttohavea materialimpactonthefinancialpositiontheactualimpactwilldependonthecompanysleaseportfolioatthetimeof adoptionthecompanycontinuestoassessallimplicationsofthestandardandrelatedfinancialdisclosure duringthefiscalfirstquarterofthefasbissuedaccountingstandardsupdateinvestmentsequity methodandjointventurestopicsimplifyingthetransitiontotheequitymethodofaccountingtheamendment intheupdateeliminatetherequirementthatwhenaninvestmentqualifiesfortheuseoftheequitymethodasaresultofan increaseinthelevelofownershipinterestordegreeofinfluenceaninvestormustadjusttheinvestmentresultsof operationsandretainedearningsretroactivelyonastepbystepbasisasiftheequitymethodhadbeenineffectduringall previousperiodsthattheinvestmenthadbeenheldtheamendmentsinthisupdateareeffectiveforallentitiesforfiscal yearsandinterimperiodswithinthosefiscalyearsbeginningafterdecembertheamendmentsshouldbe appliedprospectivelyupontheireffectivedatetoincreasesinthelevelofownershipinterestordegreeofinfluencethat resultintheapplicationoftheequitymethodearlieradoptionispermittedforanyentityinanyinterimorannualperiod theadoptionofthisstandardisnotexpectedtohaveamaterialimpactonthepresentationofthecompany consolidatedfinancialstatement duringthefiscalthirdquarterofthefasbissuedaccountingstandardsupdatestatementofcash flowstopicclassificationofcertaincashreceiptsandcashpaymentsthisupdateaddresseswhetherto presentcertainspecificcashflowitemsasoperatinginvestingorfinancingactivitiestheamendmentsinthisupdateare effectiveforpublicentitiesforfiscalyearsandinterimperiodswithinthosefiscalyearsbeginningafterdecember earlyadoptionispermittedincludingadoptioninaninterimperiodthecompanyiscurrentlyassessingtheimpact ofthefutureadoptionofthisstandardonitsconsolidatedstatementsofcashflow duringthefiscalfourthquarterofthefasbissuedaccountingstandardsupdateincometaxestopic intraentitytransfersofassetsotherthaninventorythisupdateremovesthecurrentexceptioninusgaap prohibitingentitiesfromrecognizingcurrentanddeferredincometaxexpensesorbenefitsrelatedtotransferofasset otherthaninventorywithintheconsolidatedentitythecurrentexceptiontodefertherecognitionofanytaximpactonthe transferofinventorywithintheconsolidatedentityuntilitissoldtoathirdpartyremainsunaffectedtheamendmentsin thisupdateareeffectiveforpublicentitiesforannualreportingperiodsbeginningafterdecemberearlyadoption ispermittedandshouldbeinthefirstinterimperiodifanentityissuesinterimfinancialstatementsthecompanyis currentlyassessingtheimpactofthefutureadoptionofthisstandardonitsconsolidatedfinancialstatement duringthefiscalsecondquarterofthefasbissuedaccountingstandardsupdatesimplifyingthe measurementofinventorythisupdaterequiresinventorytobemeasuredatthelowerofcostornetrealizablevaluenet realizablevalueistheestimatedsellingpricesintheordinarycourseofbusinesslessreasonablypredictablecostsof completiondisposalandtransportationthisupdatewillbeeffectiveforthecompanyforallannualandinterimperiod beginningafterdecembertheamendmentsinthisupdateshouldbeappliedprospectivelywithearlier applicationpermittedasofthebeginningofaninterimorannualreportingperiodthisupdatewillnothaveamaterial impactonthepresentationofthecompanysfinancialposition duringthefiscalsecondquarterofthefasbissuedaccountingstandardsupdaterevenuefrom contractswithcustomerswhichalongwithamendmentsissuedinandwillreplacesubstantiallyallcurrent usgaapguidanceonthistopicandeliminateindustryspecificguidanceearlyadoptionofthisstandardispermitted butnotbeforetheoriginaleffectivedateforallannualperiodsandinterimreportingperiodsbeginningafterdecember theguidancepermitstwomethodsofadoptionfullretrospectivemethodretrospectiveapplicationtoeachprior reportingperiodpresentedormodifiedretrospectivemethodretrospectiveapplicationwiththecumulativeeffectof initiallyapplyingtheguidancerecognizedatthedateofinitialapplicationandprovidingcertainadditionaldisclosure whilethecompanycontinuestoevaluatetheeffectofthestandardpreliminarilyitdoesnotanticipateamaterialimpact onitsfinancialstatementstocompletetheassessmentoftheimpactofthestandardtothefinancialstatementsthe companycontinuestoassessallimplicationsofthestandardmethodofadoptionandrelatedfinancialdisclosure additionallythecompanycontinuestomonitormodificationsclarificationsandinterpretationsissuedbythefasbthat mayaffectcurrentconclusion johnsonjohnsonannualreport cashequivalent thecompanyclassifiesallhighlyliquidinvestmentswithstatedmaturitiesofthreemonthsorlessfromdateofpurchase ascashequivalentsandallhighlyliquidinvestmentswithstatedmaturitiesofgreaterthanthreemonthsfromthedateof purchaseascurrentmarketablesecuritiesthecompanyhasapolicyofmakinginvestmentsonlywithcommercial institutionsthathaveatleastaninvestmentgradecreditratingthecompanyinvestsitscashprimarilyingovernment securitiesandobligationscorporatedebtsecuritiesmoneymarketfundsandreverserepurchaseagreementsrra rrasarecollateralizedbydepositsintheformofgovernmentsecuritiesandobligationsforanamountnotlessthan oftheirvaluethecompanydoesnotrecordanassetorliabilityasthecompanyisnotpermittedtosellor repledgetheassociatedcollateralthecompanyhasapolicythatthecollateralhasatleastanaorequivalentcredit ratingthecompanyutilizesathirdpartycustodiantomanagetheexchangeoffundsandensurethatcollateralreceivedis maintainedatofthevalueoftherrasonadailybasisrraswithstatedmaturitiesofgreaterthanthreemonth fromthedateofpurchaseareclassifiedasmarketablesecuritie investment investmentsclassifiedasheldtomaturityinvestmentsarereportedatamortizedcostandrealizedgainsorlossesare reportedinearningsinvestmentsclassifiedasavailableforsalearecarriedatestimatedfairvaluewithunrealizedgain andlossesrecordedasacomponentofaccumulatedothercomprehensiveincomeavailableforsalesecuritiesavailable forcurrentoperationsareclassifiedascurrentassetsotherwisetheyareclassifiedaslongtermmanagementdetermine theappropriateclassificationofitsinvestmentindebtandequitysecuritiesatthetimeofpurchaseandreevaluatessuch determinationateachbalancesheetdatethecompanyperiodicallyreviewsitsinvestmentsinequitysecuritiesfor impairmentandadjuststheseinvestmentstotheirfairvaluewhenadeclineinmarketvalueisdeemedtobeotherthan temporaryiflossesonthesesecuritiesareconsideredtobeotherthantemporarythelossisrecognizedinearning propertyplantandequipmentanddepreciation propertyplantandequipmentarestatedatcostthecompanyutilizesthestraightlinemethodofdepreciationoverthe estimatedusefullivesoftheasset buildingandbuildingequipment year landandleaseholdimprovement year machineryandequipment year thecompanycapitalizescertaincomputersoftwareanddevelopmentcostsincludedinmachineryandequipmentwhen incurredinconnectionwithdevelopingorobtainingcomputersoftwareforinternalusecapitalizedsoftwarecostsare amortizedovertheestimatedusefullivesofthesoftwarewhichgenerallyrangefromtoyears thecompanyreviewslonglivedassetstoassessrecoverabilityusingundiscountedcashflowswhencertaineventsor changesinoperatingoreconomicconditionsoccuranimpairmentassessmentmaybeperformedontherecoverabilityof thecarryingvalueoftheseassetsiftheassetisdeterminedtobeimpairedthelossismeasuredbasedonthedifference betweentheassetsfairvalueanditscarryingvalueifquotedmarketpricesarenotavailablethecompanywillestimate fairvalueusingadiscountedvalueofestimatedfuturecashflow revenue recognition thecompanyrecognizesrevenuefromproductsaleswhenthegoodsareshippedordeliveredandtitleandriskofloss passtothecustomerprovisionsforcertainrebatessalesincentivestradepromotionscouponsproductreturnsand discountstocustomersareaccountedforasreductionsinsalesinthesameperiodtherelatedsalesarerecorde productdiscountsgrantedarebasedonthetermsofarrangementswithdirectindirectandothermarketparticipantsas wellasmarketconditionsincludingpriceschargedbycompetitorsrebateswhichincludemedicaidareestimatedbase oncontractualtermshistoricalexperiencepatientoutcomestrendanalysisandprojectedmarketconditionsinthevarious marketsservedthecompanyevaluatesmarketconditionsforproductsorgroupsofproductsprimarilythroughthe analysisofwholesalerandotherthirdpartysellthroughandmarketresearchdataaswellasinternallygenerated information salesreturnsaregenerallyestimatedandrecordedbasedonhistoricalsalesandreturnsinformationproductsthatexhibit unusualsalesorreturnpatternsduetodatingcompetitionorothermarketingmattersarespecificallyinvestigatedand analyzedaspartoftheaccountingforsalesreturnsaccrual johnsonjohnsonannualreportsalesreturnsallowancesrepresentareserveforproductsthatmaybereturnedduetoexpirationdestructioninthefield orinspecificareasproductrecallthereturnsreserveisbasedonhistoricalreturntrendsbyproductandbymarketasa percenttogrosssalesinaccordancewiththecompanysaccountingpoliciesthecompanygenerallyissuescreditto customersforreturnedgoodsthecompanyssalesreturnsreservesareaccountedforinaccordancewithusgaap guidanceforrevenuerecognitionwhenrightofreturnexistssalesreturnsreservesarerecordedatfullsalesvaluesales returnsintheconsumerandpharmaceuticalsegmentsarealmostexclusivelynotresalablesalesreturnsforcertain franchisesinthemedicaldevicessegmentaretypicallyresalablebutarenotmaterialthecompanyinfrequently exchangesproductsfrominventoryforreturnedproductsthesalesreturnsreserveforthetotalcompanyhasbeen approximatelyofannualsalestocustomersduringthefiscalreportingyearsand promotionalprogramssuchasproductlistingallowancesandcooperativeadvertisingarrangementsarerecordedinthe yearincurredcontinuingpromotionalprogramsincludecouponsandvolumebasedsalesincentiveprogramsthe redemptioncostofconsumercouponsisbasedonhistoricalredemptionexperiencebyproductandvaluevolumebase incentiveprogramsarebasedontheestimatedsalesvolumesfortheincentiveperiodandarerecordedasproductsare soldthecompanyalsoearnsservicerevenueforcopromotionofcertainproductsandincludesitinsalestocustomer thesearrangementsareevaluatedtodeterminetheappropriateamountstobedeferredorrecordedasareductionof revenue shippingandhandle shippingandhandlingcostsincurredweremillionmillionandmillioninand respectivelyandareincludedinsellingmarketingandadministrativeexpensetheamountofrevenuereceivedfor shippingandhandlingislessthanofsalestocustomersforallperiodspresente inventory inventoriesarestatedatthelowerofcostormarketdeterminedbythefirstinfirstoutmethod intangibleassetsandgoodwill theauthoritativeliteratureonusgaaprequiresthatgoodwillandintangibleassetswithindefinitelivesbeassesse annuallyforimpairmentthecompanycompletedtheannualimpairmenttestforinthefiscalfourthquarterfuture impairmenttestswillbeperformedannuallyinthefiscalfourthquarterorsoonerifwarrantedpurchasedinprocess researchanddevelopmentisaccountedforasanindefinitelivedintangibleassetuntiltheunderlyingprojectiscomplete atwhichpointtheintangibleassetwillbeaccountedforasadefinitelivedintangibleassetorabandonedatwhichpoint theintangibleassetwillbewrittenofforpartiallyimpaire intangibleassetsthathavefiniteusefullivescontinuetobeamortizedovertheirusefullivesandarereviewedfor impairmentwhenwarrantedbyeconomicconditionsseenoteforfurtherdetailsonintangibleassetsandgoodwill financialinstrument asrequiredbyusgaapallderivativeinstrumentsarerecordedonthebalancesheetatfairvaluefairvalueistheexit pricethatwouldbereceivedtosellanassetorpaidtotransferaliabilityfairvalueisamarketbasedmeasurement determinedusingassumptionsthatmarketparticipantswoulduseinpricinganassetorliabilitytheauthoritativeliterature establishesathreelevelhierarchytoprioritizetheinputsusedinmeasuringfairvaluewithlevelhavingthehighest priorityandlevelhavingthelowestchangesinthefairvalueofderivativesarerecordedeachperiodincurrentearning orothercomprehensiveincomedependingonwhetherthederivativeisdesignatedaspartofahedgetransactionandif sothetypeofhedgetransaction thecompanydocumentsallrelationshipsbetweenhedgeditemsandderivativestheoverallriskmanagementstrategy includesreasonsforundertakinghedgetransactionsandenteringintoderivativestheobjectivesofthisstrategyare minimizeforeigncurrencyexposuresimpactonthecompanysfinancialperformanceprotectthecompanyscash flowfromadversemovementsinforeignexchangeratesensuretheappropriatenessoffinancialinstrumentsand managetheenterpriseriskassociatedwithfinancialinstitutionsseenoteforadditionalinformationonfinancial instrument johnsonjohnsonannualreport productliability accrualsforproductliabilityclaimsarerecordedonanundiscountedbasiswhenitisprobablethataliabilityhasbeen incurredandtheamountoftheliabilitycanbereasonablyestimatedbasedonexistinginformationandactuarially determinedestimateswhereapplicabletheaccrualsareadjustedperiodicallyasadditionalinformationbecome availablethecompanyaccruesanestimateofthelegaldefensecostsneededtodefendeachmatterwhenthosecost areprobableandcanbereasonablyestimate asaresultofcostandavailabilityfactorseffectivenovemberthecompanyceasedpurchasingthirdparty productliabilityinsurancethecompanyhasselfinsurancethroughawhollyownedcaptiveinsurancecompanyin additiontoaccrualsintheselfinsuranceprogramclaimsthatexceedtheinsurancecoverageareaccruedwhenlossesare probableandamountscanbereasonablyestimatedbasedontheavailabilityofpriorcoveragereceivablesforinsurance recoveriesrelatedtoproductliabilityclaimsarerecordedonanundiscountedbasiswhenitisprobablethatarecoverywill berealizedasappropriatereservesagainstthesereceivablesarerecordedforestimatedamountsthatmaynotbe collectedfromthirdpartyinsurer concentrationofcreditrisk globalconcentrationofcreditriskwithrespecttotradeaccountsreceivablescontinuestobelimitedduetothelarge numberofcustomersgloballyandadherencetointernalcreditpoliciesandcreditlimitseconomicchallengesinitaly spaingreeceandportugalthesoutherneuropeanregionhaveimpactedcertainpaymentpatternswhichhave historicallybeenlongerthanthoseexperiencedintheusandotherinternationalmarketsthetotalnettradeaccount receivablebalanceinthesoutherneuropeanregionwasapproximatelybillionasofjanuaryand approximatelybillionasofjanuaryapproximatelybillionasofjanuaryandapproximately billionasofjanuaryofthesoutherneuropeanregionnettradeaccountsreceivablebalancerelatedtothe companysconsumervisioncareanddiabetescarebusinessesaswellascertainpharmaceuticalandmedicaldevice customerswhichareinlinewithhistoricalcollectionpatterns theremainingbalanceofnettradeaccountsreceivableinthesoutherneuropeanregionhasbeennegativelyimpacte bythetimingofpaymentsfromcertaingovernmentownedorsupportedhealthcarecustomersaswellascertain distributorsofthepharmaceuticalandmedicaldeviceslocalaffiliatesthetotalnettradeaccountsreceivablebalancefor thesecustomerswereapproximatelybillionatjanuaryandbillionatjanuarythecompany continuestoreceivepaymentsfromthesecustomersandinsomecaseslatepaymentswithinterestforcustomer wherepaymentisexpectedoverperiodsoftimelongerthanoneyearrevenueandtradereceivableshavebeen discountedovertheestimatedperiodoftimeforcollectionallowancesfordoubtfulaccountshavebeenincreasedfor thesecustomersbuthavebeenimmaterialtodatethecompanywillcontinuetoworkcloselywiththesecustomerson paymentplansmonitortheeconomicsituationandtakeappropriateactionsasnecessary researchanddevelopment researchanddevelopmentexpensesareexpensedasincurredupfrontandmilestonepaymentsmadetothirdpartiesin connectionwithresearchanddevelopmentcollaborationsareexpensedasincurreduptothepointofregulatoryapproval paymentsmadetothirdpartiessubsequenttoregulatoryapprovalarecapitalizedandamortizedovertheremaininguseful lifeoftherelatedproductamountscapitalizedforsuchpaymentsareincludedinotherintangiblesnetofaccumulate amortization thecompanyentersintocollaborativearrangementstypicallywithotherpharmaceuticalorbiotechnologycompaniesto developandcommercializedrugcandidatesorintellectualpropertythesearrangementstypicallyinvolvetwoormore partieswhoareactiveparticipantsinthecollaborationandareexposedtosignificantrisksandrewardsdependentonthe commercialsuccessoftheactivitiesthesecollaborationsusuallyinvolvevariousactivitiesbyoneormorepartie includingresearchanddevelopmentmarketingandsellinganddistributionoftenthesecollaborationsrequireupfront milestoneandroyaltyorprofitsharepaymentscontingentupontheoccurrenceofcertainfutureeventslinkedtothe successoftheassetindevelopmentamountsduefromcollaborativepartnersrelatedtodevelopmentactivitiesare generallyreflectedasareductionofresearchanddevelopmentexpensebecausetheperformanceofcontract johnsonjohnsonannualreportdevelopmentservicesisnotcentraltothecompanysoperationsingeneraltheincomestatementpresentationforthese collaborationsisasfollow naturetypeofcollaboration statementofearningspresentation thirdpartysaleofproduct salestocustomer royaltiesmilestonespaidtocollaborativepartner costofproductssold postregulatoryapproval royaltiesreceivedfromcollaborativepartner otherincomeexpensenet upfrontpaymentsmilestonespaidtocollaborativepartner researchanddevelopmentexpense preregulatoryapproval researchanddevelopmentpaymentstocollaborative researchanddevelopmentexpense partner researchanddevelopmentpaymentsreceivedfrom reductionofresearchanddevelopmentexpense collaborativepartner milestonesarecapitalizedasintangibleassetsandamortizedtocostofgoodssoldovertheusefullife forallyearspresentedtherewasnoindividualprojectthatrepresentedgreaterthanofthetotalannualconsolidate researchanddevelopmentexpense thecompanyhasanumberofproductsandcompoundsdevelopedincollaborationwithstrategicpartnersincluding xareltocodevelopedwithbayerhealthcareagandimbruvicadevelopedincollaborationandcomarkete withpharmacyclicsllcanabbviecompany advertising costsassociatedwithadvertisingareexpensedintheyearincurredandareincludedinsellingmarketingand administrativeexpensesadvertisingexpensesworldwidewhichcomprisedtelevisionradioprintmediaandinternet advertisingwerebillionbillionandbillioninandrespectively incometaxe incometaxesarerecordedbasedonamountsrefundableorpayableforthecurrentyearandincludetheresultsofany differencebetweenusgaapaccountingandtaxreportingrecordedasdeferredtaxassetsorliabilitiesthecompany estimatesdeferredtaxassetsandliabilitiesbasedonenactedtaxregulationsandratesfuturechangesintaxlawsand ratesmayaffectrecordeddeferredtaxassetsandliabilitiesinthefuture thecompanyhasunrecognizedtaxbenefitsforuncertaintaxpositionsthecompanyfollowsusgaapwhich prescribesarecognitionthresholdandmeasurementattributeforthefinancialstatementrecognitionandmeasurementof ataxpositiontakenorexpectedtobetakeninataxreturnmanagementbelievesthatchangesintheseestimateswould nothaveamaterialeffectonthecompanysresultsofoperationscashflowsorfinancialposition atjanuaryandjanuarythecumulativeamountsofundistributedinternationalearningswere approximatelybillionandbillionrespectivelyatjanuaryandjanuarythecompany foreignsubsidiariesheldbalancesofcashcashequivalentsandmarketablesecuritiesintheamountsofbillionand billionrespectivelythecompanyhasnotprovideddeferredtaxesontheundistributedearningsfromcertain internationalsubsidiarieswheretheearningsareconsideredtobeindefinitelyreinvestedthecompanyintendsto continuetoreinvesttheseearningsininternationaloperationsifthecompanydecidedatalaterdatetorepatriatethese earningstotheusthecompanywouldberequiredtoprovideforthenettaxeffectsontheseamountsthecompany doesnotdeterminethedeferredtaxliabilityassociatedwiththeseundistributedearningsassuchdeterminationisnot practical seenotetotheconsolidatedfinancialstatementsforfurtherinformationregardingincometaxe netearningspershare basicearningspershareiscomputedbydividingnetearningsavailabletocommonshareholdersbytheweightedaverage numberofcommonsharesoutstandingfortheperioddilutedearningspersharereflectsthepotentialdilutionthatcould occurifsecuritieswereexercisedorconvertedintocommonstockusingthetreasurystockmethod johnsonjohnsonannualreport useofestimate thepreparationofconsolidatedfinancialstatementsinconformitywithaccountingprinciplesgenerallyacceptedinthe usrequiresmanagementtomakeestimatesandassumptionsthataffecttheamountsreportedestimatesareusedwhen accountingforsalesdiscountsrebatesallowancesandincentivesproductliabilitiesincometaxesdepreciation amortizationemployeebenefitscontingenciesandintangibleassetandliabilityvaluationsactualresultsmayormaynot differfromthoseestimate thecompanyfollowstheprovisionsofusgaapwhenrecordinglitigationrelatedcontingenciesaliabilityisrecorde whenalossisprobableandcanbereasonablyestimatedthebestestimateofalosswithinarangeisaccruedhowever ifnoestimateintherangeisbetterthananyothertheminimumamountisaccrue annualclosingdate thecompanyfollowstheconceptofafiscalyearwhichendsonthesundaynearesttotheendofthemonthof decembernormallyeachfiscalyearconsistsofweeksbuteveryfiveorsixyearsthefiscalyearconsistsofweeks andthereforeincludesadditionalshippingdaysaswasthecaseinandwillbethecaseagainin reclassification certainpriorperiodamountshavebeenreclassifiedtoconformtocurrentyearpresentation cash cash equivalent current marketable security attheendofandcashcashequivalentsandcurrentmarketablesecuritieswerecomprisedof cash current carry unrecognized unrecognized estimate cash marketable dollarsinmillion gain loss fairvalue equivalent security cash usgovtsecuritie othersovereignsecuritie usreverserepurchase agreement otherreverserepurchase agreement corporatedebtsecuritie moneymarketfund timedeposit subtotal unrealize unrealized gain loss govtsecuritie othersovereignsecuritie corporatedebtsecuritie equityinvestment subtotalavailablefor sale totalcashcashequivalent andcurrentmarketable security johnsonjohnsonannualreport current carry unrecognized unrecognized estimate cash marketable dollarsinmillion gain loss fairvalue equivalent security cash usgovtsecuritie othersovereignsecuritie usreverserepurchase agreement otherreverserepurchase agreement corporatedebtsecuritie moneymarketfund timedeposit subtotal unrealize unrealized gain loss govtsecuritie othersovereignsecuritie corporatedebtsecuritie subtotalavailablefor sale totalcashcashequivalent andcurrentmarketable security heldtomaturityinvestmentsarereportedatamortizedcostandrealizedgainsorlossesarereportedinearning availableforsalesecuritiesarereportedatfairvaluewithunrealizedgainsandlossesreportednetoftaxesinothercomprehensive income fairvalueofgovernmentsecuritiesandobligationsandcorporatedebtsecuritieswereestimatedusingquotedbroker pricesandsignificantotherobservableinput thecontractualmaturitiesoftheavailableforsaledebtsecuritiesatjanuaryareasfollow cost fair dollarsinmillion basis value duewithinoneyear dueafteroneyearthroughfiveyear dueafterfiveyearsthroughtenyear totaldebtsecuritie thecompanyinvestsitsexcesscashinbothdepositswithmajorbanksthroughouttheworldandotherhighquality moneymarketinstrumentsthecompanyhasapolicyofmakinginvestmentsonlywithcommercialinstitutionsthathaveat leastaninvestmentgradecreditrate inventory attheendofandinventorieswerecomprisedof dollarsinmillion rawmaterialsandsupplie goodsinprocess finishedgood totalinventorie johnsonjohnsonannualreport property plant equipment attheendofandpropertyplantandequipmentatcostandaccumulateddepreciationwere dollarsinmillion landandlandimprovement buildingsandbuildingequipment machineryandequipment constructioninprogress totalpropertyplantandequipmentgross lessaccumulateddepreciation totalpropertyplantandequipmentnet thecompanycapitalizesinterestexpenseaspartofthecostofconstructionoffacilitiesandequipmentinterestexpense capitalizedinandwasmillionmillionandmillionrespectively depreciationexpenseincludingtheamortizationofcapitalizedinterestwasbillioninand uponretirementorotherdisposalofpropertyplantandequipmentthecostsandrelatedamountsofaccumulate depreciationoramortizationareeliminatedfromtheassetandaccumulateddepreciationaccountsrespectivelythe differenceifanybetweenthenetassetvalueandtheproceedsarerecordedinearning intangible asset goodwill attheendofandthegrossandnetamountsofintangibleassetswere dollarsinmillion intangibleassetswithdefinitelive patentsandtrademarksgross lessaccumulatedamortization patentsandtrademarksnet customerrelationshipsandotherintangiblesgross lessaccumulatedamortization customerrelationshipsandotherintangiblesnet intangibleassetswithindefinitelive trademark purchasedinprocessresearchanddevelopment totalintangibleassetswithindefinitelive totalintangibleassetsnet goodwillasofjanuaryandjanuaryasallocatedbysegmentofbusinesswasasfollow dollarsinmillion consumer pharmaceutical meddevice total goodwillatdecember goodwillrelatedtoacquisition goodwillrelatedtodivestiture currencytranslationother goodwillatjanuary goodwillrelatedtoacquisition goodwillrelatedtodivestiture currencytranslationother goodwillatjanuary johnsonjohnsonannualreporttheweightedaverageamortizationperiodsforpatentsandtrademarksandcustomerrelationshipsandotherintangible assetsareyearsandyearsrespectivelytheamortizationexpenseofamortizableassetsincludedincostof productssoldwasbillionbillionandbillionbeforetaxforthefiscalyearsendedjanuary januaryanddecemberrespectivelytheestimatedamortizationexpenseincludingabbottmedical opticsamoforthefivesucceedingyearsapproximatesbillionbeforetaxperyearintangibleassetwritedown areincludedinotherincomeexpensenet seenotetotheconsolidatedfinancialstatementsforadditionaldetailsrelatedtoacquisitionsanddivestiture fair value measurement thecompanyusesforwardforeignexchangecontractstomanageitsexposuretothevariabilityofcashflowsprimarily relatedtotheforeignexchangeratechangesoffutureintercompanyproductsandthirdpartypurchasesofmaterial denominatedinaforeigncurrencythecompanyusescrosscurrencyinterestrateswapstomanagecurrencyrisk primarilyrelatedtoborrowingsthecompanyalsousesequitycollarcontractstomanageexposuretomarketrisk associatedwithcertainequityinvestmentsallthreetypesofderivativesaredesignatedascashflowhedge additionallythecompanyusesinterestrateswapsasaninstrumenttomanageinterestrateriskrelatedtofixedrate borrowingsthesederivativesaretreatedasfairvaluehedgesthecompanyusesforwardforeignexchangecontract designatedasnetinvestmenthedgesadditionallythecompanyusesforwardforeignexchangecontractstooffsetit exposuretocertainforeigncurrencyassetsandliabilitiestheseforwardforeignexchangecontractsarenotdesignatedas hedgesandthereforechangesinthefairvaluesofthesederivativesarerecognizedinearningstherebyoffsettingthe currentearningseffectoftherelatedforeigncurrencyassetsandliabilitie thecompanydoesnotenterintoderivativefinancialinstrumentsfortradingorspeculativepurposesorthatcontaincredit riskrelatedcontingentfeaturesorrequirementstopostcollateralexcludingequitycollarcontractbyeitherthecompany orthecounterpartyforequitycollarcontractsthecompanypledgedtheunderlyinghedgedmarketableequitysecuritie tothecounterpartyascollateralonanongoingbasisthecompanymonitorscounterpartycreditratingsthecompany considerscreditnonperformancerisktobelowbecausethecompanyprimarilyentersintoagreementswithcommercial institutionsthathaveatleastaninvestmentgradecreditratingrefertothetableonsignificantfinancialassetsand liabilitiesmeasuredatfairvaluecontainedinthisfootnoteforreceivablesandpayableswiththesecommercialinstitution asofjanuarythecompanyhadnotionalamountsoutstandingforforwardforeignexchangecontractscross currencyinterestrateswapsinterestrateswapsandequitycollarcontractsofbillionbillionbillionand billionrespectively allderivativeinstrumentsarerecordedonthebalancesheetatfairvaluechangesinthefairvalueofderivativesare recordedeachperiodincurrentearningsorothercomprehensiveincomedependingonwhetherthederivativeis designatedaspartofahedgetransactionandifsothetypeofhedgetransaction thedesignationasacashflowhedgeismadeattheentrancedateofthederivativecontractatinceptionallderivative areexpectedtobehighlyeffectivechangesinthefairvalueofaderivativethatisdesignatedasacashflowhedgeandis highlyeffectivearerecordedinaccumulatedothercomprehensiveincomeuntiltheunderlyingtransactionaffectsearnings andarethenreclassifiedtoearningsinthesameaccountasthehedgedtransactiongainsandlossesassociatedwith interestrateswapsandchangesinfairvalueofhedgeddebtattributabletochangesininterestratesarerecordedto interestexpenseintheperiodinwhichtheyoccurgainsandlossesonnetinvestmenthedgesareaccountedforthrough thecurrencytranslationaccountonanongoingbasisthecompanyassesseswhethereachderivativecontinuestobe highlyeffectiveinoffsettingchangesofhedgeditemsifandwhenaderivativeisnolongerexpectedtobehighlyeffective hedgeaccountingisdiscontinuedhedgeineffectivenessifanyisincludedincurrentperiodearningsinotherincome expensenetforforwardforeignexchangecontractscrosscurrencyinterestrateswapsnetinvestmenthedgesandequity collarcontractsforinterestrateswapsdesignatedasfairvaluehedgeshedgeineffectivenessifanyisincludedin currentperiodearningswithininterestexpenseforthecurrentreportingperiodhedgeineffectivenessassociatedwith interestrateswapswasnotmaterial duringthefiscalsecondquarterofthecompanydesignateditseurodenominatednotesissuedinmaywith duedatesrangingfromtoasanetinvestmenthedgeofthecompanysinvestmentsincertainofit internationalsubsidiariesthatusetheeuroastheirfunctionalcurrencyinordertoreducethevolatilitycausedbychange inexchangeratesduringthechangeinthecarryingvalueduetoremeasurementoftheseeuronotesresultedina millionpretaxgainreflectedinforeigncurrencytranslationadjustmentwithintheconsolidatedstatementsof comprehensiveincome johnsonjohnsonannualreport asofjanuarythebalanceofdeferrednetlossesonderivativesincludedinaccumulatedothercomprehensive incomewasmillionaftertaxforadditionalinformationseetheconsolidatedstatementsofcomprehensiveincome andnotethecompanyexpectsthatsubstantiallyalloftheamountsrelatedtoforwardforeignexchangecontractswill bereclassifiedintoearningsoverthenextmonthsasaresultoftransactionsthatareexpectedtooccuroverthat periodthemaximumlengthoftimeoverwhichthecompanyishedgingtransactionexposureismonthsexclude interestratecontractsnetinvestmenthedgesandequitycollarcontractstheamountultimatelyrealizedinearningsmay differasforeignexchangerateschangerealizedgainsandlossesareultimatelydeterminedbyactualexchangeratesat maturityofthederivative thefollowingtableisasummaryoftheactivityrelatedtoderivativesdesignatedascashflowhedgesforthefiscalyear endedjanuaryandjanuary gainloss gainloss gainloss reclassifiedfrom recognizedin recognizedin accumulatedoci dollarsinmillion accumulatedoci intoincome incomeexpense cashflowhedgesbyincomestatementcaption salestocustomer costofproductssold researchanddevelopmentexpense interestincomeinterestexpensenet otherincomeexpensenet total allamountsshowninthetableabovearenetoftax effectiveportion ineffectiveportion forwardforeignexchangecontract crosscurrencyinterestrateswap includesequitycollarcontract forthefiscalyearsendedjanuaryandjanuaryalossofmillionandalossofmillion respectivelywasrecognizedinotherincomeexpensenetrelatingtoforwardforeignexchangecontractsnot designatedashedginginstrument fairvalueistheexitpricethatwouldbereceivedtosellanassetorpaidtotransferaliabilityfairvalueisamarketbase measurementdeterminedusingassumptionsthatmarketparticipantswoulduseinpricinganassetorliabilitythe authoritativeliteratureestablishesathreelevelhierarchytoprioritizetheinputsusedinmeasuringfairvaluethelevel withinthehierarchyaredescribedbelowwithlevelhavingthehighestpriorityandlevelhavingthelow thefairvalueofaderivativefinancialinstrumentieforwardforeignexchangecontractsinterestratecontractsisthe aggregationbycurrencyofallfuturecashflowsdiscountedtoitspresentvalueattheprevailingmarketinterestratesand subsequentlyconvertedtotheusdollaratthecurrentspotforeignexchangeratethecompanydoesnotbelievethat fairvaluesofthesederivativeinstrumentsmateriallydifferfromtheamountsthatcouldberealizeduponsettlementor maturityorthatthechangesinfairvaluewillhaveamaterialeffectonthecompanysresultsofoperationscashflowsor financialpositionthecompanyalsoholdsequityinvestmentswhichareclassifiedaslevelanddebtsecuritieswhich areclassifiedaslevelthecompanydidnothaveanyothersignificantfinancialassetsorliabilitieswhichwouldrequire revisedvaluationsunderthisstandardthatarerecognizedatfairvalue thefollowingthreelevelsofinputsareusedtomeasurefairvalue levelquotedpricesinactivemarketsforidenticalassetsandliabilitie levelsignificantotherobservableinput levelsignificantunobservableinputs johnsonjohnsonannualreportthecompanyssignificantfinancialassetsandliabilitiesmeasuredatfairvalueasofjanuaryandjanuary wereasfollow dollarsinmillion level level level total total derivativesdesignatedashedginginstrument asset forwardforeignexchangecontract interestratecontract total liability forwardforeignexchangecontract interestratecontract equitycollarcontract total derivativesnotdesignatedashedginginstrument asset forwardforeignexchangecontract liability forwardforeignexchangecontract availableforsaleotherinvestment equityinvestment debtsecuritie assetsandliabilitiesareallclassifiedaslevelwiththeexceptionofequityinvestmentsofmillionwhichareclassifie aslevel includesmillionandmillionofnoncurrentassetsforthefiscalyearsendingjanuaryandjanuary respectively includesmillionandmillionofnoncurrentliabilitiesforthefiscalyearsendingjanuaryandjanuary respectively includescrosscurrencyinterestrateswapsandinterestrateswap classifiedasnoncurrentotherassetswiththeexceptionofmillionofcurrentassetsforjanuarythecarryingamount oftheequityinvestmentsweremillionandmillionasofjanuaryandjanuaryrespectivelytheunrealize gainsweremillionandmillionasofjanuaryandjanuaryrespectivelytheunrealizedlosseswere millionandmillionasofjanuaryandjanuaryrespectively classifiedascurrentmarketablesecuritie classifiedasothercurrentasset classifiedasaccountspayable seenotesandforfinancialassetsandliabilitiesheldatcarryingamountontheconsolidatedbalancesheet johnsonjohnsonannualreport borrowing thecomponentsoflongtermdebtareasfollow effective effective dollarsinmillion rate rate notesdue monthliborfrndue notesdue debenturesdue notesdue debenturesdue notesdue notesduebeurobeuro notesdue notesdue notesdue zerocouponconvertiblesubordinateddebenturesdue debenturesdue notesdue notesdue notesdue notesduebeuro debenturesdue notesdue notesdue notesduemmeuro notesduemmgbpmmgbp notesdue notesduemmeuro notesdue debenturesdue notesdue notesduebeuro notesdue notesdue debenturesdue debenturesdue notesdue notesdue notesdue subtotal lesscurrentportion totallongtermdebt weightedaverageeffectiverate johnsonjohnsonannualreport translationrateatjanuary translationrateatjanuary theexcessofthefairvalueoverthecarryingvalueofdebtwasbillioninandbillionin fairvalueofthelongtermdebtwasestimatedusingmarketpriceswhichwerecorroboratedbyquotedbrokerpricesand significantotherobservableinput thecompanyhasaccesstosubstantialsourcesoffundsatnumerousbanksworldwideinseptemberthe companysecuredanewdaycreditfacilitytotalcreditavailabletothecompanyapproximatesbillionwhich expiresonseptemberinterestchargedonborrowingsunderthecreditlineagreementsisbasedoneitherbid providedbybankstheprimerateorlondoninterbankofferedratesliborplusapplicablemarginscommitmentfee undertheagreementsarenotmaterial throughoutthecompanycontinuedtohaveaccesstoliquiditythroughthecommercialpapermarketshortterm borrowingsandthecurrentportionoflongtermdebtamountedtoapproximatelybillionattheendofofwhich billionwasborrowedunderthecommercialpaperprogramtheremainderprincipallyrepresentslocalborrowingby internationalsubsidiarie throughoutthecompanycontinuedtohaveaccesstoliquiditythroughthecommercialpapermarketshortterm borrowingsandthecurrentportionoflongtermdebtamountedtoapproximatelybillionattheendofofwhich billionwasborrowedunderthecommercialpaperprogramtheremainderprincipallyrepresentslocalborrowingby internationalsubsidiarie aggregatematuritiesoflongtermobligationscommencinginare dollarsinmillion income taxis theprovisionfortaxesonincomeconsistsof dollarsinmillion currentlypayable ustaxe internationaltaxe totalcurrentlypayable defer ustaxe internationaltaxe totaldeferre provisionfortaxesonincome johnsonjohnsonannualreport acomparisonofincometaxexpenseattheusstatutoryrateofinandtothecompany effectivetaxrateisasfollow dollarsinmillion international earningsbeforetaxesonincome taxrate usstatutoryrate internationaloperationsexcludingireland irelandandpuertoricooperation researchandorphandrugtaxcredit usstateandlocal usmanufacturingdeduction ustaxoninternationalincome additionaltaxbenefitsonsharebasedcompensation ustaxbenefitonassetbusinessdisposal allother effectivetaxrate thecompanyhassubsidiariesoperatinginpuertoricoundervarioustaxincentive theeffectivetaxratedecreasedbyascomparedtoasdescribedinnotethecompanyadopteda newaccountingstandardforthereportingofadditionaltaxbenefitsonsharebasedcompensationthatvestedorwere exercisedduringthefiscalyeartheadoptionofthisnewstandardreducedtheeffectivetaxrateoffiscalby versus theremainderofthechangeintheeffectivetaxratewasprimarilyrelatedtothelowerearningsbeforetaxesintheunite statesandthesettlementofseveraluncertaintaxpositionsinversus thedecreaseintheeffectivetaxrateascomparedtowasprimarilyattributabletotheincreasesintaxable incomeinlowertaxjurisdictionsrelativetohighertaxjurisdictionsandataxbenefitresultingfromarestructuringof internationalaffiliatesadditionallytheeffectivetaxratewasaffectedbytheitemsmentionedbelow theincreaseintheeffectivetaxrateascomparedtowasattributabletothefollowingthedivestitureofthe orthoclinicaldiagnosticsbusinessatanapproximateeffectivetaxratelitigationaccrualsatlowtaxratesthemixof earningsintohighertaxjurisdictionsprimarilytheustheaccrualofanadditionalyearofthebrandedprescriptiondrug feewhichisnottaxdeductibleandadditionalustaxexpenserelatedtoaplannedincreaseindividendsfromcurrent yearforeignearningsascomparedtotheprioryeartheseincreasestotheeffectivetaxratewerepartiallyoffsetby ataxbenefitofbillionassociatedwiththeconormedsystemsdivestiture theeffectivetaxratewasalsoreducedasthecompanyadjusteditsunrecognizedtaxbenefitsasaresultofithe federalappealscourtsdecisioninomjpharmaceuticalsincslitigationregardingcreditsunderformersectionof theinternalrevenuecodeandiiasettlementofsubstantiallyallissuesrelatedtothecompanysusinternalrevenue serviceauditoftaxyearstheimpactofthesettlementisreflectedintheustaxoninternationalincome andtheallotherlineitemswithintheabovereconciliation theitemsnotedabovereflectthekeydriversoftheratereconciliation johnsonjohnsonannualreporttemporarydifferencesandcarryforwardsforandwereasfollow deferredtax deferredtax dollarsinmillion asset liability asset liability employeerelatedobligation stockbasedcompensation depreciation nondeductibleintangible internationalrdcapitalizedfortax reservesliabilitie incomereportedfortaxpurpose netoperatinglosscarryforwardinternational miscellaneousinternational miscellaneousus totaldeferredincometaxe netofavaluationallowancerelatedtobelgiumofmillioninthisallowancewasreversedandtherelateddeferredtax assetwasutilizedtoreducecurrenttaxexpense thecompanyhaswhollyownedinternationalsubsidiariesthathavecumulativenetlossesthecompanybelievesthatitis morelikelythannotthatthesesubsidiarieswillrealizefuturetaxableincomesufficienttoutilizethesedeferredtaxasset thefollowingtablesummarizestheactivityrelatedtounrecognizedtaxbenefit dollarsinmillion beginningofyear increasesrelatedtocurrentyeartaxposition increasesrelatedtopriorperiodtaxposition decreasesrelatedtopriorperiodtaxposition settlement lapseofstatuteoflimitation endofyear theunrecognizedtaxbenefitsofbillionatjanuaryifrecognizedwouldaffectthecompanysannual effectivetaxratethecompanyconductsbusinessandfilestaxreturnsinnumerouscountriesandcurrentlyhastaxaudits inprogresswithanumberoftaxauthoritiestheirshascompleteditsauditforthetaxyearsthroughandis currentlyauditingthetaxyearsinothermajorjurisdictionswherethecompanyconductsbusinesstheyear remainopengenerallybacktotheyearthecompanybelievesitispossiblethatauditsmaybecompletedbytax authoritiesinsomejurisdictionsoverthenexttwelvemonthshoweverthecompanyisnotabletoprovideareasonably reliableestimateofthetimingofanyotherfuturetaxpaymentsrelatingtouncertaintaxposition thecompanyclassifiesliabilitiesforunrecognizedtaxbenefitsandrelatedinterestandpenaltiesaslongtermliabilitie interestexpenseandpenaltiesrelatedtounrecognizedtaxbenefitsareclassifiedasincometaxexpensethecompany recognizedaftertaxinterestexpenseofmillionmillionandmillioninandrespectivelythe totalamountofaccruedinterestwasmillionandmillioninandrespectively johnsonjohnsonannualreport employee relate obligation attheendofandemployeerelatedobligationsrecordedontheconsolidatedbalancesheetswere dollarsinmillion pensionbenefit postretirementbenefit postemploymentbenefit deferredcompensation totalemployeeobligation lesscurrentbenefitspayable employeerelatedobligationsnoncurrent prepaidemployeerelatedobligationsofmillionandmillionforandrespectivelyareincludedin otherassetsontheconsolidatedbalancesheet pension benefit plan thecompanysponsorsvariousretirementandpensionplansincludingdefinedbenefitdefinedcontributionand terminationindemnityplanswhichcovermostemployeesworldwidethecompanyalsoprovidespostretirement benefitsprimarilyhealthcaretoalleligibleusretiredemployeesandtheirdependent manyinternationalemployeesarecoveredbygovernmentsponsoredprogramsandthecosttothecompanyisnot significant retirementplanbenefitsforemployeeshiredbeforejanuaryareprimarilybasedontheemployeescompensation duringthelastthreetofiveyearsbeforeretirementandthenumberofyearsofserviceinthecompanyannounce thattheusdefinedbenefitplanwasamendedtoadoptanewbenefitformulaeffectiveforemployeeshiredonorafter januarythebenefitsarecalculatedusinganewformulabasedonemployeecompensationovertotalyearsof service internationalsubsidiarieshaveplansunderwhichfundsaredepositedwithtrusteesannuitiesarepurchasedundergroup contractsorreservesareprovide thecompanydoesnotfundretireehealthcarebenefitsinadvanceandhastherighttomodifytheseplansinthefuture inandthecompanyuseddecemberanddecemberrespectivelyasthemeasurement dateforallusandinternationalretirementandotherbenefitplans netperiodicbenefitcostsforthecompanysdefinedbenefitretirementplansandotherbenefitplansforand includethefollowingcomponent retirementplan otherbenefitplan dollarsinmillion servicecost interestcost expectedreturnonplanasset amortizationofpriorservicecostcredit amortizationofnettransitionobligation recognizedactuariallosse curtailmentsandsettlement netperiodicbenefitcost johnsonjohnsonannualreportamountsexpectedtoberecognizedinnetperiodicbenefitcostinthecomingyearforthecompanysdefinedbenefit retirementplansandotherpostretirementplans dollarsinmillion amortizationofnettransitionobligation amortizationofnetactuariallosse amortizationofpriorservicecredit unrecognizedgainsandlossesfortheuspensionplansareamortizedovertheaverageremainingfutureserviceforeach planforplanswithnoactiveemployeestheyareamortizedovertheaveragelifeexpectancytheamortizationofgain andlossesfortheotherusbenefitplansisdeterminedbyusingacorridorofthegreaterofthemarketvalueof assetsortheaccumulatedpostretirementbenefitobligationtotalunamortizedgainsandlossesinexcessofthecorridor areamortizedovertheaverageremainingfutureservice priorservicecostsbenefitsfortheuspensionplansareamortizedovertheaverageremainingfutureserviceofplan participantsatthetimeoftheplanamendmentpriorservicecostbenefitfortheotherusbenefitplansisamortizedover theaverageremainingservicetofulleligibilityageofplanparticipantsatthetimeoftheplanamendment thefollowingtablerepresentstheweightedaverageactuarialassumption retirementplan otherbenefitplan worldwidebenefitplan netperiodicbenefitcost servicecostdiscountrate interestcostdiscountrate rateofincreaseincompensationlevel expectedlongtermrateofreturnonplanasset benefitobligation discountrate rateofincreaseincompensationlevel thecompanysdiscountratesaredeterminedbyconsideringcurrentyieldcurvesrepresentinghighqualitylongterm fixedincomeinstrumentstheresultingdiscountratesareconsistentwiththedurationofplanliabilitiesforthefiscalyear thecompanychangeditsmethodologyindeterminingserviceandinterestcostfromthesingleweightedaverage discountrateapproachtodurationspecificspotratesalongthatyieldcurvetotheplansliabilitycashflowswhich managementhasconcludedisamorepreciseestimatepriortothischangeinmethodologythecompanymeasure serviceandinterestcostsutilizingasingleweightedaveragediscountratederivedfromtheyieldcurveusedtomeasure theplanobligationsthecompanyhasaccountedforthischangeasachangeinaccountingestimateandaccordingly hasaccountedforitonaprospectivebasisthischangedoesnotimpactthebenefitobligationanddidnothavea materialimpacttothefullyearresult theexpectedratesofreturnonplanassetassumptionsrepresentthecompanysassessmentoflongtermreturnson diversifiedinvestmentportfoliosgloballytheassessmentisdeterminedusingprojectionsfromexternalfinancialsource longtermhistoricalaveragesactualreturnsbyassetclassandthevariousassetclassallocationsbymarket thefollowingtabledisplaystheassumedhealthcarecosttrendratesforallindividual healthcareplan healthcarecosttrendrateassumedfornextyear ratetowhichthecosttrendrateisassumedtodeclineultimatetrend yeartheratereachestheultimatetrendrate johnsonjohnsonannualreport aonepercentagepointchangeinassumedhealthcarecosttrendrateswouldhavethefollowingeffect onepercentage onepercentage dollarsinmillion pointincrease pointdecrease healthcareplan totalinterestandservicecost postretirementbenefitobligation thefollowingtablesetsforthinformationrelatedtothebenefitobligationandthefairvalueofplanassetsatyearend andforthecompanysdefinedbenefitretirementplansandotherpostretirementplan otherbenefit retirementplan plan dollarsinmillion changeinbenefitobligation projectedbenefitobligationbeginningofyear servicecost interestcost planparticipantcontribution amendment actuarialgainslosse divestituresacquisition curtailmentssettlementsrestructure benefitspaidfromplan effectofexchangerate projectedbenefitobligationendofyear changeinplanasset planassetsatfairvaluebeginningofyear actualreturnonplanasset companycontribution planparticipantcontribution settlement divestituresacquisition benefitspaidfromplanasset effectofexchangerate planassetsatfairvalueendofyear fundedstatusendofyear amountsrecognizedinthecompanysbalancesheetconsistofthefollowe noncurrentasset currentliabilitie noncurrentliabilitie totalrecognizedintheconsolidatedbalancesheetendofyear amountsrecognizedinaccumulatedothercomprehensiveincomeconsistof thefollowe netactuarialloss priorservicecostcredit unrecognizednettransitionobligation totalbeforetaxeffect accumulatedbenefitobligationsendofyear inthecompanyofferedavoluntarylumpsumpaymentoptionbelowapredeterminedthresholdforcertaineligibleformer employeeswhoarevestedparticipantsoftheusqualifieddefinedbenefitpensionplanthedistributionofthelumpsumswa johnsonjohnsonannualreportsubstantiallycompletedbytheendoffiscaltheamountdistributedinwasapproximatelymillionthesedistribution fromtheplandidnothaveamaterialimpactonthecompanysfinancialposition otherbenefit retirementplan plan dollarsinmillion amountsrecognizedinnetperiodicbenefitcostandothercomprehensive income netperiodicbenefitcost netactuarialgainloss amortizationofnetactuarialloss priorservicecostcredit amortizationofpriorservicecostcredit effectofexchangerate totalrecognizedinothercomprehensiveincomebeforetax totalrecognizedinnetperiodicbenefitcostandothercomprehensiveincome thecompanyplanstocontinuetofunditsusqualifiedplanstocomplywiththepensionprotectionactof internationalplansarefundedinaccordancewithlocalregulationsadditionaldiscretionarycontributionsaremadewhen deemedappropriatetomeetthelongtermobligationsoftheplansforcertainplansfundingisnotacommonpracticea fundingprovidesnoeconomicbenefitconsequentlythecompanyhasseveralpensionplansthatarenotfunde inthecompanycontributedmillionandmilliontoitsusandinternationalpensionplansrespectively thefollowingtabledisplaysthefundedstatusofthecompanysusqualifiednonqualifiedpensionplansand internationalfundedandunfundedpensionplansatdecemberanddecemberrespectively usplans internationalplans qualifiedplan nonqualifiedplans fundedplan unfundedplan dollarsinmillion planasset projectedbenefitobligation accumulatedbenefitobligation overunderfundedstatus projectedbenefitobligation accumulatedbenefitobligation planswithaccumulatedbenefitobligationsinexcessofplanassetshaveanaccumulatedbenefitobligationprojected benefitobligationandplanassetsofbillionbillionandbillionrespectivelyattheendofand billionbillionandbillionrespectivelyattheendof thefollowingtabledisplaystheprojectedfuturebenefitpaymentsfromthecompanysretirementandotherbenefitplan dollarsinmillion projectedfuturebenefitpayment retirementplan otherbenefitplan thefollowingtabledisplaystheprojectedfutureminimumcontributionstotheunfundedretirementplanstheseamount donotincludeanydiscretionarycontributionsthatthecompanymayelecttomakeinthefuture dollarsinmillion projectedfuturecontribution johnsonjohnsonannualreport eachpensionplanisoverseenbyalocalcommitteeorboardthatisresponsiblefortheoveralladministrationand investmentofthepensionplansindetermininginvestmentpoliciesstrategiesandgoalseachcommitteeorboard considersfactorsincludinglocalpensionrulesandregulationslocaltaxregulationsavailabilityofinvestmentvehicle separateaccountscommingledaccountsinsurancefundsetcfundedstatusoftheplansratioofactivestoretiree durationofliabilitiesandotherrelevantfactorsincludingdiversificationliquidityoflocalmarketsandliquidityofbase currencyamajorityofthecompanyspensionfundsareopentonewentrantsandareexpectedtobeongoingplan permittedinvestmentsareprimarilyliquidandorlistedwithlittlerelianceonilliquidandnontraditionalinvestmentssuch ashedgefund thecompanysretirementplanassetallocationattheendofandandtargetallocationsforareas follow percentof target planasset allocation worldwideretirementplan equitysecuritie debtsecuritie totalplanasset determinationoffairvalueofplanasset theplanhasanestablishedandwelldocumentedprocessfordeterminingfairvaluesfairvalueisbaseduponquote marketpriceswhereavailableiflistedpricesorquotesarenotavailablefairvalueisbaseduponmodelsthatprimarily useasinputsmarketbasedorindependentlysourcedmarketparametersincludingyieldcurvesinterestratesvolatilitie equityordebtpricesforeignexchangeratesandcreditcurve whiletheplanbelievesitsvaluationmethodsareappropriateandconsistentwithothermarketparticipantstheuseof differentmethodologiesorassumptionstodeterminethefairvalueofcertainfinancialinstrumentscouldresultinadifferent estimateoffairvalueatthereportingdate valuationhierarchy theauthoritativeliteratureestablishesathreelevelhierarchytoprioritizetheinputsusedinmeasuringfairvaluethelevel withinthehierarchyaredescribedinthetablebelowwithlevelhavingthehighestpriorityandlevelhavingthelowest afinancialinstrumentscategorizationwithinthevaluationhierarchyisbaseduponthelowestlevelofinputthatis significanttothefairvaluemeasurement followingisadescriptionofthevaluationmethodologiesusedfortheinvestmentsmeasuredatfairvalue shortterminvestmentscashandquotedshortterminstrumentsarevaluedattheclosingpriceortheamountheld ondepositbythecustodianbankotherinvestmentsarethroughinvestmentvehiclesvaluedusingthenetassetvalue navprovidedbytheadministratorofthefundthenavisbasedonthevalueoftheunderlyingassetsownedbythe fundminusitsliabilitiesandthendividedbythenumberofsharesoutstandingthenavisaquotedpriceinamarket thatisnotactiveandclassifiedaslevel governmentandagencysecuritiesalimitednumberoftheseinvestmentsarevaluedattheclosingpricereportedon themajormarketonwhichtheindividualsecuritiesaretradedwherequotedpricesareavailableinanactivemarket theinvestmentsareclassifiedwithinlevelofthevaluationhierarchyifquotedmarketpricesarenotavailableforthe specificsecuritythenfairvaluesareestimatedbyusingpricingmodelsquotedpricesofsecuritieswithsimilar characteristicsordiscountedcashflowswhenquotedmarketpricesforasecurityarenotavailableinanactivemarket theyareclassifiedaslevel debtinstrumentsalimitednumberoftheseinvestmentsarevaluedattheclosingpricereportedonthemajormarket onwhichtheindividualsecuritiesaretradedwherequotedpricesareavailableinanactivemarkettheinvestmentsare classifiedaslevelifquotedmarketpricesarenotavailableforthespecificsecuritythenfairvaluesareestimatedby usingpricingmodelsquotedpricesofsecuritieswithsimilarcharacteristicsordiscountedcashflowsandareclassifie aslevelleveldebtinstrumentsarepricedbasedonunobservableinput johnsonjohnsonannualreport equitysecuritiescommonstocksarevaluedattheclosingpricereportedonthemajormarketonwhichtheindividual securitiesaretradedsubstantiallyallcommonstockisclassifiedwithinlevelofthevaluationhierarchy commingledfundstheseinvestmentvehiclesarevaluedusingthenavprovidedbythefundadministratorthenav isbasedonthevalueoftheunderlyingassetsownedbythefundminusitsliabilitiesandthendividedbythenumberof sharesoutstandingassetsinthelevelcategoryhaveaquotedmarketprice insurancecontractstheinstrumentsareissuedbyinsurancecompaniesthefairvalueisbasedonnegotiatedvalue andtheunderlyinginvestmentsheldinseparateaccountportfoliosaswellasconsideringthecreditworthinessofthe issuertheunderlyinginvestmentsaregovernmentassetbackedandfixedincomesecuritiesingeneralinsurance contractsareclassifiedaslevelastherearenoquotedpricesnorotherobservableinputsforprice otherassetsotherassetsarerepresentedprimarilybylimitedpartnershipsandrealestateinvestmentsaswellas commercialloansandcommercialmortgagesthatarenotclassifiedascorporatedebtotherassetsthatareexchange listedandactivelytradedareclassifiedaslevelwhileinactivelytradedassetsareclassifiedaslevel thefollowingtablesetsforththeretirementplansinvestmentsmeasuredatfairvalueasofdecemberand december quotedprice significant inactive significant investment marketsfor observable unobservable measuredat identicalasset input inputsa netasset level level level valueb totalasset dollarsinmillion shortterminvestmentfund governmentandagencysecuritie debtinstrument equitysecuritie commingledfund insurancecontract otherasset investmentsatfairvalue theactivityforthelevelassetsisnotsignificantforallyearspresente b peradoptionofasucertaininvestmentsthataremeasuredatfairvalueusingthenetassetvaluepershareorit equivalentpracticalexpedienthavenotbeenclassifiedinthefairvaluehierarchyasperasuprioryearamountshavebeen reclassifiedtoconformtothecurrentyearpresentationthefairvalueamountspresentedinthistableareintendedtopermit reconciliationofthefairvaluehierarchytothetotalretirementplanasset thecompanysotherbenefitplansareunfundedexceptforuscommingledfundslevelofmillionand millionatdecemberanddecemberrespectively thefairvalueofjohnsonjohnsoncommonstockdirectlyheldinplanassetswasmillionoftotalplan assetsatdecemberandmillionoftotalplanassetsatdecember saving plan thecompanyhasvoluntaryksavingsplansdesignedtoenhancetheexistingretirementprogramscoveringeligible employeesthecompanymatchesapercentageofeachemployeescontributionsconsistentwiththeprovisionsofthe planforwhichhesheiseligibletotalcompanymatchingcontributionstotheplansweremillionmillionand millioninandrespectively johnsonjohnsonannualreport capital treasury stock changesintreasurystockwere treasurystock amountsinmillionsexcepttreasurystocksharesinthousand share balanceatdecember employeecompensationandstockoptionplans repurchaseofcommonstock balanceatdecember employeecompensationandstockoptionplans repurchaseofcommonstock balanceatjanuary employeecompensationandstockoptionplans repurchaseofcommonstock balanceatjanuary aggregatesharesofcommonstockissuedwereapproximatelysharesattheendofand cashdividendspaidwerepershareincomparedwithdividendsofpershareinandper sharein onoctoberthecompanyannouncedthatitsboardofdirectorsapprovedasharerepurchaseprogram authorizingthecompanytopurchaseuptobillionofthecompanyssharesofcommonstocktherepurchase programhasnotimelimitandmaybesuspendedforperiodsordiscontinuedatanytimeanysharesacquiredwillbe availableforgeneralcorporatepurposesthecompanyintendstofinancethesharerepurchaseprogramthroughavailable cashandaccesstothecapitalmarketsasofjanuarybillionhasbeenrepurchasedundertheprogram onjulythecompanyannouncedthatitsboardofdirectorsapprovedasharerepurchaseprogram authorizingthecompanytopurchaseuptobillionofthecompanyssharesofcommonstockthissharerepurchase programwascompletedonapril accumulate comprehensive income componentsofothercomprehensiveincomelossconsistofthefollowing gain total gain loss accumulate foreign loss employee currency benefit derivative comprehensive dollarsinmillion translation security plan hedge incomeloss december netchange december netchange january netchanges january amountsinaccumulatedothercomprehensiveincomearepresentednetoftherelatedtaximpactforeigncurrency translationisnotadjustedforincometaxeswhereitrelatestopermanentinvestmentsininternationalsubsidiariesfor additionaldetailsoncomprehensiveincomeseetheconsolidatedstatementsofcomprehensiveincome johnsonjohnsonannualreportdetailsonreclassificationsoutofaccumulatedothercomprehensiveincome gainlossonsecuritiesreclassificationsreleasedtootherincomeexpensenet employeebenefitplansreclassificationsareincludedinnetperiodicbenefitcostseenoteforadditional detail gainlossonderivativeshedgesreclassificationstoearningsarerecordedinthesameaccountasthe hedgedtransactionseenoteforadditionaldetail international currency translation fortranslationofitssubsidiariesoperatinginnonusdollarcurrenciesthecompanyhasdeterminedthatthelocal currenciesofitsinternationalsubsidiariesarethefunctionalcurrenciesexceptthoseinhighlyinflationaryeconomieswhich aredefinedasthosewhichhavehadcompoundcumulativeratesofinflationoformoreduringthepastthreeyear orwhereasubstantialportionofitscashflowsarenotinthelocalcurrency inconsolidatinginternationalsubsidiariesbalancesheetcurrencyeffectsarerecordedasacomponentofaccumulate othercomprehensiveincomethisequityaccountincludestheresultsoftranslatingcertainbalancesheetassetsand liabilitiesatcurrentexchangeratesandsomeaccountsathistoricalratesexceptforthoselocatedinhighlyinflationary economiesthetranslationofbalancesheetaccountsforhighlyinflationaryeconomiesarereflectedintheoperatingresult arollforwardofthechangesduringandforforeigncurrencytranslationadjustmentsisincludedin note netcurrencytransactiongainsandlossesincludedinotherincomeexpensewerelossesofmillionmillion andmillioninandrespectively earning share thefollowingisareconciliationofbasicnetearningspersharetodilutednetearningspershareforthefiscalyearsende januaryjanuaryanddecember inmillionsexceptpershareamount basicnetearningspershare averagesharesoutstandingbasic potentialsharesexercisableunderstockoptionplan lesssharesrepurchasedundertreasurystockmethod convertibledebtshare adjustedaveragesharesoutstandingdilute dilutednetearningspershare thedilutednetearningspersharecalculationincludedthedilutiveeffectofconvertibledebtthatisoffsetbytherelate reductionininterestexpenseofmillionaftertaxforyearandmillionforyearsand thedilutednetearningspersharecalculationforandincludedallsharesrelatedtostockoptionsas theexercisepriceofalloptionswaslessthantheaveragemarketvalueofthecompanysstock rental expense lease commitment rentalsofspacevehiclesmanufacturingequipmentandofficeanddataprocessingequipmentunderoperatinglease wereapproximatelymillionmillionandmillioninandrespectively johnsonjohnsonannualreport theapproximateminimumrentalpaymentsrequiredunderoperatingleasesthathaveinitialorremainingnoncancelable leasetermsinexcessofoneyearatjanuaryare dollarsinmillion total commitmentsundercapitalleasesarenotsignificant common stock stock option plan stock compensation agreement atjanuarythecompanyhadstockbasedcompensationplansthesharesoutstandingareforcontractsunder thecompanyslongtermincentiveplanandthelongtermincentiveplanthelongtermincentive planexpiredaprilalloptionsandrestrictedsharesgrantedsubsequenttothatdatewereunderthelong termincentiveplanunderthelongtermincentiveplanthecompanymayissueuptomillionsharesof commonstockplusanysharescanceledexpiredforfeitedornotissuedfromthelongtermincentiveplan subsequenttoaprilsharesavailableforfuturegrantsunderthelongtermincentiveplanwere millionattheendof thecompensationcostthathasbeenchargedagainstincomefortheseplanswasmillionmillionand millionforandrespectivelythetotalincometaxbenefitrecognizedintheincomestatementfor sharebasedcompensationcostswasmillionmillionandmillionforand respectivelyanadditionaltaxbenefitofmillionwasrecognizedinduetotheadoptionofanewaccounte standardforthereportingofadditionaltaxbenefitsonsharebasedcompensationasdescribedinnotethetotal unrecognizedcompensationcostwasmillionmillionandmillionforandrespectively theweightedaverageperiodforthiscosttoberecognizedwasyearsyearsandyearsfor andrespectivelysharebasedcompensationcostscapitalizedaspartofinventorywereinsignificantinallperiod thecompanysettlesemployeebenefitequityissuanceswithtreasurysharestreasurysharesarereplenishedthroughout theyearforthenumberofsharesusedtosettleemployeebenefitequityissuance stockoption stockoptionsexpireyearsfromthedateofgrantandvestoverserviceperiodsthatrangefrommonthstoyearsall optionsaregrantedattheaverageofthehighandlowpricesofthecompanyscommonstockonthenewyorkstock exchangeonthedateofgrant thefairvalueofeachoptionawardwasestimatedonthedateofgrantusingtheblackscholesoptionvaluationmodel thatusestheassumptionsnotedinthefollowingtableforgrantsexpectedvolatilityrepresentsablendedrateof yeardailyhistoricalaveragevolatilityrateandaweekaverageimpliedvolatilityratebasedonatthemoneytraded johnsonjohnsonoptionswithalifeofyearsforandgrantsexpectedvolatilityrepresentsablendedrate ofyearweeklyhistoricaloverallvolatilityrateandaweekaverageimpliedvolatilityratebasedonatthemoney tradedjohnsonjohnsonoptionswithalifeofyearsforallgrantshistoricaldataisusedtodeterminetheexpectedlife oftheoptiontheriskfreeratewasbasedontheustreasuryyieldcurveineffectatthetimeofgrant theaveragefairvalueofoptionsgrantedwasandinandrespectivelythefair valuewasestimatedbasedontheweightedaverageassumptionsof riskfreerate expectedvolatility expectedlifeinyear expecteddividendyield johnsonjohnsonannualreportasummaryofoptionactivityundertheplanasofjanuaryjanuaryanddecemberand changesduringtheyearsendingonthosedatesispresentedbelow aggregate intrinsic weight value outstanding average dollarsin sharesinthousand share exerciseprice millions sharesatdecember optionsgrante optionsexercised optionscanceledforfeite sharesatdecember optionsgrante optionsexercised optionscanceledforfeite sharesatjanuary optionsgrante optionsexercised optionscanceledforfeited sharesatjanuary thetotalintrinsicvalueofoptionsexercisedwasmillionmillionandmillioninand respectively thefollowingtablesummarizesstockoptionsoutstandingandexercisableatjanuary sharesinthousand outstanding exercisable average average average exercise exercise exercisepricerange option life price option price averagecontractualliferemaininginyear stockoptionsoutstandingatjanuaryanddecemberwereandanaveragelifeofyearsand andanaveragelifeofyearsrespectivelystockoptionsexercisableatjanuaryanddecember wereatanaveragepriceofandatanaveragepriceofrespectively restrictedshareunitsandperformance shareunit thecompanygrantsrestrictedshareunitswhichvestoverserviceperiodsthatrangefrommonthstoyearsthe companyalsograntsperformanceshareunitswhicharepaidinsharesofjohnsonjohnsoncommonstockafterthe endofathreeyearperformanceperiodwhetheranyperformanceshareunitsvestandtheamountthatdoesvestistied tothecompletionofserviceperiodsthatrangefrommonthstoyearsandtheachievementoverathreeyearperiodof threeequallyweightedgoalsthatdirectlyalignwithorhelpdrivelongtermtotalshareholderreturnoperationalsale adjustedoperationalearningspershareandrelativetotalshareholderreturnthenumberofsharesactuallyearnedatthe endofthethreeyearperiodwillvarybasedonlyonactualperformancefromtoofthetargetnumberof performanceshareunitsgrante johnsonjohnsonannualreport asummaryoftherestrictedshareunitsandperformanceshareunitsactivityundertheplansasofjanuaryis presentedbelow outstanding outstanding restricted performance sharesinthousand shareunit shareunit sharesatdecember grant issue canceledforfeite sharesatdecember grant issue canceledforfeite sharesatjanuary grant issue canceledforfeite sharesatjanuary theaveragefairvalueoftherestrictedshareunitsgrantedwasandinand respectivelyusingthefairmarketvalueatthedateofgrantthefairvalueofrestrictedshareunitswasdiscountedfor dividendswhicharenotpaidontherestrictedshareunitsduringthevestingperiodthefairvalueofrestrictedshareunit issuedwasmillionmillionandmillioninandrespectively theweightedaveragefairvalueoftheperformanceshareunitsgrantedwasandinand calculatedusingtheweightedaveragefairmarketvalueforeachofthethreecomponentgoalsatthedateofgrant thefairvaluesforthesalesandearningspersharegoalsofeachperformanceshareunitwereestimatedonthedateof grantusingthefairmarketvalueofthesharesatthetimeoftheawarddiscountedfordividendswhicharenotpaidonthe performanceshareunitsduringthevestingperiodthefairvaluefortherelativetotalshareholderreturngoalofeach performanceshareunitwasestimatedonthedateofgrantusingthemontecarlovaluationmodelthefairvalueof performanceshareunitsissuedwasmillionmillionandmillioninandrespectively segment business geographic area salestocustomer dollarsinmillion consumer unitedstate international total pharmaceutical unitedstate international total medicaldevice unitedstate international total worldwidetotal johnsonjohnsonannualreportincomebeforetax identifiableasset dollarsinmillion consumer pharmaceutical medicaldevice total lessexpensenotallocatedtosegment generalcorporate worldwidetotal additionstoproperty depreciationand plantequipment amortization dollarsinmillion consumer pharmaceutical medicaldevice segmentstotal generalcorporate worldwidetotal salestocustomer longlivedasset dollarsinmillion unitedstate europe westernhemisphereexcludingus asiapacificafrica segmentstotal generalcorporate othernonlonglivedasset worldwidetotal seenoteforadescriptionofthesegmentsinwhichthecompanyoperate exportsalesarenotsignificantinthecompanyhadtwowholesalersdistributingproductsforallthreesegment thatrepresentedapproximatelyandofthetotalconsolidatedrevenuesinandthecompany hadonewholesalerdistributingproductsforallthreesegmentsthatrepresentedapproximatelyand respectivelyofthetotalconsolidatedrevenue amountsnotallocatedtosegmentsincludeinterestincomeexpenseandgeneralcorporateincomeexpense generalcorporateincludescashcashequivalentsandmarketablesecuritie includesnetlitigationexpenseofmillionandarestructuringrelatedchargeofmillioninthemedicaldevicessegment thepharmaceuticalsegmentincludesapositiveadjustmentofbilliontopreviousreserveestimatesaninprocessresearchand developmentexpenseofmillionandgainsfromthedivestituresofthecontrolledsubstancerawmaterialandactive pharmaceuticalingredientapibusinessandcertainanestheticproductsineurope themedicaldevicessegmentincludesarestructuringrelatedchargeofmillionanintangibleassetwritedownofmillion relatedtoacclarentsynthesintegrationcostsofmillionandmillionexpenseforthecostassociatedwiththedepuyasr tmhipprogramincludesmillionofinprocessresearchanddevelopmentexpensecomprisedofmillionandmillion inthepharmaceuticalandmedicaldevicessegmentsrespectivelyincludesnetlitigationexpenseofmillioncomprisedof millioninthepharmaceuticalsegmentandmillioninthemedicaldevicessegmentwhichincludedthegainfromthe litigationsettlementagreementwithguidantformillionthemedicaldevicessegmentincludesagainofbillionfromthe divestitureofthecordisbusinessthepharmaceuticalsegmentincludesagainofmillionfromtheusdivestitureof nucyntaandapositiveadjustmentofbilliontopreviousreserveestimatesincludingmanagedmedicaidrebatesthe consumersegmentincludesagainofmillionfromthedivestitureofsplendabrand johnsonjohnsonannualreport includesnetlitigationexpenseofmillioncomprisedofmillionmillionandmillioninthemedicaldevice pharmaceuticalandconsumersegmentsrespectivelyincludesmillionofinprocessresearchanddevelopmentexpense comprisedofmillionandmillioninthepharmaceuticalandmedicaldevicessegmentsrespectivelythemedicaldevice segmentincludesanetgainofmillionfromthedivestitureoftheorthoclinicaldiagnosticsbusinesssynthesintegration costsofmillionandmillionexpenseforthecostassociatedwiththedepuyasrtmhipprogramthepharmaceutical segmentincludesanadditionalyearofthebrandedprescriptiondrugfeeofmillionandapositiveadjustmentofbillionto previousreserveestimate longlivedassetsincludepropertyplantandequipmentnetforandofandrespectivelyand intangibleassetsandgoodwillnetforandofandrespectively select quarterly financial datum unaudite selectedunauditedquarterlyfinancialdatafortheyearsandaresummarizedbelow dollarsinmillionsexceptpershare second fourth second fourth datum quarter quarter quarter quarter quarter quarter quarter quarter segmentsalestocustomer consumer pharmaceutical medicaldevice totalsale grossprofit earningsbeforeprovisionfortaxeson income netearning basicnetearningspershare dilutednetearningspershare thefirstquarterhasbeenrecasttoreflecttheadoptionofasuseenotetotheconsolidatedfinancialstatementsfor moredetailsthefirstquarterofincludesarestructuringchargeofmillionaftertaxmillionbeforetaxandnet litigationexpenseofmillionaftertaxmillionbeforetax thesecondquarterofincludesarestructuringchargeofmillionaftertaxmillionbeforetaxandnetlitigation expenseofmillionaftertaxmillionbeforetax thethirdquarterofincludesarestructuringchargeofmillionaftertaxmillionbeforetaxandnetlitigationexpense ofmillionaftertaxmillionbeforetax thefourthquarterofincludesarestructuringchargeofmillionaftertaxmillionbeforetaxandnetlitigation expenseofmillionaftertaxmillionbeforetax thefirstquarterofincludesanetlitigationgainofmillionaftertaxmillionbeforetaxandmillionaftertax millionbeforetaxforcostsassociatedwiththedepuyasrtmhipprogram thesecondquarterofincludesnetlitigationexpenseofmillionaftertaxmillionbeforetax thethirdquarterofincludesnetlitigationexpenseofmillionaftertaxmillionbeforetax thefourthquarterofincludesarestructuringchargeofmillionaftertaxmillionbeforetaxmillionaftertax millionbeforetaxfromimpairmentofinprocessresearchanddevelopmentandsynthesintegrationcostsofmillionafter taxmillionbeforetaxadditionallythefourthquarterofincludesthegainonthecordisdivestiture johnsonjohnsonannualreport business combination divestiture certainbusinesseswereacquiredformillionincashandmillionofliabilitiesassumedduringthese acquisitionswereaccountedforusingtheacquisitionmethodandaccordinglyresultsofoperationshavebeeninclude inthefinancialstatementsfromtheirrespectivedatesofacquisition theacquisitionsprimarilyincludedvogueinternationalllcaprivatelyheldcompanyfocusedonthemarkete developmentanddistributionofsaloninfluencedandnatureinspiredhaircareandotherpersonalproductsneuwave medicalincaprivatelyheldmedicaldevicecompanythatmanufacturesandmarketsminimallyinvasivesofttissue microwaveablationsystemsneostratacompanyincagloballeaderindermocosmeticsandtheglobalrightsforthe commercializationofrhinocortallergysprayoutsidetheunitedstate theexcessofpurchasepriceovertheestimatedfairvalueoftangibleassetsacquiredamountedtomillionandha beenassignedtoidentifiableintangibleassetswithanyresidualrecordedtogoodwill thenetpurchasepriceforvogueinternationalllcofbillionwasprimarilyrecordedasamortizableintangibleasset forbillionandgoodwillforbilliontheweightedaveragelifeforthebillionoftotalamortizableintangiblesis approximatelyyearsthetrademarkassetvaluesweredeterminedtohavedefinitelivesrangingfromtoyear withthemajoritybeingyearsthegoodwillisprimarilyattributabletosynergiesexpectedtoarisefromthebusiness acquisitionandisexpectedtobedeductiblefortaxpurposestheassetsacquiredwererecordedintheconsumer segment duringthefiscalthirdquarterofthecompanyannouncedadefinitiveagreementtoacquireabbottmedicaloptic amoawhollyownedsubsidiaryofabbottlaboratoriesforbillionincashtheacquisitionwillinclude ophthalmicproductsrelatedtocataractsurgerylaserrefractivesurgeryandconsumereyehealththetransactionclose onfebruarythepurchasepriceallocationisinprogressandisexpectedtoresultinanallocationofsignificant valuetotheamortizableintangibleassetswithanyresidualrecordedasgoodwill onjanuarysubsequenttoyearendthecompanyannouncedadefinitivetransactionagreementunderwhich thecompanywilllaunchanallcashtenderofferinswitzerlandtoacquirealloftheoutstandingsharesofactelionltdfor persharepayableinusdollarsforapproximatelybillionaspartofthetransactionimmediatelypriortothe completionoftheacquisitionactelionwillspinoutitsdrugdiscoveryoperationsandearlystageclinicaldevelopment assetsintoanewlycreatedswissbiopharmaceuticalcompanyrdnewcothesharesofrdnewcowhichwillbe listedonthesixswissexchangesixwillbedistributedtoactelionsshareholdersasastockdividenduponclosingof thetenderthecompanywillinitiallyholdofthesharesofrdnewcoandhaverightstoanadditionalofrd newcoequitythroughaconvertiblenoteactelionhasestablishedaleadingfranchiseofdifferentiatedinnovative productsforpulmonaryarterialhypertensionpahthatishighlycomplementarytotheexistingportfolioofthecompany theadditionofactelionsspecialtyinmarketmedicinesandlatestageproductsisconsistentwiththecompanysefforts togrowinattractiveandcomplementarytherapeuticareasandservepatientswithseriousillnessesandsignificantunmet medicalneedtheclosingissubjecttothedemergerantitrustclearanceandothercustomaryclosingcondition onfebruarysubsequenttoyearendthecompanyreceivedabindingofferfromintegralifesciencesholding corporationtopurchasethecodmanneurosurgerybusinessforapproximatelybillion subsequenttoyearendthecompanyannounceditisengaginginaprocesstoevaluatepotentialstrategicoptionsfor thejohnsonjohnsondiabetescarecompaniesspecificallylifescanincanimascorporationandcalibramedical incstrategicoptionsmayincludetheformationofoperatingpartnershipsjointventuresorstrategicalliancesasaleof thebusinessesorotheralternativeseitherseparatelyortogetheralloptionswillbeevaluatedtodeterminetheb opportunitytodrivefuturegrowthandmaximizeshareholdervaluetherecanbenoassurancethatthisprocesswillresult inanytransactionorotherstrategicalternativeofanykindthereforetherewerenoassetsheldforsaleasofjanuary relatedtotheannouncement certainbusinesseswereacquiredformillionincashandmillionofliabilitiesassumedduringthe assumedliabilitiesprimarilyrepresentthefairvalueofthecontingentconsiderationofmilliontheseacquisition wereaccountedforusingtheacquisitionmethodandaccordinglyresultsofoperationshavebeenincludedinthe financialstatementsfromtheirrespectivedatesofacquisition theacquisitionsprimarilyincludedxolimitedaprivatelyheldbiopharmaceuticalcompanydevelopingananti thrombinantibodyandnoviratherapeuticsincaprivatelyheldclinicalstagebiopharmaceuticalcompanydeveloping innovativetherapiesforcurativetreatmentofchronichepatitisbvirusinfection johnsonjohnsonannualreport theexcessofpurchasepriceovertheestimatedfairvalueoftangibleassetsacquiredamountedtomillionandha beenassignedtoidentifiableintangibleassetswithanyresidualrecordedtogoodwillofthisamountapproximately millionhasbeenidentifiedasthevalueofiprdprimarilyassociatedwiththeacquisitionsofxolimitedandnovira therapeuticsincthevalueoftheiprdwascalculatedusingcashflowprojectionsdiscountedfortheinherentriskin theprojects theiprdrelatedtotheacquisitionofxolimitedofmillionisassociatedwitharecombinanthumanantibody developedtomimictheactivityofahumanantibodywhichappearstoproduceananticoagulatedstatewithout predispositiontobleedingaprobabilityofsuccessfactorofwasusedtoreflectinherentclinicalandregulatory riskthediscountrateappliedwa theiprdrelatedtotheacquisitionofnoviratherapeuticsincofmillionisassociatedwithitsleadcandidatenvr whichisaninvestigationalsmallmoleculedirectactingantiviralfororaladministrationinpatientswithhbvthat inhibitsthehbvcoreorcapsidproteinaprobabilityofsuccessfactorofwasusedtoreflectinherentclinicaland regulatoryriskthediscountrateappliedwa certainbusinesseswereacquiredformillionincashandmillionofliabilitiesassumedduringthese acquisitionswereaccountedforusingtheacquisitionmethodandaccordinglyresultsofoperationshavebeeninclude inthefinancialstatementsfromtheirrespectivedatesofacquisition theacquisitionsincludedcovagenagaprivatelyheldbiopharmaceuticalcompanyspecializinginthe developmentofmultispecificproteintherapeuticsthroughthefynomabtechnologyplatformaliosbiopharmainca privatelyheldclinicalstagebiopharmaceuticalcompanyfocusedondevelopingtherapiesforviraldiseasesandthe orsltmelectrolytereadytodrinkbrandfromjagdaleindustriesltdtheexcessofpurchasepriceovertheestimatedfair valueoftangibleassetsacquiredamountedtomillionandhasbeenassignedtoidentifiableintangibleassetswith anyresidualrecordedtogoodwillofthisamountapproximatelymillionhasbeenidentifiedasthevalueofiprd associatedwiththeacquisitionsofcovagenagandaliosbiopharmaincthevalueoftheiprdwascalculatedusing cashflowprojectionsdiscountedfortheinherentriskintheproject theiprdrelatedtotheacquisitionofaliosbiopharmaincofmillionisassociatedwithaliosleadcompound alanorallyadministeredantiviraltherapyfortreatmentofinfantswithrespiratorysyncytialvirusrsvaprobability ofsuccessfactorofwasusedtoreflectinherentclinicalandregulatoryriskthediscountrateappliedwa theiprdrelatedtotheacquisitionofcovagenagofmillionisassociatedwithcovagensleadcompound covacurrentlyinphasebstudyforpsoriasisandholdingpotentialasatreatmentforabroadrangeof inflammatorydiseasesincludingrheumatoidarthritisaprobabilityofsuccessfactorofwasusedtoreflectinherent clinicalandregulatoryriskthediscountrateappliedwasduringthecompanyrecordedachargeforthe impairmentoftheiprdrelatedtotheacquisitionofcovagenag inthecompanycompletedtheacquisitionofsynthesincforapurchasepriceofbillionincashandstock inconnectionwiththeacquisitionofsynthesincthecompanyenteredintotwoacceleratedsharerepurchaseasr agreementsinthecompanysettledtheremainingliabilitiesundertheasragreementswhilethecompany believesthatthetransactionsundereachasragreementandaseriesofrelatedinternaltransactionswereconsummate inataxefficientmannerinaccordancewithapplicablelawitispossiblethattheinternalrevenueservicecouldassert oneormorecontrarypositionstochallengethetransactionsfromataxperspectiveifchallengedanamountuptothe totalpurchasepriceforthesynthessharescouldbetreatedassubjecttoapplicableustaxatapproximatelythe statutoryratetothecompanyplusinterest supplementalproformainformationforandinaccordancewithusgaapstandardsrelatedto businesscombinationsandgoodwillandotherintangibleassetsisnotprovidedastheimpactoftheaforementione acquisitionsdidnothaveamaterialeffectonthecompanysresultsofoperationscashflowsorfinancialposition duringthecompanydivestituresincludedthecontrolledsubstancerawmaterialandactivepharmaceutical ingredientapibusinesscertainanestheticproductsineuropeandcertainnonstrategicconsumerbrandsinthe pretaxgainsonthedivestitureswereapproximatelybillion duringthecompanydivestituresincludedthecordisbusinesstocardinalhealththesplendabrandto heartlandfoodproductsgroupandtheuslicenserightstonucyntatapentadolnucyntaertapentadol extendedreleasetabletsandnucyntatapentadoloralsolutioninthepretaxgainsonthedivestitureswere approximatelybillion duringthecompanydivestituresincludedtheorthoclinicaldiagnosticsbusinesstothecarlylegrouptheky brandtoreckittbenckisergroupplcintheusandcertainothermarketsandthebenecolbrandtoraisioplc johnsonjohnsonannualreportinthepretaxgainsonthedivestitureswereapproximatelybillionthecompanycompletedthedivestitureof itsorthoclinicaldiagnosticsbusinesstothecarlylegroupforapproximatelybillionandthecompanyrecordeda pretaxgainofapproximatelybillionorthoclinicaldiagnosticsresultsareincludedinthecompanysmedical devicessegment legal proceeding johnsonjohnsonandcertainofitssubsidiariesareinvolvedinvariouslawsuitsandclaimsregardingproductliability intellectualpropertycommercialandothermattersgovernmentalinvestigationsandotherlegalproceedingsthatarise fromtimetotimeintheordinarycourseoftheirbusiness thecompanyrecordsaccrualsforlosscontingenciesassociatedwiththeselegalmatterswhenitisprobablethata liabilitywillbeincurredandtheamountofthelosscanbereasonablyestimatedasofjanuarythecompanyhas determinedthattheliabilitiesassociatedwithcertainlitigationmattersareprobableandcanbereasonablyestimatedthe companyhasaccruedforthesemattersandwillcontinuetomonitoreachrelatedlegalissueandadjustaccrualsasmight bewarrantedbasedonnewinformationandfurtherdevelopmentsinaccordancewithascfortheseand otherlitigationandregulatorymattersdiscussedbelowforwhichalossisprobableorreasonablypossiblethecompany isunabletoestimatethepossiblelossorrangeoflossbeyondtheamountsalreadyaccruedamountsaccruedforlegal contingenciesoftenresultfromacomplexseriesofjudgmentsaboutfutureeventsanduncertaintiesthatrelyheavilyon estimatesandassumptionstheabilitytomakesuchestimatesandjudgmentscanbeaffectedbyvariousfactor includingwhetherdamagessoughtintheproceedingsareunsubstantiatedorindeterminatescientificandlegaldiscovery hasnotcommencedorisnotcompleteproceedingsareinearlystagesmatterspresentlegaluncertaintiesthereare significantfactsindisputeortherearenumerouspartiesinvolve inthecompanysopinionbasedonitsexaminationofthesemattersitsexperiencetodateanddiscussionswithcounsel theultimateoutcomeoflegalproceedingsnetofliabilitiesaccruedinthecompanysbalancesheetisnotexpectedto haveamaterialadverseeffectonthecompanysfinancialpositionhowevertheresolutionoforincreaseinaccrualsfor oneormoreofthesemattersinanyreportingperiodmayhaveamaterialadverseeffectonthecompanysresultsof operationsandcashflowsforthatperiod productliability johnsonjohnsonandcertainofitssubsidiariesareinvolvedinnumerousproductliabilityclaimsandlawsuitsinvolving multipleproductsclaimantsinthesecasesseeksubstantialcompensatoryandwhereavailablepunitivedamageswhile thecompanybelievesithassubstantialdefensesitisnotfeasibletopredicttheultimateoutcomeoflitigationthe companyhasestablishedaccrualsforproductliabilityclaimsandlawsuitsincompliancewithascbasedon currentlyavailableinformationwhichinsomecasesmaybelimitedthecompanyaccruesanestimateofthelegal defensecostsneededtodefendeachmatterwhenthosecostsareprobableandcanbereasonablyestimatedforcertain ofthesemattersthecompanyhasaccruedadditionalamountssuchasestimatedcostsassociatedwithsettlement damagesandotherlossestotheextentadverseverdictshavebeenrenderedagainstthecompanythecompanydoe notrecordanaccrualuntilalossisdeterminedtobeprobableandcanbereasonablyestimatedproductliabilityaccrual canrepresentprojectedproductliabilityforthousandsofclaimsaroundtheworldeachindifferentlitigationenvironment andwithdifferentfactpatternschangestotheaccrualsmayberequiredinthefutureasadditionalinformationbecomes available themostsignificantofthesecasesincludethedepuyasrxlacetabularsystemanddepuyasrhipresurface systemthepinnacleacetabularcupsystempelvicmeshesrisperdalxareltoandjohnsonsbaby powderasofjanuaryintheustherewereapproximatelyplaintiffswithdirectclaimsinpendinglawsuit regardinginjuriesallegedlyduetothedepuyasrxlacetabularsystemanddepuyasrhipresurfacingsystem withrespecttothepinnacleacetabularcupsystemwithrespecttopelvicmesheswith respecttorisperdalwithrespecttoxareltoandwithrespecttojohnsonsbabypowder inaugustdepuyorthopaedicsincdepuyannouncedaworldwidevoluntaryrecallofitsasrxlacetabular systemanddepuyasrhipresurfacingsystemusedinhipreplacementsurgeryclaimsforpersonalinjuryhavebeen madeagainstdepuyandjohnsonjohnsonthenumberofpendinglawsuitsisexpectedtofluctuateascertainlawsuit aresettledordismissedandadditionallawsuitsarefiledcasesfiledinfederalcourtsintheunitedstateshavebeen organizedasamultidistrictlitigationintheunitedstatesdistrictcourtforthenortherndistrictofohiolitigationhas alsobeenfiledincountriesoutsideoftheunitedstatesprimarilyintheunitedkingdomcanadaaustraliaireland johnsonjohnsonannualreport germanyanditalyinnovemberdepuyreachedanagreementwithacourtappointedcommitteeoflawyer representingasrhipsystemplaintiffstoestablishaprogramtosettleclaimswitheligibleasrhippatientsintheunite stateswhohadsurgerytoreplacetheirasrhipsknownasrevisionsurgeryasofaugustthissettlement coveredapproximatelypatientsinfebruarydepuyreachedanadditionalagreementwhicheffectively extendstheexistingsettlementprogramtoasrhippatientswhohadrevisionsurgeriesafteraugustandprior tofebruarythissecondagreementisestimatedtocoverapproximatelyadditionalpatientstheestimated costoftheseagreementsiscoveredbyexistingaccrualsthissettlementprogramisexpectedtobringtoaclose significantasrhiplitigationactivityintheunitedstateshowevermanylawsuitsintheunitedstateswillremainandthe settlementprogramdoesnotaddresslitigationoutsideoftheunitedstatesinaustraliaasettlementwasreachedwith representativesofaclassactionlawsuitpendinginthefederalcourtofnewsouthwalesthatresolvestheclaimsofthe majorityofasrhippatientsinthatcountrythecompanycontinuestoreceiveinformationwithrespecttopotentialcosts associatedwiththisrecallonaworldwidebasisthecompanyhasestablishedaccrualsforthecostsassociatedwiththe depuyasrhipprogramandrelatedproductliabilitylitigationchangestotheseaccrualsmayberequiredinthefuture asadditionalinformationbecomesavailable claimsforpersonalinjuryhavealsobeenmadeagainstdepuyandjohnsonjohnsonrelatingtothepinnacle acetabularcupsystemusedinhipreplacementsurgerythenumberofpendingproductliabilitylawsuitscontinuesto increaseandthecompanycontinuestoreceiveinformationwithrespecttopotentialcostsandtheanticipatednumberof casescasesfiledinfederalcourtsintheunitedstateshavebeenorganizedasamultidistrictlitigationintheunite statesdistrictcourtforthenortherndistrictoftexaslitigationhasalsobeenfiledincountriesoutsideoftheunite statesprimarilyintheunitedkingdomthecompanyhasestablishedanaccrualfordefensecostsinconnectionwith productliabilitylitigationassociatedwiththepinnacleacetabularcupsystemchangestothisaccrualmaybe requiredinthefutureasadditionalinformationbecomesavailable claimsforpersonalinjuryhavebeenmadeagainstethiconincethiconandjohnsonjohnsonarisingoutofethicon pelvicmeshdevicesusedtotreatstressurinaryincontinenceandpelvicorganprolapsethenumberofpendingproduct liabilitylawsuitscontinuestoincreaseandthecompanycontinuestoreceiveinformationwithrespecttopotentialcosts andtheanticipatednumberofcasescasesfiledinfederalcourtsintheunitedstateshavebeenorganizedasamulti districtlitigationintheunitedstatesdistrictcourtforthesoutherndistrictofwestvirginiainadditionclassactionsand individualpersonalinjurycasesorclaimshavebeencommencedinvariouscountriesoutsideoftheunitedstate includingclaimsandcasesintheunitedkingdomthenetherlandsbelgiumitalyandvenezuelaandclassactionsin israelaustraliaandcanadaseekingdamagesforallegedinjuryresultingfromethiconspelvicmeshdevicesthe companyhasestablishedanaccrualwithrespecttoproductliabilitylitigationassociatedwithethiconspelvicmesh productschangestothisaccrualmayberequiredinthefutureasadditionalinformationbecomesavailable claimsforpersonalinjuryhavebeenmadeagainstjanssenpharmaceuticalsincandjohnsonjohnsonarisingoutofthe useofrisperdalindicatedforthetreatmentofschizophreniaacutemanicormixedepisodesassociatedwithbipolari disorderandirritabilityassociatedwithautismandrelatedcompoundslawsuitshavebeenprimarilyfiledinstatecourtsin pennsylvaniacaliforniaandmissouriotheractionsarependinginvariouscourtsintheunitedstatesandcanadathe numberofpendingproductliabilitylawsuitscontinuestoincreaseandthecompanycontinuestoreceiveinformationwith respecttopotentialcostsandtheanticipatednumberofcasesthecompanyhasestablishedanaccrualwithrespectto productliabilitylitigationassociatedwithrisperdalchangestothisaccrualmayberequiredinthefuturea additionalinformationbecomesavailable claimsforpersonalinjuryhavebeenmadeagainstjanssenpharmaceuticalsincandjohnsonjohnsonarisingoutofthe useofxareltoanoralanticoagulantthenumberofpendingproductliabilitylawsuitscontinuestoincreaseandthe companycontinuestoreceiveinformationwithrespecttopotentialcostsandtheanticipatednumberofcasescase filedinfederalcourtsintheunitedstateshavebeenorganizedasamultidistrictlitigationintheunitedstatesdistrict courtfortheeasterndistrictoflouisianainadditioncaseshavebeenfiledinstatecourtsacrosstheunitedstate manyofthesecaseshavebeenconsolidatedintoastatemasstortlitigationinphiladelphiapennsylvaniaandthereare coordinatedproceedingsindelawarecaliforniaandmissouriclassactionlawsuitsalsohavebeenfiledincanadathe companyhasestablishedanaccrualfordefensecostsinconnectionwithproductliabilitylitigationassociatedwith xareltochangestothisaccrualmayberequiredinthefutureasadditionalinformationbecomesavailable claimsforpersonalinjuryhavebeenmadeagainstjohnsonjohnsonconsumerincandjohnsonjohnsonarisingout oftheuseofjohnsonsbabypowderthenumberofpendingproductliabilitylawsuitscontinuestoincreaseandthe companycontinuestoreceiveinformationwithrespecttopotentialcostsandtheanticipatednumberofcaseslawsuit havebeenprimarilyfiledinstatecourtsinmissourinewjerseyandcaliforniainadditionafederalmultidistrictlitigation proceedinghasbeencreatedforthislitigationinthedistrictcourtofnewjerseythecompanyhasestablishedan johnsonjohnsonannualreportaccrualfordefensecostsinconnectionwithproductliabilitylitigationassociatedwithjohnsonsbaby powderchangestothisaccrualmayberequiredinthefutureasadditionalinformationbecomesavailable intellectualproperty certainsubsidiariesofjohnsonjohnsonaresubjectfromtimetotimetolegalproceedingsandclaimsrelatedto patenttrademarkandotherintellectualpropertymattersarisingoutoftheirbusinessesmanyofthesemattersinvolve challengestothecoverageandorvalidityofthepatentsonvariousproductsandallegationsthatcertainofthecompanys productsinfringethepatentsofthirdpartiesalthoughthesesubsidiariesbelievethattheyhavesubstantialdefensesto thesechallengesandallegationswithrespecttoallsignificantpatentstherecanbenoassuranceastotheoutcomeof thesemattersalossinanyofthesecasescouldadverselyaffecttheabilityofthesesubsidiariestoselltheirproduct resultinlossofsalesduetolossofmarketexclusivityrequirethepaymentofpastdamagesandfutureroyaltiesandmay resultinanoncashimpairmentchargeforanyassociatedintangibleassetthemostsignificantofthesemattersare describedbelow medicaldevice injunerembrandtvisiontechnologieslprembrandtfiledapatentinfringementlawsuitagainstjohnson johnsonvisioncareincjjvciintheunitedstatesdistrictcourtfortheeasterndistrictoftexasallegingthatjjvcis manufactureandsaleofitsacuvueadvanceandacuvueoasyshydrogelcontactlensesinfringetheirus patentnothepatentrembrandtisseekingmonetaryreliefthecasewastransferredtotheunite statesdistrictcourtforthemiddledistrictoffloridainmaythejuryreturnedaverdictholdingthatneitherofthe accusedlensesinfringesthepatentrembrandtappealedandinaugusttheunitedstatescourtofappeal forthefederalcircuitaffirmedthedistrictcourtsjudgmentrembrandtaskedthedistrictcourttograntitanewtrial basedonallegednewevidenceandinjulythedistrictcourtdeniedrembrandtsmotionrembrandtappeale andthecourtofappealsoverturnedthatrulinginaprilandremandedthecasetothedistrictcourtforanewtrial jjvcismotiontoreconsiderandpetitionforreviewwiththeunitedstatessupremecourtwerebothdeniedanewtrial isscheduledforaugust indecemberthestateofisraelfiledalawsuitinthedistrictcourtintelavivjaffaagainstomrix biopharmaceuticalsincandvariousaffiliatesomrixinthelawsuitthestateclaimedthatanemployeeofagovernment ownedhospitalwastheinventoronseveralpatentsrelatedtofibringluetechnologythattheemployeedevelopedwhilehe wasagovernmentemployeethestateclaimedthathehadnorighttotransferanyintellectualpropertytoomrixbecause itbelongstothestatethestatesoughtdamagesplusroyaltiesonquixilandevicelproductsoralternatively transferofthepatentstothestatethecasewassettledindecember lifescanfiledapatentinfringementlawsuitagainstunistriptechnologiesllcunistripintheunitedstatesdistrict courtforthedistrictofnorthcarolinainmayallegingthatthemakingandmarketingofunistripsstripsforusein lifescansbloodglucosemonitorsinfringeuspatentnosthepatentandthe patentinaugusttheunitedstatespatentandtrademarkofficeusptodeterminedthatthepatentis invalidinjanuarytheinvaliditydecisionwasupheldonappeallifescanfiledamotionforrehearingwhichwa deniedinjulyunistripbroughtalawsuitagainstlifescanintheunitedstatesdistrictcourtfortheeasterndistrict ofpennsylvaniaallegingantitrustviolationsrelatingtomarketingpracticesforlifescanstrips inmarchmedinolltdmedinolfiledapatentinfringementlawsuitagainstcordiscorporationcordisand johnsonjohnsonintheunitedstatesdistrictcourtforthesoutherndistrictofnewyorkallegingthatallofcordiss salesofthecypherandcypherselectstentsmadeintheunitedstatessincewillfullyinfringedfourof medinolspatentsdirectedtothegeometryofarticulatedstentsmedinolisseekingdamagesandattorneysfeesafter trialinjanuarythedistrictcourtdismissedthecasefindingmedinolunreasonablydelayedbringingitsclaimsand medinoldidnotappealthedecisioninseptemberthedistrictcourtdeniedamotionbymedinoltovacatethe judgmentandgrantitanewtrialmedinolsappealofthisdecisionhasbeendismissedmedinolhasfiledapetitionfor reviewwiththeunitedstatessupremecourtcordiswasdivestedinandthecompanyretainedanyliabilitythat mayresultfromthiscase innovembermedideallcmedideafiledapatentinfringementlawsuitagainstdepuyorthopaedicsincinthe unitedstatesdistrictcourtforthenortherndistrictofillinoisalleginginfringementbytheattunekneesystemoftwo patentsrelatingtoposteriorstabilizedkneesystemsspecificallymedideaallegesthatthesofcamtmcontactfeatureof theattuneposteriorstabilizedkneeproductsinfringesthepatentsinsuitmedideaisseekingmonetarydamagesand injunctiverelief johnsonjohnsonannualreport indecemberethiconendosurgeryincandethiconendosurgeryllcnowknownasethiconllcsue covidienincintheusdistrictcourtforthedistrictofmassachusettsseekingadeclarationthatcovidiensuspatent nosandareeitherinvalidornotinfringedbyethicon ensealxlargejawtissuesealerproductensealxtheensealxproductisscheduledtolaunchinthe unitedstatesandeuropeinthefirstquarterof pharmaceutical inaprilmorphosysagagermanbiotechcompanyfiledapatentinfringementlawsuitagainstjanssenbiotech incjbigenmabusincandgenmabascollectivelygenmabintheunitedstatesdistrictcourtforthedistrictof delawareallegingthatjbismanufactureandsaleofdarzalexdaratumumabwillfullyinfringesmorphosysus patentnomorphosysisseekingmoneydamagesjbilicensespatentsandthecommercialrightsto darzalexfromgenmabinjunejbifiledamotiontodismissthelawsuitinnovembermorphosys soughtleavetoaddanotherpatenttothecaseuspatentnoandinfebruarythecourtgrantedthe requesttrialinthecaseiscurrentlyscheduledtocommenceinaugust inaugustsandozltdandhexalagcollectivelysandozfiledalawsuitintheenglishhighcourtagainstgd searlellcapfizercompanyandjanssensciencesirelanducjsiallegingthatsearlessupplementaryprotection certificatespcgbspcwhichisexclusivelylicensedtojsiisinvalidandshouldberevokedjanssencilag limitedsellsprezistadarunavirintheukpursuanttothislicenseinoctobersearleandjsicounterclaime againstsandozforthreatenedinfringementofthespcbasedonstatementsofitsplanstolaunchgenericdarunavirinthe uktrialofthecasehasbeenscheduledtobegininlateaprilearlymay remicaderelatedcase usproceeding inseptemberjanssenbiotechincjbiandnyulangonemedicalcenternyureceivedanofficeactionfrom theunitedstatespatentandtrademarkofficeusptorejectingtheclaimsinuspatentnorelatingto remicadeinfliximabthepatentinareexaminationproceedinginstitutedbyathirdpartythepatentisco ownedbyjbiandnyuandnyugrantedjbianexclusivelicensetonyusrightsunderthepatentthepatent expiresinseptemberfollowingseveralofficeactionsbythepatentexaminerincludingtwofurtherrejectionsand responsesbyjbitheusptoissuedafurtheractionmaintainingitsrejectionofthepatentjbifiledanoticeof appealtotheusptospatenttrialandappealboardinnovemberthepatenttrialandappealboardissueda decisionupholdingtheexaminersrejectionjbihasfiledanappealtotheuscourtofappealsforthefederalcircuit inaugustcelltrionhealthcarecoltdandcelltrioninctogethercelltrionfiledanapplicationwiththeusfood anddrugadministrationfdaforapprovaltomakeandsellitsowninfliximabbiosimilarinmarchjbifiledalawsuit intheunitedstatesdistrictcourtforthedistrictofmassachusettsagainstcelltrionandhospirahealthcarecorporation hospirawhichhasexclusiveusmarketingrightsforcelltrionsinfliximabbiosimilarseekingamongotherthingsa declaratoryjudgmentthattheirbiosimilarproductinfringesorpotentiallyinfringesseveraljbipatentsincludingthe patentanduspatentnothepatentinaugustthedistrictcourtgrantedbothcelltrion andhospirasmotionsforsummaryjudgmentofinvalidityofthepatentjbihasappealedthosedecisionstotheus courtofappealsforthefederalcircuitthiscaseandtheappealofthereexaminationofthepatenthavebeen designatedcompanioncasesandwillbeheardbythesamepanelofjudgesinthefederalcircuit injunejbifiledtwoadditionalpatentinfringementlawsuitsassertingthepatentoneagainstcelltrioninthe unitedstatesdistrictcourtforthedistrictofmassachusettsandtheotheragainsthyclonelaboratoriesincthe manufacturerofthecellculturemediathatcelltrionusestomakeitsbiosimilarproductintheunitedstatesdistrictcourt forthedistrictofutahalthoughthepatentisalreadyassertedintheexistinglawsuitagainstcelltriontheadditional lawsuitexpandstheclaimstoincludeanyuseofthecellculturemediamadeintheunitedstatestomanufacture celltrionsbiosimilarthisadditionallawsuitagainstcelltrionhasbeenconsolidatedwiththeexistinglawsuitdiscusse abovehospirahasmovedtodismissallcountsofthelawsuitrelatedtothepatentastoitcelltrionhasmovedto dismissallcountsofthelawsuitrelatedtothepatentwithoutprejudiceforfailuretojoinallthecoownersofthe patentasplaintiffsthetrialhasbeenpostponedpendingresolutionofthesemotion thefdaapprovedcelltrionsinfliximabbiosimilarforsaleintheunitedstatesinaprilandthedayperiodfor noticeoflaunchofabiosimilarproductunderthebiologicspricecompetitionandinnovationacthaspasse johnsonjohnsonannualreporthospirasparentcompanypfizerincbeganshipmentofcelltrionsinfliximabbiosimilartowholesalersintheunited statesinlatenovemberintroductiontotheusmarketofthebiosimilarwillresultinareductioninussalesof remicade canadianproceedings inmarchhospirafiledanimpeachmentproceedingagainstthekennedyinstituteofrheumatologykennedy challengingthevalidityofacanadianpatentrelatedtoremicadeafeldmanpatentwhichisexclusivelylicensedto jbiinoctoberkennedyalongwithjbijanssenincjanssenandcilaggmbhinternationalbothaffiliatesofjbi filedacounterclaimforinfringementagainstcelltrionandhospirathecounterclaimallegesthattheproductsdescribedin celltrionsandhospirasmarketingapplicationstohealthcanadafortheirsubsequententrybiologicssebto remicadewouldinfringethefeldmanpatentsownedbykennedyatrialinthispatentactionconcludedinoctober andclosingargumentstookplaceinjanuarythepartiesareawaitingadecision injanuaryhealthcanadaapprovedcelltrionssebtoremicadeallowingcelltriontomarketitsinfliximab biosimilarincanadaregardlessofthependingpatentactioninjunehealthcanadaapprovedhospirassebto remicadeinjulyjanssenfiledalawsuittocompelthecanadianministerofhealthtowithdrawthenoticeof complianceforhospirassebbecausehospiradidnotserveanoticeofallegationonjanssentoaddressthepatent listedbyjanssenonthepatentregisterinmarchthepartiesenteredintoasettlementagreementwherebyhealth canadaagreedtoaconsentjudgmentsettingasidehospirasnoticeofcompliancesubjecttohealthcanadasappeal whichwasfiledinjuneneverthelesshospirabeganmarketinganinfliximabbiosimilarasadistributorunder celltrionsnoticeofcomplianceinoctobertheappealscourtreversedtheconsentjudgmentjanssenhasfile anapplicationforleavetoappealwiththesupremecourtofcanadahospiracontinuestomarketandsellcelltrion infliximabbiosimilarincanada incanadaiftheremicadepatentdiscussedaboveisfoundtobeinvalidfollowingallappealsitcouldnotberelie upontopreventthefurtherintroductionofinfliximabbiosimilarspriortotheaugustexpirydateofthepatent litigationagainstfilersofabbreviatednewdrugapplicationsanda thefollowingsummarizeslawsuitspendingagainstgenericcompaniesthathavefiledabbreviatednewdrugapplications andaswiththefdaorundertakensimilarregulatoryprocessesoutsideoftheunitedstatesseekingtomarketgeneric formsofproductssoldbyvarioussubsidiariesofjohnsonjohnsonpriortoexpirationoftheapplicablepatentscovering thoseproductstheseandastypicallyincludeallegationsofnoninfringementinvalidityandunenforceabilityofthe applicablepatentsintheeventthesubsidiariesarenotsuccessfulintheseactionsorthestatutorymonthstaysofthe andasexpirebeforetheunitedstatesdistrictcourtrulingsareobtainedthethirdpartycompaniesinvolvedwillhavethe abilityuponapprovalofthefdatointroducegenericversionsoftheproductsatissuetothemarketresultinginthe potentialforsubstantialmarketshareandrevenuelossesforthoseproductsandwhichmayresultinanoncash impairmentchargeinanyassociatedintangibleassetinadditionfromtimetotimesubsidiariesmaysettletheseaction andsuchsettlementscaninvolvetheintroductionofgenericversionsoftheproductsatissuetothemarketpriortothe expirationoftherelevantpatentstheinterpartesreviewiprprocesswiththeunitedstatespatentandtrademark officeusptocreatedundertheamericainventsactisalsobeingusedbygenericcompaniesinconjunction withtheseandasandlawsuitstochallengepatentsheldbythecompanyssubsidiarie concerta indecemberjanssenincandalzacorporationfiledanoticeofapplicationagainstactavispharmacompany actavisinresponsetoactavisnoticeofallegationseekingapprovaltomarketagenericversionofconcertabefore theexpirationofcanadianpatentnothepatentindecemberthecanadianfederalcourt allowedtheapplicationandissuedanorderpreventingactavisfromobtainingmarketingapprovalanoticeof complianceforitsgenericversionofconcertauntiltheexpirationofthepatentactavisdidnotcommencean appealpriortothedeadlinefordoingsoandthusispreventedfromobtaininganoticeofcomplianceforageneric versionofconcertauntiltheexpirationofthepatent inoctoberalzacorporationandjanssenpharmaceuticalsincfiledapatentinfringementlawsuitintheus districtcourtforthedistrictofdelawareagainstamnealpharmaceuticalsofnewyorkllcandamnealpharmaceutical llcinresponsetoamnealsandaseekingapprovaltomarketagenericversionofconcertabeforetheexpirationof unitedstatespatentnosandinnovemberamnealfiledamotionforjudgmentonthe pleadingsarguingthatcertainclaimsofthepatentsareinvalidandothersarenotinfringedjanssenhasopposedthe motion johnsonjohnsonannualreport zytiga injuneandjulyjanssenbiotechincjbireceivednoticesofparagraphivcertificationfromseveralcompanie advisingoftheirrespectiveandasseekingapprovalforagenericversionofzytigabeforetheexpirationofoneor morepatentsrelatingtozytigainjulyjbijanssenoncologyincjanssenoncologyandjanssenresearch developmentllccollectivelyjanssenandbtginternationalltdbtgfiledapatentinfringementlawsuitintheunite statesdistrictcourtforthedistrictofnewjerseyagainstseveralgenericandaapplicantsandcertainoftheiraffiliate andorsuppliersinresponsetotheirrespectiveandasseekingapprovaltomarketagenericversionofzytigabefore theexpirationofunitedstatespatentnosthepatentandorthepatentthegeneric companiesincludeactavislaboratoriesflincactavisamnealpharmaceuticalsllcandamnealpharmaceuticalsof newyorkllccollectivelyamnealapotexincandapotexcorpcollectivelyapotexcitronpharmallccitron drreddyslaboratoriesltdanddrreddyslaboratoriesinccollectivelydrreddysmylanpharmaceuticalsinc andmylaninccollectivelymylanparpharmaceuticalsincandparpharmaceuticalcompaniesinccollectivelypar sunpharmaceuticalindustriesltdandsunpharmaceuticalsindustriesinccollectivelysuntevapharmaceutical usainctevawockhardtbioagwockhardtusallcandwockhardtltdcollectivelywockhardtwestward pharmaceuticalcorpwestwardandhikmapharmaceuticalsllchikmathecourtenteredastayofthelawsuit againstparandcitronaseachagreedtobeboundbythedecisionagainsttheotherdefendantsintheactionthe patentexpiredindecemberandthustheinfringementactionsconcernonlythepatentinfebruarythe courtsetatrialdateofoctober inaugustjanssenandbtgfiledanadditionaljurisdictionalprotectivelawsuitagainstthemylandefendantsinthe unitedstatesdistrictcourtforthenortherndistrictofwestvirginiawhichhasbeenstayed inaugustjanssenreceivedanoticeofparagraphivcertificationfromheterousainctheusregulatoryagent forheterolabslimitedunitvadivisionofheterolabslimitedcollectivelyheteroadvisingofheterosandaseeke approvalforagenericversionofzytigabeforeexpirationofthepatentinseptemberjanssenandbtg filedanamendedcomplaintinthenewjerseylawsuittoaddallegedinfringementofthepatentbyhetero inmarchjanssenfiledamotioninthenewjerseylawsuittocorrectinventorshipofthepatenttoaddan inventorandifgrantedforleavetoamendthecomplaintaccordinglyinjanuarythecourtgrantedjanssens motionandjanssenfiledasecondamendedcomplaintaddingbtgasacoownerofthepatentandacoplaintiff regardingthepatentinfringementclaim inmarchjanssenreceivedanoticefromamerigenpharmaceuticalslimitedamerigenadvisingofamerigens andaseekingapprovalforagenericversionofzytigabeforeexpirationofthepatentinresponsejanssenand btgfiledaseparatepatentinfringementlawsuitintheunitedstatesdistrictcourtforthedistrictofnewjerseyagainst amerigeninmay inmayjanssenreceivedanoticeofparagraphivcertificationfromglenmarkpharmaceuticalsinconbehalfof glenmarkpharmaceuticalssaawhollyownedsubsidiaryofglenmarkpharmaceuticalsltdcollectivelyglenmark advisingofglenmarksandaseekingapprovalforagenericversionofzytigabeforeexpirationofthepatentin responseinjunejanssenandbtgfiledapatentinfringementlawsuitintheunitedstatesdistrictcourtforthe districtofnewjerseyagainstglenmarkthepartieshavestipulatedtoadismissalofglenmarkpharmaceuticalsltd thefilingoftheabovereferencedlawsuitstriggeredastayuntiloctoberduringwhichtimethefdawillnotgrant finalapprovalofthegenericsandasunlessthereisanearlierdistrictcourtdecisionfindingthepatentsinsuitinvalidor notinfringe ineachoftheabovelawsuitsjanssenisseekinganorderenjoiningthedefendantsfrommarketingtheirgenericversion ofzytigabeforetheexpirationoftherelevantpatent indecemberamerigenfiledapetitionforaninterpartesreviewintheusptoseekingtoinvalidatethepatent inmaytheusptograntedtheinterpartesreviewandadecisionastothevalidityofthepatentisexpected bymayinjuneargentumpharmaceuticalsllcandmylanpharmaceuticalsincfiledpetitionsforinterparte reviewintheusptoseekingtoinvalidatethepatentandmovedtojointheinterpartesreviewfiledbyamerigenthe usptoinstitutedargentumspetitionandgrantedargentumsmotionforjoinderandinjanuarygrantedmylans petitionforinterpartesreviewbutdeniedmylansmotionforjoinderinaugustwockhardtbioagfiledapetition forinterpartesreviewintheusptoseekingtoinvalidatethepatentwhichtheusptograntedinjanuaryin februaryactavisamnealdrreddyssuntevawestwardandhikmafiledajointpetitionforinterpartesreview intheusptoseekingtoinvalidatethepatentandmovedtojointheinterpartesreviewfiledbymylan johnsonjohnsonannualreportcomplera inaugustandseptemberjanssenpharmaceuticanvandjanssensciencesirelanduccollectivelyjanssenand gileadsciencesincandgileadsciencesirelanduccollectivelygileadfiledpatentinfringementlawsuitsintheunite statesdistrictcourtsforthedistrictofdelawareandthedistrictofwestvirginiarespectivelyagainstmylanincand mylanpharmaceuticalsinccollectivelymylaninresponsetomylansandaseekingapprovaltomarketageneric versionofcomplerabeforetheexpirationofunitedstatespatentnosthepatentthe patentandthepatent inthewestvirginiaactioninseptembermylanfiledananswerandcounterclaimsassertinginvalidityandnon infringementofthepatentpatentandpatentaswellasunitedstatespatentnothe patentinmarchthedistrictofwestvirginiacourtstayedthelawsuitandscheduledaconditionaltrialdatein februaryinaccordancewiththescheduleinthefirstfileddelawarelawsuitdescribedbelow inthedelawareactioninjanuaryandmarchjanssenandgileadamendedtheircomplainttoaddclaimsforpatent infringementwithrespecttothepatentandunitedstatespatentnosthepatentthe patentthepatentandthepatentmylanfiledamotiontodismissthesuitfor lackofpersonaljurisdictionandamotiontodismissstrikeorsevertheinfringementclaimsregardingtheand patentsinseptemberthedelawaredistrictcourtdeniedbothofmylansmotionsatrialinthedelaware actionhasbeenscheduledforfebruary ineachoftheselawsuitsjanssenisseekinganorderenjoiningthedefendantsfrommarketingtheirgenericversionsof complerabeforetheexpirationoftherelevantpatent xarelto anumberofgenericcompanieshavefiledandasseekingapprovaltomarketgenericversionsofxareltoinoctober janssenpharmaceuticalsincjpiandbayerpharmaagandbayerintellectualpropertygmbhcollectively bayerfiledpatentinfringementlawsuitsintheunitedstatesdistrictcourtforthedistrictofdelawareagainstaurobindo pharmalimitedaurobindopharmausaincbreckenridgepharmaceuticalincmicrolabsusaincandmicrolabs ltdcollectivelymicromylanpharmaceuticalsincmylanincmylanprinstonpharmaceuticalincsigmapharm laboratoriesllctorrentpharmaceuticalslimitedandtorrentpharmaincinresponsetothosepartiesrespective andasseekingapprovaltomarketgenericversionsofxareltobeforetheexpirationofbayersunitedstatespatent nosthepatentthepatentandthepatentrelatingtoxarelto jpiistheexclusivelicenseeoftheassertedpatent innovembermylanmovedtodismisstheactionindecemberjpibayerandmylanstipulatedandagreedto dismisstheclaimsagainstmylanandsuspendfurtherbriefingandargumentonmylansmotiontodismisspending appealsrelatingtopersonaljurisdictionovermylanpharmaceuticalsincinthedistrictofdelawareinfebruarya similarpatentinfringementactionbyjpiandbayeragainstinvagenpharmaceuticalsincinvageninresponseto invagensnoticeofparagraphivcertificationadvisingofitsandaseekingfdaapprovalforagenericxarelto productbeforeexpirationoftherelevantpatentswasconsolidatedwiththeoriginalcasethedistrictcourthassetatrial dateofmarch inapriljpiandbayerfiledaseparatepatentinfringementactioninthedistrictofdelawareagainstmicroin responsetotheirnoticeofparagraphivcertificationadvisingoftheirandaseekingfdaapprovalforageneric xareltoproductbeforeexpirationoftheandpatentsinmaythisactionwasconsolidatedwiththe originalaction injulyjpiandbayerfiledaseparatepatentinfringementactioninthedistrictofdelawareagainstbreckenridge pharmaceuticalincinresponsetoitsnoticeofparagraphivcertificationadvisingofitsandaseekingfdaapprovalfor agenericxareltoproductbeforeexpirationoftheandpatentsthisactionhasbeenconsolidatedwiththe originalaction ineachoftheselawsuitsjpiisseekinganorderenjoiningthedefendantsfrommarketingtheirgenericversionsof xareltobeforetheexpirationoftherelevantpatent inoctobermylanfiledpetitionsforinterpartesreviewintheusptoseekingtoinvalidatetheand patent johnsonjohnsonannualreport governmentproceeding likeothercompaniesinthepharmaceuticalandmedicaldevicesindustriesjohnsonjohnsonandcertainofit subsidiariesaresubjecttoextensiveregulationbynationalstateandlocalgovernmentagenciesintheunitedstatesand othercountriesinwhichtheyoperateasaresultinteractionwithgovernmentagenciesisongoingthemostsignificant litigationbroughtbyandinvestigationsconductedbygovernmentagenciesarelistedbelowitispossiblethatcriminal chargesandsubstantialfinesandorcivilpenaltiesordamagescouldresultfromgovernmentinvestigationsorlitigation averagewholesalepriceawplitigation johnsonjohnsonandseveralofitspharmaceuticalsubsidiariesthejjawpdefendantsalongwithnumerousother pharmaceuticalcompaniesaredefendantsinaseriesoflawsuitsinstateandfederalcourtsinvolvingallegationsthatthe pricingandmarketingofcertainpharmaceuticalproductsamountedtofraudulentandotherwiseactionableconduct becauseamongotherthingsthecompaniesallegedlyreportedaninflatedaveragewholesalepriceawpforthedrug atissuepayorsallegedthattheyusedthoseawpsincalculatingproviderreimbursementlevelsmanyofthesecase bothfederalactionsandstateactionsremovedtofederalcourtwereconsolidatedforpretrialpurposesinamultidistrict litigationmdlintheunitedstatesdistrictcourtforthedistrictofmassachusettstheplaintiffsinthesecasesinclude threeclassesofprivatepersonsorentitiesthatpaidforanyportionofthepurchaseofthedrugsatissuebasedonawp andstategovernmententitiesthatmademedicaidpaymentsforthedrugsatissuebasedonawpinjuneaftera trialonthemeritsthemdlcourtdismissedtheclaimsoftwooftheplaintiffclassesagainstthejjawpdefendantsin marchthecourtdismissedtheclaimsofthethirdclassagainstthejjawpdefendantswithoutprejudice awpcasesbroughtbyvariousattorneysgeneralhaveproceededtotrialagainstothermanufacturersseveralstate casesagainstcertainjohnsonjohnsonsubsidiarieshavebeensettledincludingthecaseinwisconsinwhichsettledin februarycasesarestillpendinginillinoisnewjerseyandutahthecasesinillinoisandnewjerseyhavenotyet proceededtotrialinutahtheclaimsbroughtbytheattorneygeneralweredismissedbythecourtinbutthestate mayappealthedismissalaftertheconclusionofsimilarpendingmattersagainstotherdefendantsintheawpcase againstthejjawpdefendantsbroughtbythecommonwealthofpennsylvaniafollowingatrialinthe pennsylvaniacommonwealthcourtfoundinfavorofthecommonwealthwithregardtocertainofitsclaimsunderthe pennsylvaniaunfairtradepracticesandconsumerprotectionlawandinfavorofthejjawpdefendantsonthe commonwealthsremainingclaimsfollowinganappealtothepennsylvaniasupremecourtthatvacatedthatjudgment thecommonwealthcourtenteredasubsequentjudgmentinfavorofthejjawpdefendantsonallclaimsthat subsequentjudgmenthasbeenupheldbythepennsylvaniasupremecourtinasuccessiveappeal mcneilconsumerhealthcare startinginjunemcneilconsumerhealthcaredivisionofmcneilppcincnowjohnsonjohnsonconsum incmcneilconsumerhealthcaredivisionmcneilconsumerhealthcareandcertainaffiliatesincludingjohnson johnsonthecompaniesreceivedgrandjurysubpoenasfromtheunitedstatesattorneysofficefortheeasterndistrict ofpennsylvaniarequestingdocumentsbroadlyrelatingtorecallsofvariousproductsofmcneilconsumerhealthcareand thefdainspectionsofthefortwashingtonpennsylvaniaandlancasterpennsylvaniamanufacturingfacilitiesaswellas certaindocumentsrelatingtorecallsofasmallnumberofproductsofothersubsidiariesinadditioninfebruarythe governmentservedmcneilppcincnowjohnsonjohnsonconsumerincjjciwithacivilinvestigativedemand seekingrecordsrelevanttoitsinvestigationtodetermineiftherewasaviolationofthefederalfalseclaimsactinmarch mcneilppcincnowjjcienteredaguiltypleaintheunitedstatesdistrictcourtfortheeasterndistrictof pennsylvaniatoamisdemeanorviolationoftheusfooddrugandcosmeticactmcneilppcincnowjjciagree topayamillionfineandamillionforfeituretoresolvethematter thecompanieshavealsoreceivedcivilinvestigativedemandsfrommultiplestateattorneysgeneralofficesbroadly relatingtothemcneilrecallissuesthecompaniescontinuetocooperatewiththeseinquirieswhicharebee coordinatedthroughamultistatecoalitionifaresolutioncannotbereachedwiththismultistatecoalitionitispossible thatindividualstateattorneysgeneralofficesmayfilecivilmonetaryclaimsagainstthecompanie injanuarytheoregonattorneygeneralfiledacivilcomplaintagainstjohnsonjohnsonmcneilppcincnow jjciandmcneilhealthcarellcinstatecourtallegingcivilviolationsoftheoregonunlawfultradepracticesactrelate toanearlierrecallofamcneilotcproductinnovemberthestatecourtgrantedamotionbythecompaniesto dismissoregonscomplaintinitsentiretywithprejudiceinnovemberthestatecourtofappealsreversedthetrial courtandreinstatedoregonsconsumerprotectionclaimsinfebruarytheoregonsupremecourtdeniedthe companiespetitionforreviewandthecasewassentbacktothetrialcourt johnsonjohnsonannualreportopioidslitigation asdescribedbelowjohnsonjohnsonjjandjanssenpharmaceuticalsincjpialongwithotherpharmaceutical companieshavebeennamedinfourlawsuitsallegingclaimsrelatedtomarketingofopioidsincludingduragesic nucyntaandnucyntaerandhavebeensubpoenaedbytwootherstatesforinformationrelatedtoopioid marketingpractice inmaysantaclaraandorangecountiesincaliforniafiledacomplaintinstatecourtinorangecountycalifornia againstnumerouspharmaceuticalmanufacturersincludingjjandjpiallegingclaimsrelatedtoopioidmarkete practicesincludingfalseadvertisingunfaircompetitionandpublicnuisancethecountiesseekinjunctiveandmonetary reliefinfebruarythedefendantsfiledmotionschallengingthesufficiencyofthecomplaintinaugustthe courtstayedthecaseuntilthefdaconcludesitsongoinginquiryintothesafetyandeffectivenessoflongtermopioid treatmentfollowingamotionbythecountiestoliftthestayinoctoberthecourtkeptthestayinplaceinpart requestedthepartiestoconferandadjournedthematteruntilalaterdate injunethecityofchicagofiledacomplaintincookcountycircuitcourtagainstthesamegroupof pharmaceuticalmanufacturersincludingjjandjpialleginganumberofclaimsrelatedtoopioidmarketingpractice includingconsumerfraudviolationsandfalseclaimsandseekinginjunctiveandmonetaryreliefthecasewaslater removedtotheunitedstatesdistrictcourtforthenortherndistrictofillinoisindecemberjjandjpifileda motiontodismissthecityofchicagosfirstamendedcomplaintwhichwasgrantedwithleavetofileanamende complaintthecityfiledasecondamendedcomplaintandinnovemberjjandjpifiledamotiontodismissthe secondamendedcomplaintinseptemberthecourtdismissedeightofthecitystencausesofactionandgranted thecityonefinalopportunitytorepleadthedismissedclaimsthecityfiledathirdamendedcomplaintinoctober andindecemberjjandjpifiledananswerastotwocausesofactionandamotiontodismisstheremaine causesofaction inseptemberthetennesseeattorneygeneraldivisionofconsumeraffairsissuedarequestforinformationtojpi andotherpharmaceuticalcompaniesrelatedtoopioidsmarketingpractice inaugustthenewhampshireattorneygeneralconsumerprotectionandantitrustbureauissuedasubpoenato jpiandotherpharmaceuticalcompaniesrelatedtoopioidsmarketingpracticesinoctoberthestatefiledamotion inthestateofnewhampshiresuperiorcourttoenforcethesubpoenajpiandtheotherpharmaceuticalcompanie subsequentlyfiledajointmotionforinjunctivereliefandaprotectiveordertoprecludethestatefromengagingprivate contingentfeecounseltoparticipateinthestatesinvestigationoranysubsequentenforcementactioninmarch thecourtgrantedtheprotectiveorderonthegroundsthatthestatehadnotobtainedrequisiteexecutiveandlegislative approvalstoretainprivatecounselbutrejectedthecontentionthatthecontingencyfeeagreementwasotherwise unlawfulallpartieshaveappealedthemarchrulingtothenewhampshiresupremecourtinaugustthe courtdeniedthepharmaceuticalcompaniesjointmotiontoenforcetheprotectiveorderonthegroundthattheunderlye deficiencylegislativeapprovalhadbeencuredinseptemberthestatestipulatedtostayenforcementofany subpoenaspendingthenewhampshiresupremecourtsconsiderationofthecompaniesappealofthemarch ruling indecemberthestateofmississippifiledacomplaintinthechancerycourtofthefirstjudicialdistrictofhind countyagainstsubstantiallythesamegroupofpharmaceuticalmanufacturersasinthesuitsbroughtbythecalifornia countiesandcityofchicagoincludingjjandjpialleginganumberofclaimsrelatedtoopioidmarketingpracticesand seekingpenaltiesandinjunctiveandmonetaryreliefinmarchdefendantsfiledamotiontotransfervenueand motionstodismissthecomplaint inaugustthecountyofsuffolkinnewyorkfiledacomplaintagainstseveralpharmaceuticalmanufacturersin newyorksupremecourtincludingjjandjpiallegingclaimsrelatedtoopioidmarketingincludingclaimsbasedon deceptiveactsandpracticesfalseadvertisingfraudandunjustenrichmentthecomplaintseekspenaltiesandinjunctive andmonetaryrelief infebruarythecountyoferieandthecountyofbroomeinnewyorkeachfiledacomplaintinnewyorksupreme courtagainstseveralpharmaceuticalmanufacturersincludingjpibothcomplaintsallegeclaimsrelatedtoopioid marketingpracticesincludingstatutoryclaimsfordeceptiveactsandpracticesfalseadvertisingandviolationof newyorkssocialserviceslawandcommonlawcausesofactionforpublicnuisancefraudandunjustenrichment eachcountyisseekingcompensatoryandpunitivedamagesandcost johnsonjohnsonannualreport inseptembersynthesincsynthesreceivedacivilinvestigativedemandissuedpursuanttothefalseclaimsact fromtheunitedstatesattorneysofficefortheeasterndistrictofpennsylvaniathedemandsoughtinformationregarde allegationsthatfellowshipshadbeenofferedtohospitalsinexchangeforagreementstopurchaseproductssyntheshas produceddocumentsandinformationinresponsetothedemandandiscooperatingwiththeinquiry inmayacclarentincacclarentreceivedasubpoenafromtheunitedstatesattorneysofficeforthedistrictof massachusettsrequestingdocumentsbroadlyrelatingtothesalesmarketingandallegedofflabelpromotionbyacclarent oftherelievastratusmicroflowspacerproducttherelievastratusspacerinmarchacclarent executedacivilsettlementwiththeunitedstatesjusticedepartmentandotheragenciestoresolvethisinvestigation johnsonjohnsonwasnotapartytothissettlementandtherewasnoadmissionofliabilityinaseparatematterinjuly theformerpresidentceoandvicepresidentofsalesofacclarenttheformeracclarentofficerswereconvicte ofmisdemeanorviolationsinconnectionwiththesaleandmarketingoftherelievastratusspacerthereareno chargesagainstacclarentethiconincorjohnsonjohnsoninthismatter inaugustdepuyorthopaedicsincdepuyincnowdepuysynthesincandjohnsonjohnsonservicesinc receivedaninformalrequestfromtheunitedstatesattorneysofficeforthedistrictofmassachusettsandthecivil divisionoftheunitedstatesdepartmentofjusticetheunitedstatesfortheproductionofmaterialsrelatingtothe depuyasrxlhipdeviceinjulytheunitedstatesnotifiedtheunitedstatesdistrictcourtforthedistrictof massachusettsthatithaddeclinedtointerveneinaquitamcasefiledpursuanttothefalseclaimsactagainstthe companiesinfebruarythedistrictcourtgrantedthecompaniesmotiontodismisswithprejudiceunsealedthe quitamcomplaintanddeniedthequitamrelatorsrequestforleavetofileafurtheramendedcomplaintthequitam relatorsappealedthecasetotheunitedstatescourtofappealsforthefirstcircuitthefirstcircuitsdecisioninthe caseispendingsinceoctoberagroupofstateattorneysgeneralhaveissuedcivilinvestigativedemand relatingtothedevelopmentsalesandmarketingofseveralofdepuyorthopaedicsincshipproductsthestatesare seekingmonetaryandinjunctivereliefinjulytheoregondepartmentofjusticewhichwasinvestigatingthese mattersindependentlyoftheotherstatesannouncedasettlementofitsasrxlhipdeviceinvestigationforatotal paymentofmilliontothestateoforegon inoctoberjohnsonjohnsonwascontactedbythecaliforniaattorneygeneralsofficeregardingamultistate attorneygeneralinvestigationofthemarketingofsurgicalmeshproductsforherniaandurogynecologicalpurposesby johnsonjohnsonssubsidiaryethiconincethiconjohnsonjohnsonandethiconhavesinceenteredintoaserie oftollingagreementswiththestatesandthedistrictofcolumbiaparticipatinginthemultistateinvestigationandhave respondedtocivilinvestigativedemandsservedbycertainoftheparticipatingstatesthestatesareseekingmonetary andinjunctivereliefinmaycaliforniaandwashingtonfiledcivilcomplaintsagainstjohnsonjohnsonandethicon allegingviolationsoftheirconsumerprotectionstatutesinaugustkentuckyfiledasimilarcomplaintagainstthe companiesjohnsonjohnsonandethiconhaveenteredintoanewtollingagreementwiththeremainingstatesand thedistrictofcolumbia indecembertherakosinctherakosformerlyasubsidiaryofjohnsonjohnsonandpartoftheorthoclinical diagnosticsincocdfranchisereceivedaletterfromthecivildivisionoftheunitedstatesattorneysofficeforthe easterndistrictofpennsylvaniainformingtherakosthattheunitedstatesattorneysofficewasinvestigatingthesale andmarketingofuvadexmethoxsalenandtheuvarxtssystemduringtheperiodtothepresenttheunite statesattorneysofficerequestedthatocdandjohnsonjohnsonpreservedocumentsthatcouldrelatetothe investigationtherakoswassubsequentlyacquiredbyanaffiliateofgorescapitalpartnersiiilpinjanuaryand ocdwasdivestedinjunefollowingthedivestitureofocdjohnsonjohnsonretainsocdsportionofany liabilitythatmayresultfromtheinvestigationforactivitythatoccurredpriortothesaleoftherakosinmarchand marchtheunitedstatesattorneysofficerequestedthatjohnsonjohnsonproducecertaindocumentsand johnsonjohnsoniscooperatingwiththerequest injunethemississippiattorneygeneralfiledacomplaintinchancerycourtofthefirstjudicialdistrictofhind countymississippiagainstjohnsonjohnsonandjohnsonjohnsonconsumercompaniesincnowjohnson johnsonconsumerincjjcithecomplaintallegesthatdefendantsfailedtodiscloseallegedhealthrisksassociate withfemaleconsumersuseoftalccontainedinjohnsonsbabypowderandjohnsonsshowertoshower aproductnolongersoldbyjjciandseeksinjunctiveandmonetaryreliefthismatteriscurrentlyscheduledfortrialin september inmarchjanssenpharmaceuticalsincjpireceivedacivilinvestigativedemandfromtheunitedstate attorneysofficeforthesoutherndistrictofnewyorkrelatedtojpiscontractualrelationshipswithpharmacybenefit johnsonjohnsonannualreportmanagersovertheperiodfromjanuarytothepresentwithregardtocertainofjpispharmaceuticalproductsthe demandwasissuedinconnectionwithaninvestigationunderthefalseclaimsact injanuaryjanssenpharmaceuticalsincjpireceivedacivilinvestigativedemandcidfromtheunitedstate departmentofjusticedojrelatingtoallegationsconcerningthesalesandmarketingpracticesofolysiotmjpiis cooperatingwithdojinappropriatelyrespondingtothecid infebruaryjohnsonjohnsonreceivedasubpoenafromtheunitedstatesattorneysofficeforthedistrictof massachusettsseekingtheproductionofrecordspertainingtopaymentstoanyccharitableorganizationthat providesfinancialassistancetomedicarepatientsmultiplepharmaceuticalcompanieshavepubliclyreportedreceiptof similarsubpoenasandongoinginquirie inrecentyearsjohnsonjohnsonhasreceivednumerousrequestsfromavarietyofunitedstatescongressional committeestoproduceinformationrelevanttoongoingcongressionalinquiriesitisthepolicyofjohnsonjohnsonto cooperatewiththeseinquiriesbyproducingtherequestedinformation generallitigation injunefollowingthepublicannouncementthatorthoclinicaldiagnosticsincocdhadreceivedagrandjury subpoenafromtheunitedstatesdepartmentofjusticeantitrustdivisioninconnectionwithaninvestigationthatha sincebeenclosedmultipleclassactioncomplaintswerefiledagainstocdbydirectpurchasersseekingdamagesfor allegedpricefixingthesecaseswereconsolidatedforpretrialpurposesintheunitedstatesdistrictcourtforthe easterndistrictofpennsylvaniaasinrebloodreagentantitrustlitigationinaugustthedistrictcourtgranteda motionfiledbytheplaintiffsforclasscertificationinapriltheunitedstatescourtofappealsforthethirdcircuit reversedtheclasscertificationrulingandremandedthecasetothedistrictcourtforfurtherproceedingsinoctober thedistrictcourtagaingrantedthemotionbytheplaintiffsforclasscertificationinjulyocdfiledamotion forsummaryjudgmentocdwasdivestedinandjohnsonjohnsonretainedanyliabilitythatmayresultfromthese case inseptemberjohnsonjohnsonjohnsonjohnsonincandmcneilconsumerhealthcaredivisionofjohnson johnsonincreceivedanoticeofcivilclaimfiledbynickfieldinthesupremecourtofbritishcolumbiacanadathe bccivilclaimthebccivilclaimisaputativeclassactionbroughtonbehalfofpersonswhoresideinbritishcolumbia andwhopurchasedduringtheperiodbetweenseptemberandinoraboutdecemberoneormorevarious mcneilinfantsorchildrensoverthecountermedicinesthatweremanufacturedatthefortwashingtonpennsylvania facilitythebccivilclaimallegesthatthedefendantsviolatedthebcbusinesspracticesandconsumerprotectionact andothercanadianstatutesandcommonlawsbysellingmedicinesthatwereallegedlynotsafeandoreffectiveordid notcomplywithcanadiangoodmanufacturingpracticestheclasscertificationhearingscheduledforoctober wasadjournedandthereiscurrentlynodatesetforthatheare inmaytwopurportedclassactionswerefiledinfederalcourtoneintheunitedstatesdistrictcourtforthecentral districtofcaliforniaandoneintheunitedstatesdistrictcourtforthesoutherndistrictofillinoisagainstjohnson johnsonjjandjohnsonjohnsonconsumercompaniesincnowjohnsonjohnsonconsumerincjjcialleging violationsofstateconsumerfraudstatutesbasedonnondisclosureofallegedhealthrisksassociatedwithtalccontaine injohnsonsbabypowderandjohnsonsshowertoshoweraproductnolongersoldbyjjcibothcase seekinjunctivereliefandmonetarydamagesneitherincludesaclaimforpersonalinjuriesinoctoberbothcase weretransferredtotheunitedstatesdistrictcourtforthedistrictcourtofnewjerseyaspartofanewlycreatedfederal multidistrictlitigationindecemberjjandjjcifiledamotiontodismissoneofthecases inaugustunitedstatescustomsandborderprotectionuscbpissuedapenaltynoticeagainstjanssenortho llcjanssenorthoassessingpenaltiesfortheallegedimproperclassificationofdarunavirethanolatetheactive pharmaceuticalingredientinprezistainconnectionwithitsimportationintotheunitedstatesinoctober janssenorthosubmittedapetitionforreliefinresponsetothepenaltynoticeinmayuscbpissuedan amendedpenaltynoticeassessingsubstantialpenaltiesandjanssenorthofileditspetitionforreliefinjuly inmarchandapriloverputativeclassactioncomplaintswerefiledbycontactlenspatientsinanumberofcourt aroundtheunitedstatesagainstjohnsonjohnsonvisioncareincjjvciothercontactlensmanufacturer distributorsandretailersallegingverticalandhorizontalconspiraciestofixtheretailpricesofcontactlensesthe complaintsallegethatthemanufacturersreachedagreementswitheachotherandcertaindistributorsandretailers concerningthepricesatwhichsomecontactlensescouldbesoldtoconsumerstheplaintiffsareseekingdamagesand injunctivereliefalloftheclassactioncasesweretransferredtotheunitedstatesdistrictcourtforthemiddledistrictof johnsonjohnsonannualreport floridainjunetheplaintiffsfiledaconsolidatedclassactioncomplaintinnovemberandindecember jjvciandotherdefendantsfiledmotionstodismissinjunethecourtdeniedthemotionstodismiss discoveryisongoe inapriljohnsonjohnsonvisioncareincjjvcifiledacomplaintintheunitedstatesdistrictcourtforthe districtofutahagainstthestateofutahseekingadeclaratoryjudgmentthatalawpassedbythestatetobanunilateral pricingpoliciessolelyinthecontactlensmarketviolatesthecommerceclauseoftheunitedstatesconstitutionthe courtdeniedjjvcismotionforapreliminaryinjunctionjjvciappealedargumentontheappealwasheldinaugust indecembertheappellatecourtdeniedjjvcisappeal inapriladimmunecorporationltdadimmunecommencedanarbitrationintheinternationalcourtofarbitration internationalchamberofcommerceagainstcrucellswitzerlandagnowjanssenvaccinesagandcrucellholland bvnowjanssenvaccinespreventionbvcollectivelycrucelladimmuneclaimsthatcrucellbreachedcertain agreementsrelatingtothesupplyoffluantigenwhencrucellceasedpurchasingfluantigenfromadimmuneindecember adimmunefileditsstatementofclaimseekingmonetarydamagesthearbitrationhearingtookplaceinnovember andthepartiesareawaitingaruling inaugusttwothirdpartypayorsfiledapurportedclassactionintheunitedstatesdistrictcourtfortheeastern districtoflouisianaagainstjanssenresearchdevelopmentllcjanssenorthollcjanssenpharmaceuticalsinc orthomcneiljanssenpharmaceuticalsincandjohnsonjohnsonaswellascertainbayerentitiesallegingthatthe defendantsimproperlymarketedandpromotedxareltoassaferandmoreeffectivethanlessexpensivealternative medicationswhilefailingtofullydiscloseitsrisksthecomplaintseeksdamagesinanunspecifiedamount johnsonjohnsonoritssubsidiariesarealsopartiestoanumberofproceedingsbroughtunderthecomprehensive environmentalresponsecompensationandliabilityactcommonlyknownassuperfundandcomparablestatelocalor foreignlawsinwhichtheprimaryreliefsoughtisthecostofpastandorfutureremediation restructuring thecompanyannouncedrestructuringactionsinitsmedicaldevicessegmenttobetterservetheneedsofpatientsand customersintodaysevolvinghealthcaremarketplacethecompanyisundertakingactionstostrengthenitsgotomarket modelacceleratethepaceofinnovationfurtherprioritizekeyplatformsandgeographiesandstreamlineoperationswhile maintaininghighqualitystandard thecompanyestimatesthatinconnectionwithitsplansitwillrecordpretaxrestructuringrelatedchargesof approximatelybilliontobillioninthecompanyrecordedapretaxchargeofmillionofwhich millionwasincludedincostofproductssoldandmillionwasincludedinotherincomeexpenseseetablebelow foradditionaldetailstotalprojectcostsofbillionhavebeenrecordedsincetherestructuringhasbeen announce additionallyaspartoftheplanthecompanyexpectsthattherestructuringactionswillresultinpositioneliminationsof approximatelytopercentofthemedicaldevicessegmentsglobalworkforceoverthenexttwoyearssubjecttoany consultationproceduresincountrieswhererequiredapproximatelypositionshavebeeneliminatedsincethe restructuringwasannounce thecompanyestimatesthatapproximatelyonehalfofthecumulativepretaxcostswillresultincashoutlaysinclude approximatelymillionofemployeeseveranceapproximatelyonehalfofthecumulativepretaxcostsarenoncash relatingprimarilytofacilityrationalizationinventorywriteoffsandintangibleassetwriteoff johnsonjohnsonannualreportthefollowingtablesummarizestheseverancechargesandtheassociatedspendingunderthisinitiativethroughthefiscal yearende dollarsinmillion severance assetwriteoff total restructuringcharge activity reservebalancejanuary currentyearactivity charge cashpayment settlednoncash reservebalancejanuary cashoutlaysforseveranceareexpectedtobesubstantiallypaidoutoverthenextmonthsinaccordancewiththecompanysplan andlocallaw otherincludesprojectexpensesuchassalariesforemployeessupportingtheinitiativeandconsultingexpense johnsonjohnsonannualreport report independent register public accounting firm totheshareholdersandboardofdirectorsofjohnsonjohnson inouropiniontheaccompanyingconsolidatedbalancesheetsandtherelatedconsolidatedstatementsofearningsof comprehensiveincomeofequityandofcashflowspresentfairlyinallmaterialrespectsthefinancialpositionof johnsonjohnsonanditssubsidiariesatjanuaryandjanuaryandtheresultsoftheiroperationsand theircashflowsforeachofthethreeyearsintheperiodendedjanuaryinconformitywithaccountingprinciples generallyacceptedintheunitedstatesofamericaalsoinouropinionthecompanymaintainedinallmaterialrespect effectiveinternalcontroloverfinancialreportingasofjanuarybasedoncriteriaestablishedininternalcontrol integratedframeworkissuedbythecommitteeofsponsoringorganizationsofthetreadwaycommission cosothecompanysmanagementisresponsibleforthesefinancialstatementsformaintainingeffectiveinternal controloverfinancialreportingandforitsassessmentoftheeffectivenessofinternalcontroloverfinancialreporting includedintheaccompanyingmanagementsreportoninternalcontroloverfinancialreportingourresponsibilityisto expressopinionsonthesefinancialstatementsandonthecompanysinternalcontroloverfinancialreportingbasedon ourintegratedauditsweconductedourauditsinaccordancewiththestandardsofthepubliccompanyaccounte oversightboardunitedstatesthosestandardsrequirethatweplanandperformtheauditstoobtainreasonable assuranceaboutwhetherthefinancialstatementsarefreeofmaterialmisstatementandwhethereffectiveinternalcontrol overfinancialreportingwasmaintainedinallmaterialrespectsourauditsofthefinancialstatementsincludedexamine onatestbasisevidencesupportingtheamountsanddisclosuresinthefinancialstatementsassessingtheaccounte principlesusedandsignificantestimatesmadebymanagementandevaluatingtheoverallfinancialstatement presentationourauditofinternalcontroloverfinancialreportingincludedobtaininganunderstandingofinternalcontrol overfinancialreportingassessingtheriskthatamaterialweaknessexistsandtestingandevaluatingthedesignand operatingeffectivenessofinternalcontrolbasedontheassessedriskourauditsalsoincludedperformingsuchother proceduresasweconsiderednecessaryinthecircumstanceswebelievethatourauditsprovideareasonablebasisfor ouropinion asdiscussedinnotetotheconsolidatedfinancialstatementsthecompanychangedthemannerinwhichitaccount forandpresentscertainelementsofsharebasedpaymentsin acompanysinternalcontroloverfinancialreportingisaprocessdesignedtoprovidereasonableassuranceregardingthe reliabilityoffinancialreportingandthepreparationoffinancialstatementsforexternalpurposesinaccordancewith generallyacceptedaccountingprinciplesacompanysinternalcontroloverfinancialreportingincludesthosepoliciesand proceduresthatipertaintothemaintenanceofrecordsthatinreasonabledetailaccuratelyandfairlyreflectthe transactionsanddispositionsoftheassetsofthecompanyiiprovidereasonableassurancethattransactionsare recordedasnecessarytopermitpreparationoffinancialstatementsinaccordancewithgenerallyacceptedaccounte principlesandthatreceiptsandexpendituresofthecompanyarebeingmadeonlyinaccordancewithauthorizationsof managementanddirectorsofthecompanyandiiiprovidereasonableassuranceregardingpreventionortimelydetection ofunauthorizedacquisitionuseordispositionofthecompanysassetsthatcouldhaveamaterialeffectonthefinancial statement becauseofitsinherentlimitationsinternalcontroloverfinancialreportingmaynotpreventordetectmisstatementsalso projectionsofanyevaluationofeffectivenesstofutureperiodsaresubjecttotheriskthatcontrolsmaybecomeinadequate becauseofchangesinconditionsorthatthedegreeofcompliancewiththepoliciesorproceduresmaydeteriorate spricewaterhousecoopersllp florhamparknewjersey february johnsonjohnsonannualreportmanagement report internal control financial reporting undersectionofthesarbanesoxleyactofmanagementisrequiredtoassesstheeffectivenessofthe companysinternalcontroloverfinancialreportingasoftheendofeachfiscalyearandreportbasedonthatassessment whetherthecompanysinternalcontroloverfinancialreportingiseffective managementofthecompanyisresponsibleforestablishingandmaintainingadequateinternalcontroloverfinancial reportingthecompanysinternalcontroloverfinancialreportingisdesignedtoprovidereasonableassuranceastothe reliabilityofthecompanysfinancialreportingandthepreparationofexternalfinancialstatementsinaccordancewith generallyacceptedaccountingprinciple internalcontrolsoverfinancialreportingnomatterhowwelldesignedhaveinherentlimitationsthereforeinternalcontrol overfinancialreportingdeterminedtobeeffectivecanprovideonlyreasonableassurancewithrespecttofinancial statementpreparationandmaynotpreventordetectallmisstatementsmoreoverprojectionsofanyevaluationof effectivenesstofutureperiodsaresubjecttotheriskthatcontrolsmaybecomeinadequatebecauseofchangesin conditionsorthatthedegreeofcompliancewiththepoliciesorproceduresmaydeteriorate thecompanysmanagementhasassessedtheeffectivenessofthecompanysinternalcontroloverfinancialreportingas ofjanuaryinmakingthisassessmentthecompanyusedthecriteriaestablishedbythecommitteeof sponsoringorganizationsofthetreadwaycommissioncosoininternalcontrolintegratedframework thesecriteriaareintheareasofcontrolenvironmentriskassessmentcontrolactivitiesinformationandcommunication andmonitoringthecompanysassessmentincludedextensivedocumentingevaluatingandtestingthedesignand operatingeffectivenessofitsinternalcontrolsoverfinancialreporting basedonthecompanysprocessesandassessmentasdescribedabovemanagementhasconcludedthatasof januarythecompanysinternalcontroloverfinancialreportingwaseffective theeffectivenessofthecompanysinternalcontroloverfinancialreportingasofjanuaryhasbeenauditedby pricewaterhousecoopersllpanindependentregisteredpublicaccountingfirmasstatedintheirreportwhichappear salexgorsky sdominicjcaruso alexgorsky dominicjcaruso chairmanboardofdirector executivevicepresident chiefexecutiveofficer chieffinancialofficer johnsonjohnsonannualreport shareholder return performance graph setforthbelowarelinegraphscomparingthecumulativetotalshareholderreturnonthecompanyscommonstockfor periodsoffiveyearsandtenyearsendingdecemberagainstthecumulativetotalreturnofthestandard poorsstockindexthestandardpoorspharmaceuticalindexandthestandardpoorshealthcareequipment indexthegraphsandtablesassumethatwasinvestedondecemberanddecemberineachof thecompanyscommonstockthestandardpoorsstockindexthestandardpoorspharmaceuticalindexand thestandardpoorshealthcareequipmentindexandthatalldividendswerereinveste year shareholder return performance jj vs indices johnson johnson sp index sp pharmaceucidcal index sp healthcare equipment index year cagr jj sp sp pharm sp hc equip johnsonjohnson spindex sppharmaceuticalindex sphealthcareequipmentindex year shareholder return performance jj vs indices johnson johnson sp index sp pharmaceucidcal index sp healthcare equipment index year cagr jj sp sp pharm sp hc equip johnsonjohnson spindex sppharmaceuticalindex sphealthcareequipmentindex johnsonjohnsonannualreportitem change disagreement accountant account financial disclosure notapplicable item control procedure disclosurecontrolsandproceduresattheendoftheperiodcoveredbythisreportthecompanyevaluatedthe effectivenessofthedesignandoperationofitsdisclosurecontrolsandproceduresthecompanysdisclosurecontrols andproceduresaredesignedtoensurethatinformationrequiredtobedisclosedbythecompanyinthereportsthatit filesorsubmitsundertheexchangeactisrecordedprocessedsummarizedandreportedwithinthetimeperiods specifiedinthesecsrulesandformsdisclosurecontrolsandproceduresincludewithoutlimitationcontrolsand proceduresdesignedtoensurethatinformationrequiredtobedisclosedbythecompanyinthereportsthatitfilesor submitsundertheexchangeactisaccumulatedandcommunicatedtothecompanysmanagementincludingitsprincipal executiveandprincipalfinancialofficersorpersonsperformingsimilarfunctionsasappropriatetoallowtimelydecision regardingrequireddisclosurealexgorskychairmanandchiefexecutiveofficeranddominicjcarusoexecutivevice presidentchieffinancialofficerreviewedandparticipatedinthisevaluationbasedonthisevaluationmessrsgorsky andcarusoconcludedthatasoftheendoftheperiodcoveredbythisreportthecompanysdisclosurecontrolsand procedureswereeffective reportsoninternalcontroloverfinancialreportingtheinformationcalledforbythisitemisincorporatedhereinby referencetomanagementsreportoninternalcontroloverfinancialreportingandtheattestationregardinginternal controlsoverfinancialreportingincludedinthereportofindependentregisteredpublicaccountingfirmincludedin itemofthisreport changesininternalcontroloverfinancialreportingduringthefiscalquarterendedjanuarytherewereno changesinthecompanysinternalcontroloverfinancialreportingidentifiedinconnectionwiththeevaluationrequire underrulesaanddundertheexchangeactthathavemateriallyaffectedorarereasonablylikelyto materiallyaffectthecompanysinternalcontroloverfinancialreporte thecompanyisimplementingamultiyearenterprisewideinitiativetointegratesimplifyandstandardizeprocessesand systemsforthehumanresourcesinformationtechnologyprocurementsupplychainandfinancefunctionstheseare enhancementstosupportthegrowthofthecompanysfinancialsharedservicecapabilitiesandstandardizefinancial systemsthisinitiativeisnotinresponsetoanyidentifieddeficiencyorweaknessinthecompanysinternalcontrolover financialreportinginresponsetothisinitiativethecompanyhasandwillcontinuetoalignandstreamlinethedesignand operationofitsfinancialcontrolenvironment item b information notapplicable johnsonjohnsonannualreport iii item director executive officer corporate governance theinformationcalledforbythisitemisincorporatedhereinbyreferencetothediscussionoftheauditcommitteeunder thecaptionitemelectionofdirectorsboardcommitteesandthematerialunderthecaptionsitemelectionof directorsandstockownershipandsectioncompliancesectionabeneficialownershipreporte complianceintheproxystatementandthematerialunderthecaptionexecutiveofficersoftheregistrantinpartiof thisreport thecompanyscodeofbusinessconductwhichcoversallemployeesincludingthechiefexecutiveofficerchief financialofficerandcontrollermeetstherequirementsofthesecrulespromulgatedundersectionofthe sarbanesoxleyactofthecodeofbusinessconductisavailableonthecompanyswebsiteat wwwjnjcomcodeofbusinessconductandcopiesareavailabletoshareholderswithoutchargeuponwrittenrequestto thesecretaryatthecompanysprincipalexecutiveofficesanysubstantiveamendmenttothecodeofbusinessconduct oranywaiverofthecodegrantedtothechiefexecutiveofficerthechieffinancialofficerorthecontrollerwillbe postedonthecompanyswebsiteatwwwinvestorjnjcomgovcfmwithinfivebusinessdaysandretainedonthewebsite foratleastoneyear inadditionthecompanyhasadoptedacodeofbusinessconductethicsformembersoftheboardofdirectorsand executiveofficersthecodeofbusinessconductethicsformembersoftheboardofdirectorsandexecutiveofficer isavailableonthecompanyswebsiteatwwwinvestorjnjcomgovboardconductcfmandcopiesareavailableto shareholderswithoutchargeuponwrittenrequesttothesecretaryatthecompanysprincipalexecutiveofficesany substantiveamendmenttothecodeoranywaiverofthecodegrantedtoanymemberoftheboardofdirectorsorany executiveofficerwillbepostedonthecompanyswebsiteatwwwinvestorjnjcomgovcfmwithinfivebusinessdaysand retainedonthewebsiteforatleastoneyear item executive compensation theinformationcalledforbythisitemisincorporatedhereinbyreferencetothematerialunderthecaptionsitem electionofdirectorsdirectorcompensationcompensationcommitteereportcompensationdiscussionand analysisandexecutivecompensationtablesintheproxystatement thematerialincorporatedhereinbyreferencetothematerialunderthecaptioncompensationcommitteereportinthe proxystatementshallbedeemedfurnishedandnotfiledinthisreportandshallnotbedeemedincorporatedby referenceintoanyfilingunderthesecuritiesactofasamendedorthesecuritiesexchangeactofas amendedasaresultofthisfurnishingexcepttotheextentthatthecompanyspecificallyincorporatesitbyreference item security ownership certain beneficial owner management relate stockholder matter theinformationcalledforbythisitemisincorporatedhereinbyreferencetothematerialunderthecaptionitemstock ownershipandsectioncomplianceintheproxystatementandnotecommonstockstockoptionplansand stockcompensationagreementsofthenotestoconsolidatedfinancialstatementsinitemofthisreport johnsonjohnsonannualreportequity compensation plan information thefollowingtableprovidescertaininformationasofjanuaryconcerningthesharesofthecompanyscommon stockthatmaybeissuedunderexistingequitycompensationplans numberof securitiesto beissuedupon weightedaverage numberofsecuritie exerciseof exercisepriceof remainingavailablefor outstanding outstanding futureissuanceunderequity plancategory optionsandright optionsandright compensationplan equitycompensationplansapprovedbysecurity holder equitycompensationplansnotapprovedbysecurity holder total includedinthiscategoryarethefollowingequitycompensationplanswhichhavebeenapprovedbythecompanysshareholder longtermincentiveplanandlongtermincentiveplan thiscolumnexcludessharesreflectedunderthecolumnnumberofsecuritiestobeissueduponexerciseofoutstandingoption andright thelongtermincentiveplanexpiredaprilalloptionsandrestrictedsharesgrantedsubsequenttothatdatewere underthelongtermincentiveplan item certain relationship relate transaction director independence theinformationcalledforbythisitemisincorporatedhereinbyreferencetothematerialunderthecaptionsitem electionofdirectorsdirectorindependenceandrelatedpartytransactionsintheproxystatement item principal accountant fee service theinformationcalledforbythisitemisincorporatedhereinbyreferencetothematerialunderthecaptionitem ratificationofappointmentofindependentregisteredpublicaccountingfirmintheproxystatement johnsonjohnsonannualreport iv item exhibit financial statement schedule thefollowingdocumentsarefiledaspartofthisreport financialstatement consolidatedbalancesheetsatendoffiscalyearsand consolidatedstatementsofearningsforfiscalyearsand consolidatedstatementsofcomprehensiveincomeforfiscalyearsand consolidatedstatementsofequityforfiscalyearsand consolidatedstatementsofcashflowsforfiscalyearsand notestoconsolidatedfinancialstatement reportofindependentregisteredpublicaccountingfirm allschedulesareomittedbecausetheyarenotapplicableortherequiredinformationisincludedinthefinancial statementsornote exhibitsrequiredtobefiledbyitemlofregulationsk theinformationcalledforbythisitemisincorporatedhereinbyreferencetotheexhibitindexinthisreport item summary registrantsmayvoluntarilyincludeasummaryofinformationrequiredbyformkunderthisitemthecompanyha electednottoincludesuchsummaryinformation johnsonjohnsonannualreportsignature pursuanttotherequirementsofsectionofthesecuritiesexchangeactoftheregistranthasdulycausedthis reporttobesignedonitsbehalfbytheundersignedthereuntodulyauthorized datefebruary johnsonjohnson registrant sagorsky agorskychairmanboardofdirector andchiefexecutiveofficer pursuanttotherequirementsofthesecuritiesexchangeactofthisreporthasbeensignedbelowbythefollowe personsonbehalfoftheregistrantandinthecapacitiesandonthedatesindicate signature title date sagorsky chairmanboardofdirector february agorsky chiefexecutiveofficer principalexecutiveofficer sdjcaruso chieffinancialofficer february djcaruso principalfinancialofficer srakapusta controllerandchiefaccountingofficer february rakapusta principalaccountingofficer smcbeckerle director february mcbeckerle sdsdavis director february dsdavis sieldavis director february ieldavis smbmcclellan director february mbmcclellan sammulcahy director february ammulcahy swdperez director february wdperez scprince director february cprince saewashington director february aewashington srawilliams director february rawilliams johnsonjohnsonannualreport exhibit index regsk exhibittable itemno descriptionofexhibit restatedcertificateofincorporationeffectivefebruaryincorporatedhereinbyreferencetoexhibitiofthe registrantsformkannualreportforthefiscalyearendedjanuary ii bylawsofthecompanyasamendedeffectivejanuaryincorporatedhereinbyreferencetoexhibitthe registrantsformkcurrentreportfiledjanuary upontherequestofthesecuritiesandexchangecommissiontheregistrantwillfurnishacopyofallinstrumentsdefiningthe rightsofholdersoflongtermdebtoftheregistrant longtermincentiveplanincorporatedhereinbyreferencetoexhibitoftheregistrantssregistrationstatement filedwiththecommissiononmayfileno b formofstockoptioncertificaterestrictedshareunitcertificateandperformanceshareunitcertificateunderthe longtermincentiveplanincorporatedhereinbyreferencetoexhibitsandoftheregistrantsformk currentreportfiledjanuary c longtermincentiveplanincorporatedhereinbyreferencetoappendixaoftheregistrantsproxystatementfiledwith thecommissiononmarch formofstockoptioncertificaterestrictedshareunitcertificateandperformanceshareunitcertificateunderthe longtermincentiveplanincorporatedhereinbyreferencetoexhibitsandoftheregistrantsformq quarterlyreportfiledmay e executiveincentiveplanasamendedincorporatedhereinbyreferencetoexhibitfoftheregistrantsformkannual reportforthefiscalyearendeddecember f domesticdeferredcompensationcertificateofextracompensationplanincorporatedhereinbyreferencetoexhibitg oftheregistrantsformkannualreportfortheyearendeddecember g amendmentstothecertificateofextracompensationplaneffectiveasofjanuaryincorporatedhereinbyreferenceto exhibitjoftheregistrantsformkannualreportfortheyearendeddecember h certificatesoflongtermperformanceplanincorporatedhereinbyreferencetoexhibitoftheregistrantsform qquarterlyreportforthequarterendedseptember amendedandrestateddeferredfeeplanfordirectorsincorporatedhereinbyreferencetoexhibitkoftheregistrants formkannualreportforthefiscalyearendedjanuary j executiveincomedeferralplanamendedandrestatedincorporatedhereinbyreferencetoexhibitoftheregistrants formqquarterlyreportforthequarterendedseptember k excesssavingsplanincorporatedhereinbyreferencetoexhibitjoftheregistrantsformkannualreportforthe fiscalyearendeddecember l amendmentstothejohnsonjohnsonexcesssavingsplaneffectiveasofjanuaryincorporatedhereinbyreference toexhibitpoftheregistrantsformkannualreportforthefiscalyearendeddecember excessbenefitplansupplementalretirementplanincorporatedhereinbyreferencetoexhibithoftheregistrantsform kannualreportforthefiscalyearendedjanuary n amendmentstotheexcessbenefitplanofjohnsonjohnsonandaffiliatedcompanieseffectiveasofjanuary incorporatedhereinbyreferencetoexhibitroftheregistrantsformkannualreportforthefiscalyearende december amendmenttotheexcessbenefitplanofjohnsonjohnsonandaffiliatedcompanieseffectiveasofjanuary incorporatedhereinbyreferencetoexhibitqoftheregistrantsformkannualreportforthefiscalyearende december p executivelifeplanagreementincorporatedhereinbyreferencetoexhibitioftheregistrantsformkannualreport forthefiscalyearendedjanuary q executivelifeplanagreementclosureletterincorporatedhereinbyreferencetoexhibitoftheregistrantsformq quarterlyreportforthequarterendedmarch r johnsonjohnsonretirementsavingsplanjohnsonjohnsonsavingsplanforunionrepresentedemployeesandjohnson johnsonsavingsplanincorporatedhereinbyreferencetoexhibitsandoftheregistrantsformsfiledwith thecommissiononmay employmentagreementfordrpaulusstoffelsincorporatedhereinbyreferencetoexhibitoftheregistrantsformq quarterlyreportforthequarterendedseptember summaryofemploymentarrangementsforsandraepetersonincorporatedhereinbyreferencetoexhibittofthe registrantsformkannualreportfortheyearendeddecember johnsonjohnsonannualreportu severancepayplanofjohnsonjohnsonandusaffiliatedcompaniesamendedandrestatedasofoctober incorporatedhereinbyreferencetoexhibitoftheregistrantsformqquarterlyreportforthequarterende september v firstamendmenttotheseverancepayplanofjohnsonjohnsonandusaffiliatedcompaniesasamendedandrestate effectiveoctoberincorporatedhereinbyreferencetoexhibitoftheregistrantsformqquarterlyreportfor thequarterendedjune w secondamendmenttotheseverancepayplanofjohnsonjohnsonandusaffiliatedcompaniesasamendedandrestate effectiveoctoberincorporatedhereinbyreferencetoexhibitxoftheregistrantsformkannualreportfor thefiscalyearendedjanuary statementofcomputationofratioofearningstofixedchargesfiledwiththisdocument subsidiariesfiledwiththisdocument consentofindependentregisteredpublicaccountingfirmfiledwiththisdocument certificationofchiefexecutiveofficerpursuanttosectionofthesarbanesoxleyactfiledwiththisdocument b certificationofchieffinancialofficerpursuanttosectionofthesarbanesoxleyactfiledwiththisdocument certificationofchiefexecutiveofficerpursuanttosectionofthesarbanesoxleyactfurnishedwiththisdocument b certificationofchieffinancialofficerpursuanttosectionofthesarbanesoxleyactfurnishedwiththisdocument xbrlextensiblebusinessreportinglanguagethefollowingmaterialsfromthisreportforthefiscalyearendedjanuary formattedinextensivebusinessreportinglanguagexbrliconsolidatedbalancesheetsiiconsolidate statementsofearningsiiiconsolidatedstatementsofcomprehensiveincomeivconsolidatedstatementsofequityv consolidatedstatementsofcashflowsandvinotestotheconsolidatedfinancialstatement managementcontractorcompensatoryplan acopyofanyoftheexhibitslistedabovewillbeprovidedwithoutchargetoanyshareholdersubmittingawrittenrequest specifyingthedesiredexhibitstothesecretaryattheprincipalexecutiveofficesofthecompany thefollowingexhibitsindicatedasbeingfiledwiththisdocumentareomittedfromtheprintedversionofthisannual report exhibit exhibit exhibit johnsonjohnsonannualreport thispageintentionallyleftblankexhibita certificationofchiefexecutiveofficer pursuanttosectionofthesarbanesoxleyact ialexgorskycertifythat ihavereviewedthisannualreportonformkforthefiscalyearendedjanuarythereportof johnsonjohnsonthecompany basedonmyknowledgethisreportdoesnotcontainanyuntruestatementofamaterialfactoromittostatea materialfactnecessarytomakethestatementsmadeinlightofthecircumstancesunderwhichsuchstatementswere madenotmisleadingwithrespecttotheperiodcoveredbythisreport basedonmyknowledgethefinancialstatementsandotherfinancialinformationincludedinthisreportfairly presentinallmaterialrespectsthefinancialconditionresultsofoperationsandcashflowsofthecompanyasofand fortheperiodspresentedinthisreport thecompanysothercertifyingofficersandiareresponsibleforestablishingandmaintainingdisclosurecontrol andproceduresasdefinedinexchangeactrulesaeanddeandinternalcontroloverfinancial reportingasdefinedinexchangeactrulesafanddfforthecompanyandhave adesignedsuchdisclosurecontrolsandproceduresorcausedsuchdisclosurecontrolsandprocedure tobedesignedunderoursupervisiontoensurethatmaterialinformationrelatingtothecompanyincludingit consolidatedsubsidiariesismadeknowntousbyotherswithinthoseentitiesparticularlyduringtheperiodin whichthisreportisbeingprepare bdesignedsuchinternalcontroloverfinancialreportingorcausedsuchinternalcontroloverfinancial reportingtobedesignedunderoursupervisiontoprovidereasonableassuranceregardingthereliabilityof financialreportingandthepreparationoffinancialstatementsforexternalpurposesinaccordancewithgenerally acceptedaccountingprinciple cevaluatedtheeffectivenessofthecompanysdisclosurecontrolsandproceduresandpresentedinthis reportourconclusionsabouttheeffectivenessofthedisclosurecontrolsandproceduresasoftheendofthe periodcoveredbythisreportbasedonsuchevaluationand ddisclosedinthisreportanychangeinthecompanysinternalcontroloverfinancialreportingthat occurredduringthecompanysmostrecentfiscalquarterthecompanysfourthfiscalquarterinthecaseofan annualreportthathasmateriallyaffectedorisreasonablylikelytomateriallyaffectthecompanysinternalcontrol overfinancialreportingand thecompanysothercertifyingofficersandihavedisclosedbasedonourmostrecentevaluationofinternal controloverfinancialreportingtothecompanysauditorsandtheauditcommitteeofthecompanysboardof directorsorpersonsperformingtheequivalentfunction aallsignificantdeficienciesandmaterialweaknessesinthedesignoroperationofinternalcontrolover financialreportingwhicharereasonablylikelytoadverselyaffectthecompanysabilitytorecordprocess summarizeandreportfinancialinformationand banyfraudwhetherornotmaterialthatinvolvesmanagementorotheremployeeswhohaveasignificant roleinthecompanysinternalcontroloverfinancialreporte salexgorsky alexgorsky chiefexecutiveofficer datefebruary johnsonjohnsonannualreportexhibitb certificationofchieffinancialofficer pursuanttosectionofthesarbanesoxleyact idominicjcarusocertifythat ihavereviewedthisannualreportonformkforthefiscalyearendedjanuarythereportof johnsonjohnsonthecompany basedonmyknowledgethisreportdoesnotcontainanyuntruestatementofamaterialfactoromittostatea materialfactnecessarytomakethestatementsmadeinlightofthecircumstancesunderwhichsuchstatementswere madenotmisleadingwithrespecttotheperiodcoveredbythisreport basedonmyknowledgethefinancialstatementsandotherfinancialinformationincludedinthisreportfairly presentinallmaterialrespectsthefinancialconditionresultsofoperationsandcashflowsofthecompanyasofand fortheperiodspresentedinthisreport thecompanysothercertifyingofficersandiareresponsibleforestablishingandmaintainingdisclosurecontrol andproceduresasdefinedinexchangeactrulesaeanddeandinternalcontroloverfinancial reportingasdefinedinexchangeactrulesafanddfforthecompanyandhave adesignedsuchdisclosurecontrolsandproceduresorcausedsuchdisclosurecontrolsandprocedure tobedesignedunderoursupervisiontoensurethatmaterialinformationrelatingtothecompanyincludingit consolidatedsubsidiariesismadeknowntousbyotherswithinthoseentitiesparticularlyduringtheperiodin whichthisreportisbeingprepare bdesignedsuchinternalcontroloverfinancialreportingorcausedsuchinternalcontroloverfinancial reportingtobedesignedunderoursupervisiontoprovidereasonableassuranceregardingthereliabilityof financialreportingandthepreparationoffinancialstatementsforexternalpurposesinaccordancewithgenerally acceptedaccountingprinciple cevaluatedtheeffectivenessofthecompanysdisclosurecontrolsandproceduresandpresentedinthis reportourconclusionsabouttheeffectivenessofthedisclosurecontrolsandproceduresasoftheendofthe periodcoveredbythisreportbasedonsuchevaluationand ddisclosedinthisreportanychangeinthecompanysinternalcontroloverfinancialreportingthat occurredduringthecompanysmostrecentfiscalquarterthecompanysfourthfiscalquarterinthecaseofan annualreportthathasmateriallyaffectedorisreasonablylikelytomateriallyaffectthecompanysinternalcontrol overfinancialreportingand thecompanysothercertifyingofficersandihavedisclosedbasedonourmostrecentevaluationofinternal controloverfinancialreportingtothecompanysauditorsandtheauditcommitteeofthecompanysboardof directorsorpersonsperformingtheequivalentfunction aallsignificantdeficienciesandmaterialweaknessesinthedesignoroperationofinternalcontrolover financialreportingwhicharereasonablylikelytoadverselyaffectthecompanysabilitytorecordprocess summarizeandreportfinancialinformationand banyfraudwhetherornotmaterialthatinvolvesmanagementorotheremployeeswhohaveasignificant roleinthecompanysinternalcontroloverfinancialreporte sdominicjcaruso dominicjcaruso chieffinancialofficer datefebruary johnsonjohnsonannualreportexhibita certificationofchiefexecutiveofficer pursuanttosectionofthesarbanesoxleyact theundersignedalexgorskythechiefexecutiveofficerofjohnsonjohnsonanewjerseycorporationthe companypursuanttouscasadoptedpursuanttosectionofthesarbanesoxleyactof herebycertifiesthattothebestofmyknowledge thecompanysannualreportonformkforthefiscalyearendedjanuarythereportfully complieswiththerequirementsofsectionaofthesecuritiesexchangeactofand theinformationcontainedinthereportfairlypresentsinallmaterialrespectsthefinancialconditionand resultsofoperationsofthecompany salexgorsky alexgorsky chiefexecutiveofficer datedfebruary thiscertificationisbeingfurnishedtothesecwiththisreportonformkpursuanttosectionofthe sarbanesoxleyactofandshallnotexcepttotheextentrequiredbysuchactbedeemedfiledbythecompany forpurposesofsectionofthesecuritiesexchangeactofasamendedorotherwisesubjecttotheliabilityof thatsection johnsonjohnsonannualreportexhibitb certificationofchieffinancialofficer pursuanttosectionofthesarbanesoxleyact theundersigneddominicjcarusothechieffinancialofficerofjohnsonjohnsonanewjerseycorporationthe companypursuanttouscasadoptedpursuanttosectionofthesarbanesoxleyactof herebycertifiesthattothebestofmyknowledge thecompanysannualreportonformkforthefiscalyearendedjanuarythereportfully complieswiththerequirementsofsectionaofthesecuritiesexchangeactofand theinformationcontainedinthereportfairlypresentsinallmaterialrespectsthefinancialconditionand resultsofoperationsofthecompany sdominicjcaruso dominicjcaruso chieffinancialofficer datedfebruary thiscertificationisbeingfurnishedtothesecwiththisreportonformkpursuanttosectionofthe sarbanesoxleyactofandshallnotexcepttotheextentrequiredbysuchactbedeemedfiledbythecompany forpurposesofsectionofthesecuritiesexchangeactofasamendedorotherwisesubjecttotheliabilityof thatsection johnsonjohnsonannualreportthispageintentionallyleftblankthispageintentionallyleftblankreconciliationofnongaapfinancialmeasure incr dollarsinmillionsexceptpersharedata decr earningsbeforeprovisionfortaxesonincomeasreporte intangibleassetamortizationexpense restructuringother litigationexpensenet depuyasrtmhipprogram inprocessresearchanddevelopment earningsbeforeprovisionfortaxesonincomeasadjuste netearningsasreported intangibleassetamortizationexpense restructuringother litigationexpensenet depuyasrtmhipprogram inprocessresearchanddevelopment netearningsasadjuste dilutednetearningspershareasreported intangibleassetamortizationexpense restructuringother litigationexpensenet depuyasrtmhipprogram inprocessresearchanddevelopment dilutednetearningspershareasadjuste operationaldilutednetearningspershareasadjustedatforeigncurrencyexchange rate impactofcurrencyatforeigncurrencyexchangerate operationaldilutednetearningspershareasadjustedatforeigncurrencyexchange rate includesmillionrecordedincostofproductssoldandmillionrecordedinotherincomeexpenseinand millionrecordedincostofproductssoldin thecompanyprovidesearningsbeforeprovisionfortaxesonincomenetearningsandnetearningspersharedilutedon anadjustedbasisbecausemanagementbelievesthatthesemeasuresprovideusefulinformationtoinvestorsamongother thingsthesemeasuresmayassistinvestorsinevaluatingthecompanysresultsofoperationsperiodoverperiodin variousperiodsthesemeasuresmayexcludesuchitemsasintangibleassetamortizationexpensesignificantcost associatedwithacquisitionsrestructuringlitigationandchangesinapplicablelawsandregulationsincludingsignificant accountingortaxmattersthesespecialitemsmaybehighlyvariabledifficulttopredictandofasizethatsometimeshas substantialimpactonthecompanysreportedresultsofoperationsforaperiodmanagementusesthesemeasure internallyforplanningforecastingandevaluatingtheperformancesofthecompanysbusinessesincludingallocate resourcesandevaluatingresultsrelativetoemployeeperformancecompensationtargetsunlikeearningsbeforeprovision fortaxesonincomenetearningsandnetearningspersharedilutedpreparedinaccordancewithgaapadjuste earningsbeforeprovisionfortaxesonincomeadjustednetearningsandadjustednetearningspersharedilutedmaynot becomparablewiththecalculationofsimilarmeasuresforothercompaniesthelimitationsofusingthesenongaap financialmeasuresasperformancemeasuresarethattheyprovideaviewofthecompanysresultsofoperationswithout includingalleventsduringaperiodsuchasintangibleassetamortizationexpensetheeffectsofanacquisitiontheortho clinicaldiagnosticsdivestiturerestructuringlitigationandchangesinapplicablelawsandregulationsincluding significantaccountingortaxmattersanddonotprovideacomparableviewofthecompanysperformancetoother companiesinthehealthcareindustryinvestorsshouldconsidernongaapfinancialmeasuresinadditiontoandnota replacementsfororsuperiortomeasuresoffinancialperformancepreparedinaccordancewithgaap johnsonjohnsonannualreportboard director senior management alexgorsky alexgorsky chairmanboardofdirector chiefexecutiveofficer chairmanexecutivecommittee marycbeckerle chiefexecutiveofficeranddirector dominicjcaruso huntsmancancerinstituteattheuniversityofutah executivevicepresidentchieffinancialofficer distinguishedprofessorofbiology collegeofscienceuniversityofutah joaquinduato executivevicepresidentworldwidechairmanpharmaceuticals dscottdavis formerchairmanandchiefexecutiveofficer petermfasolo unitedparcelserviceinc executivevicepresidentchiefhumanresourcesofficer ianeldavis ronaldakapusta chairmanrollsroyceholdingsplc corporatecontroller formerchairmanandworldwidemanagingdirector chiefaccountingofficer mckinseycompany ashleymcevoy markbmcclellan companygroupchairmanconsumermedicaldevice directordukerobertjmargolismd jorgemesquita centerforhealthpolicy executivevicepresidentworldwidechairmanconsumer annemmulcahy sandraepeterson formerchairmanandchiefexecutiveofficer executivevicepresidentgroupworldwidechairman xeroxcorporation garyjpruden williamdperez executivevicepresidentworldwidechairmanmedicaldevice retiredpresidentandchiefexecutiveofficer wmwrigleyjrcompany michellerryan treasurer charlesprince retiredchairmanandchiefexecutiveofficer michaelesnee citigroupinc worldwidevicepresidentglobalcorporateaffairs chiefcommunicationsofficer aeugenewashington dukeuniversityschancellorforhealthaffair thomasjspellmaniii presidentandchiefexecutiveofficer corporatesecretary dukeuniversityhealthsystem assistantgeneralcounsel ronaldawilliam paulusstoffel formerchairmanandchiefexecutiveofficer executivevicepresidentchiefscientificofficer aetnainc jennifertaubert companygroupchairmanpharmaceuticalstheamerica michaelhullmann executivevicepresidentgeneralcounsel kathrynewengel worldwidevicepresidentjohnsonjohnsonsupplychain memberexecutivecommittee johnsonjohnsonannualreportprincipaloffice stockliste johnsonjohnsononline onejohnsonjohnsonplaza johnsonjohnsoncommonstock ourwebsitewwwjnjcom newbrunswicknewjersey listedonnewyorkstockexchange stocksymboljnj httpwwwjnjcommediacenter annualmeetingofshareholder shareholderrelationscontact thursdayapril thomasjspellmaniii wwwfacebookcomjnj corporatesecretary ameasterndoorsopenatam statetheatre wwwtwittercomjnjcare livingstonavenue investorrelationscontact wwwtwittercomjnjnews newbrunswicknewjersey josephjwolk allshareholdersasoftherecorddateof vicepresidentinvestorrelations wwwyoutubecomjnj februaryareinvitedtoattend aformalnoticeofannualmeete httpwwwlinkedincomcompany johnsonjohnson proxystatementandproxyhavebeen investorrelationswebsite madeavailabletoshareholder wwwinvestorjnjcom thejohnsonjohnsonyearin annualreportonformkand stocktransferagentandregistrar reviewisavailableonourwebsiteat proxystatement questionsregardingstockholding wwwyearinreviewjnjcom johnsonjohnsonsannualreportonformk certificatereplacementtransferdividend theinformationonthesewebsitesshould forthefiscalyearendedjanuaryis andaddresschangesshouldbedirectedto notbedeemedtobepartofthisannual includedinthisannualreportinitsentiretywith ourstocktransferagentandregistrarat report theexceptionofcertainexhibitstheformk computersharetrustcompanyna completewithallofitsexhibitsisavailableonour pobox websiteatwwwinvestorjnjcomseccfmandthe collegestationtx secswebsiteatwwwsecgov overnightmail shareholdersmayalsoobtaincopiesofthe computersharetrustcompanyna exhibitsourannualreporton qualitycirclesuite formkandourproxystatement collegestationtx withoutchargeuponwrittenrequesttothe officeofthecorporatesecretaryatour shareholderwebsite principalofficeaddressorbycalle wwwcomputersharecominvestor dividendreinvestmentplan electronicdeliverynotification theplanallowsforfullorpartialdividend theproxystatementandourannual reinvestmentandadditionalweeklycash reportareavailableonourwebsite investmentsuptoperyearin wwwinvestorjnjcomgov johnsonjohnsoncommonstockwithout annualmeetingmaterialscfmshareholderswho pershareorservicechargesonstock c receivepapercopiesofourproxystatementand purchasesifyouareinterestedin annualreportbymailcanelecttoreceiveinstead participatingintheplanandneedan anemailmessagewithalinktothosedocument enrollmentformandormoreinformation ontheinternetregisteredshareholdersmay pleasecalltheplanadministrator thejohnsonjohnsonannualreport enrollinelectronicdeliveryat computersharetrustcompanynaat containsmanyofthevaluabletrademarks wwwcomputersharenacomgreenbeneficial andtradenamesownedandusedbythe shareholderswhoholdsharesofjohnson outsidetheusoraccessonlineat johnsonjohnsonfamilyofcompaniesin johnsoncommonstockthroughabankbrokeror wwwcomputersharecominvestor theunitedstatesandinternationallyto otherholderofrecordgenerallycanenrollfor distinguishproductsandservicesof electronicdeliveryatenrollicsdeliverycomjnj hearingimpaired outstandingquality shareholderswhohaveinquiriesregarde johnsonjohnson stockrelatedmatterscancommunicate directlywithcomputersharetrustcompany naviaatelecommunicationsdevicetdd thetelephonenumberforthisserviceis outsidetheuscare world person time inspire unite people